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Effective treatment of tuberculosis requires at least six months of 
combination therapy involving four antibiotics. Alterations in the physiological 
state of Mycobacterium tuberculosis during infection may reduce drug efficacy 
and prolong treatment, but these adaptations are incompletely defined. To 
investigate the mechanisms limiting antibiotic efficacy, I performed a 
comprehensive genetic study to identify M. tuberculosis genes and pathways 
important for bacterial survival during antibiotic treatment in vivo. First, I identified 
mutants in the glycerol kinase enzyme, GlpK, that promote survival under 
combination therapy. Similar glycerol catabolic mutants are enriched in 
extensively drug-resistant clinical isolates, indicating that these mutations may 
promote survival and the development of resistance in humans. A majority of 
these mutations are frameshifts within a homopolymeric region of the glpK gene, 
leading to the hypothesis that M. tuberculosis may reversibly produce drug-
tolerant phenotypes through genetic variation introduced at homopolymer sites 
as a strategy for survival during antibiotic treatment. Second, I identified bacterial 
mutants with altered susceptibility to individual first-line anti-mycobacterial drugs. 
Many of these mutations did not have obvious effects in vitro, demonstrating that 
a wide variety of natural genetic variants can influence drug efficacy in vivo 
without altering standard drug-susceptibility tests. A number of these genes are 
enriched in drug-resistant clinical isolates, indicating that these genetic variants 
influence treatment outcome. Together, these data suggest new targets for 
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improving therapy, as well as mechanisms of genetic adaptations that can 
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 1 
CHAPTER I: Introduction 
 
Tuberculosis 
Mycobacterium tuberculosis: the causative agent of tuberculosis 
Robert Koch identified “tubercle bacillus” as the causative agent of 
tuberculosis in 1882 (1), leading to over a century of research into the bacterial 
organism Mycobacterium tuberculosis. Genomic sequencing of bacterial isolates 
indicates that M. tuberculosis, an obligate human pathogen, has been infecting 
humans for 70,000 years and has evolved in parallel to humans (2). Currently 
there are 7 known lineages of M. tuberculosis. Each evolved with human 
migration, leading to increased adaptation between geographical lineages and 
regional human populations (2, 3). Co-evolution with humans has resulted in a 
highly specific human pathogen, reflected in genetic differences between non-
pathogenic Mycobacterium species and M. tuberculosis (4). Most commonly, 
infection with M. tuberculosis manifests as a pulmonary disease. Bacteria are 
transmitted via the inhalation of droplet nuclei expelled from an infected 
individual. This mode of transmission is most efficient in dense populations, 
leading to the hypothesis that increasing density of the human population 
resulted in widespread tuberculosis infection (2). 
Tuberculosis (TB) remains a modern-day global health problem, causing 
more deaths worldwide than any other infectious agent (5). The World Health 
Organization estimates that 1.7 billion people are infected with M. tuberculosis. 
Most individuals are latently infected, where the infection is controlled and 
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asymptomatic. Approximately five to ten percent progress to active disease 
during their lifetime. Treatment of latent infections decreases the risk of activation 
(5). In 2018, an estimated ten million people were diagnosed with TB (5). 
Effective therapy requires antibiotic treatment with multiple drugs administered 
for at least six months, and has a treatment success rate of 85%. Despite 
availability of effective treatments, approximately 1.2 million deaths were caused 
by TB in 2018 (5).  
 
Antibiotic treatment 
 Treatment of TB requires lengthy regimens of multiple antibiotics. Without 
treatment, the estimated mortality rate of TB is 70% (6). Streptomycin, the first 
antibiotic effective against M. tuberculosis, was introduced in 1946. Clinical trials 
showed improvement in mortality as compared to bedrest (7); however, 
streptomycin resistance was also observed (8). This result led to clinical trials of 
a combination therapy of streptomycin and para-amino-salicylic acid (PAS) in the 
1950s, and a decrease in streptomycin resistance during treatment was 
observed (9). In 1952, clinical trials were performed comparing the efficacy of 
isoniazid and the current combination therapy (10-12). These trials led to the 
recommendation of a three-drug regimen for at least twelve months or longer for 
active TB patients (13).  
After a series of clinical trials in the 1980s, a six-month, short-course 
treatment regimen consisting of four antibiotics was introduced (14) and remains 
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the current standard of care. Treatment of drug-susceptible TB (DS-TB) requires 
administration of isoniazid (INH), ethambutol (EMB), rifampin (RIF), and 
pyrazinamide (PZA) for two months, followed by four months of INH and RIF 
(15). Each of these antibiotics have distinct mechanisms of action, discussed 
below, that target multiple essential pathways in M. tuberculosis (Figure 1.1).  
Isoniazid and rifampin are key components of this regimen, administered 
for the full 6 months. Isoniazid (INH) targets cell wall synthesis, disrupting the 
production of mycolic acids (16, 17). INH is a pro-drug activated by the bacterial 
catalase-peroxidase KatG to form INH-NAD adducts. These INH-NAD adducts 
target the enzyme InhA (18, 19), the NADH dependent eonyl-ACP reductase 
involved in the fatty acid synthase type II system (FASII) (20, 21). Inhibition of 
InhA by INH leads to the accumulation of long-chain fatty acids, prevention of 
mycolic acid biosynthesis and cell death (17, 22). Rifampin (RIF) is a broad-
spectrum transcription inhibitor. RIF binds the -subunit of the DNA-dependent 
RNA polymerase and blocks the initiation of transcription (23-26) and has 
bactericidal affects against M. tuberculosis.  
Ethambutol and pyrazinamide are important in the first 2 months of 
treatment to prevent resistance development and enhance early sterilization. 
Ethambutol (EMB), another cell wall synthesis inhibitor disrupting 
arabinogalactan production (27), targets the emb operon. This operon encodes 
three arabinosyl-transferases involved in the production of arabinan chains for 
both arabinogalactan and lipoarabinomannan (LAM) (27-29), resulting in growth 
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arrest. Pyrazinamide (PZA) is a pro-drug activated by the bacterial 
pyrazinamidase PncA to form pyrazinoic acid (POA) (30, 31) resulting in strong 
sterilizing activity against M. tuberculosis when combined with INH (32). PZA 
displays poor in vitro potency which has made identification of its mechanism of 
action difficult, although several have been proposed (33-39). Most recently, it 
has been observed that POA binds to the aspartate decarboxylase PanD (40-
44), which has an essential role in the biosynthesis of coenzyme A (45). 
Inhibition of PanD by PZA results in reduction of coenzyme A followed by 
accumulation of fatty acids, affecting central carbon metabolism (42). The diverse 
targets of these antibiotics result in multiple toxicities for the bacteria and, when 










              
Figure 1.1 | Mechanisms of first-line TB antibiotics. 
 
The current treatment for DS-TB infections, while effective, is not ideal. Six 
months of treatment with multiple antibiotics is difficult for patients due to 
significant side effects and the challenge of adhering to the regimen for such an 
extended time (46-48). Relapse rates are often explained by poor adherence; 
however, even with directly observed therapy (DOT) or under stringent 
observation in clinical trials, treatment fails in approximately 10% of cases (49). 
Insufficient treatment contributes to the overall global burden of TB as well as the 
development of resistant infections. Understanding how M. tuberculosis survives 
such lengthy treatment regimens is a major goal of the TB field, both to gain 






Strategies to survive antibiotic treatment 
Inherent properties of Mycobacterium tuberculosis 
Due to the early observation that many compounds have little success in 
TB treatment, decades of work has been done to investigate the inherent 
resistance properties of M. tuberculosis. The presence of a lipid-rich, thick cell 
wall, creates a strong barrier that limits antibiotic entry into the cell. Certain 
antibiotics are pumped out of the cell by transporters or targeted by bacterial 
enzymes that modify them and prevent activity. Additionally, the host response to 
infection can negatively impact therapy through the formation of inflammatory 
lesions that reduce drug penetration. These physiological conditions prevent the 
use of many common antibiotics and also limit the efficacy of current TB 
therapies. As the development of genetic resistance renders certain therapies 
ineffective, an understanding of inherent resistance mechanisms, discussed 
below, is critical for the development of new antibiotics. 
 Cell wall permeability. The main components of the cell wall include the 
cytoplasmic membrane, the periplasm, the mycomembrane, and surface lipids. 
The high lipid composition of the cell wall presents a barrier to hydrophilic 
compounds. Early investigation of diffusion of compounds across bacterial 
membranes observed that mycobacterium membranes are three orders of 
magnitude less permeable than gram-negative membranes (50). Mycolic acids, 
the main component of the mycomembrane, make up 34% of the membrane 
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weight (51), reducing membrane fluidity (52, 53). Overall, this cell wall structure 
produces a thick, hydrophobic, rigid barrier to many small molecules. 
 Efflux pumps. Transporters spanning the membrane to efflux small 
molecules are a method of defense utilized by many bacteria, including M. 
tuberculosis. A large number of efflux pumps are encoded in the M. tuberculosis 
genome in comparison to other organisms (54). Multidrug transporters in M. 
tuberculosis have been studied since the 1990s and are known to efflux multiple 
distinct classes of antibiotics (55-58). Efflux pump expression can be induced 
under multiple different conditions such as intracellular growth, environmental 
stresses, and antibiotic treatment (59-62). A number of these pumps are 
expressed at elevated levels in clinical isolates (63). Using pump inhibitors as a 
combination therapy to treat TB is of great interest given the clinical impact of 
these transporters (64). 
 Enzymatic inhibition. Shortly after the introduction of penicillins, it was 
observed that M. tuberculosis was unaffected by this class of antibiotics (65). 
Later work would show that this inherent resistance is due to the expression of a 
-lactamase, BlaC, which degrades some -lactams (66-68). -lactamase 
inhibitors in combination with -lactams can re-sensitize -lactam-resistant 
bacteria. This treatment approach has gained interest in treatment of M. 
tuberculosis as antibiotic resistance has increased and new effective regimens 
are needed (69). Another enzymatic defense used by M. tuberculosis is the 
expression of Erm(37), a methyltransferase which methylates the 23S rRNA 
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resulting in intrinsic resistance to macrolides (70, 71). Both the modification of 
antibiotics and of antibiotic targets are successful defense strategies by the 
bacteria that need to be overcome during the development of new treatment 
regimens. 
 Pathology. The host response to infection also complicates TB treatment. 
Following infection with M. tuberculosis, the immune system is activated. Cells 
are recruited to the site(s) of infection, forming lesions surrounding infected 
tissue. These lesions, known as granulomas, play a complex role in infection by 
both working to control bacterial growth by enclosing infected cells and also 
aiding in transmission upon break-down and release of necrotic tissue (72, 73). 
Lesions also impact effective antibiotic treatment as antibiotics must penetrate 
the multiple layers of cell types to reach the bacteria (74). While RIF and PZA are 
able to efficiently accumulate in lesions at minimum inhibitory concentration 
(MIC) levels, INH only accumulates in 65 percent of lesions (74). However, RIF 
and PZA are only administered together for the first two months of therapy. 
Therefore, during the continuation phase of INH and RIF there may be transient 
monotherapy in these lesions. Additionally, recent studies have shown that 
individual antibiotics sterilize lesions variably and at different rates (75). Both 
decreased concentration of antibiotics and transient monotherapy limit the 
effectiveness of treatment and potentially increase the development of 
resistance. Identification of antibiotics which successfully penetrate lesions is 




 Resistance to the antibiotics used for TB was observed shortly after the 
introduction of the first treatment regimen (8). In 2018, an estimated half a million 
new cases of drug-resistant TB were reported globally (5). Treatment of drug-
resistant infections requires longer regimens with more toxic antibiotics and has 
decreased success rates compared to DS-TB (5). Lack of evidence of horizontal 
gene transfer (HGT) in pathogenic M. tuberculosis indicates that all resistance-
conferring mutations occur de novo during infection. Here, I will discuss the 
mechanisms of genetic resistance observed for each of the first-line antibiotics 
used to treat DS-TB. 
 Isoniazid. Early investigators of INH resistance observed decreased 
catalase activity in resistant isolates. In the 1990s, genetic experiments identified 
KatG as the INH-activating catalase-peroxidase and that mutations in the katG 
gene confer INH resistance (76, 77). Shortly after, katG mutations were identified 
in resistant clinical isolates (78-80). Mutations in katG are the most common 
resistance-conferring mutations, specifically the mutation S315T (81). While 
deficient in the activation of INH, these mutants retain essential catalase-
peroxidase activity which may be advantageous in vivo (82). Mutations in the 
target of INH, inhA, are also present in resistant isolates. Most commonly, 
promoter mutations leading to overexpression of inhA are found (83). Mutations 
located in the open reading frame confer resistance via a decrease in affinity for 
INH-NAD binding (81, 83, 84). Additionally, mutations disrupting formation of 
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INH-NAD adducts also cause resistance. Observed mutations in ndh, encoding 
the type II NADH dehydrogenase, lead to NADH accumulation and competitive 
inhibition of InhA binding (83, 85, 86). Additional genes have been identified in 
INH resistant strains; however, many of these mutations are rare or found only in 
strains containing more common resistance-conferring mutations (87). Due to 
resistance-conferring mutations occurring in multiple locations in the genome, 
INH susceptibility testing is performed phenotypically. 
 Ethambutol. Resistance to EMB is most commonly caused by mutations 
within the emb operon (88). Multiple mutations in embA, embB, and embC were 
observed in resistant clinical isolates and transformation of these mutations into 
susceptible isolates conferred EMB resistance (89, 90). The most frequently 
observed clinical mutations are in embB (88-90). Additionally, EmbB306 
mutations have been shown to alter susceptibility to other antibiotics, such as 
INH and RIF, and are found in strains containing additional resistance-conferring 
mutations (91, 92), indicating that these mutations potentially provide a stepping 
stone for progressive resistance development. While a majority of EMB resistant 
strains contain mutations in the emb operon, mutations in other genes and 
regions have also been identified (88), potentially complicating phenotypic and 
molecular susceptibility testing for EMB. 
Rifampin. High-level RIF resistance is confined to mutations within a 
region in the -subunit of the RNA polymerase, known as the rifampin resistance-
determining region (RRDR). Mutations in the M. tuberculosis rpoB gene, 
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encoding the -subunit, was first described in 1993 through PCR-analysis of 
resistant clinical isolates (93). Due the specificity of the location of these 
mutations, PCR-based susceptibility testing was soon introduced (94), and 
molecular testing for RIF resistance remains the current standard. While RNA 
polymerase mutations result in fitness costs for the bacteria (3, 95), these deficits 
can be alleviated by compensatory mutations which have been identified in rpoA 
and rpoC in clinical isolates (96). RIF resistance is highly associated with MDR 
infections. Therefore, due to the speed and efficiency of molecular testing, a 
majority of RIF-resistant infections are categorized as MDR when choosing 
treatment regimens. 
Pyrazinamide. Loss of pyrazinamidase activity in PZA resistant M. 
tuberculosis strains is a known resistance mechanism (30). The bacterial 
pyrazinamidase PncA, the activator for PZA, is the most commonly mutated gene 
in PZA resistant strains (31, 97, 98). PncA is non-essential for bacterial survival 
and mutations are observed throughout the entire gene; however, three regions 
associated with the active site are the most commonly mutated (97, 99, 100). 
Mutations in additional genes outside of pncA, including rpsA and panD, have 
been observed in rare cases (36, 101-103). Although PZA is a critical component 
in TB treatment, susceptibility testing is not ideal due to poor in vitro efficacy of 
PZA. Testing requires acidified media and low bacterial density, resulting in 
inconsistent and false resistance results (104). Despite these challenges, 
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molecular testing is less sensitive than most phenotypic tests and, therefore, not 
recommended (105). 
M. tuberculosis has evolved genetic resistance for each of the first-line 
antibiotics used to treat DS-TB which negatively affects patient outcomes and the 
spread of disease. Additionally, resistance to the second-line and injectable 
antibiotics used to treat multi-drug resistant (MDR-TB) and extensively-drug 
resistant (XDR-TB) infections is now common. Treatment of these resistant 
infections requires longer regimens with more toxic and expensive antibiotics, 
increasing the global health burden of TB. 
 
Tolerance 
 Antibiotic tolerance is a bacterial survival strategy. In this case, non-
resistant populations have decreased antibiotic sensitivity, resulting in the 
requirement of prolonged therapy to achieve successful treatment and the 
prevention of relapse. Experimentally, tolerant populations do not have different 
minimum inhibitory concentrations (MIC), but alterations in minimum bactericidal 
concentrations (MBC) and rate of killing (106, 107), as first described in 1970 
(108). Early observation of tolerance phenotypes described the clinical 
implications of the decreased efficacy of cell wall inhibitors against slow and non-
growing bacterial populations in multiple organisms (106, 109-111). Antibiotic 
tolerance can be phenotypically regulated through mechanisms resulting in 
physiological changes or genetically controlled. A common example of genetic 
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tolerance is the use of phase and antigenic variation to produce heritable 
tolerance in bacterial populations, which can occur via multiple mechanisms, 
such as slip-strand-mispairing (SSM), recombination, and epigenetic regulation 
(112). Antibiotic tolerance has been described in M. tuberculosis populations 
(113), and is a major contributing factor to the need for lengthy treatment. I will 
discuss the known mechanisms of antibiotic tolerance in M. tuberculosis below. 
Slow growth and dormancy. Differences in antibiotic efficacy between 
growing and non-growing bacteria were observed as early as 1957 (114, 115). 
M. tuberculosis is inherently a slow-growing organism, with a doubling time of 
approximately 20 hours in vitro which greatly slows to approximately 100 hours 
during infection (116, 117). Growth rate also varies based on asymmetrical cell 
growth and division, resulting in differential susceptibility to certain antibiotics 
(118). Additional observations of heterogeneity in daughter cells further 
implicates cell division as a mechanism of tolerance in M. tuberculosis (119). 
Different environments encountered during infection, such as hypoxia and 
nutrient deprivation, lead to non-replicating, metabolically active bacterial 
populations (120-125). Cell wall remodeling is a major adaptation in these 
environments through mechanisms such as alterations to peptidoglycan cross-
linking and cell wall thickening (126, 127). These changes result in reduced drug 
uptake, leading to drug tolerance (128). Identification of new antibiotics which 
target both replicating and non-replicating populations remains a major goal in 
the improvement of TB treatment. 
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 Metabolism alterations. A unique characteristic of M. tuberculosis is its 
ability to co-catabolize multiple different carbon sources feeding into distinct 
pathways (129). The current knowledge of M. tuberculosis central carbon 
metabolism under different environmental conditions has been gained through a 
combination of genomics, transcriptomics, metabolomics and systems modeling 
(129-136). Previous work has shown that, during infection, bacteria utilize fatty 
acids as a main carbon source (132, 133, 137-140). In response to 
environmental stresses, such as hypoxia, there is a change in carbon flux and an 
accumulation of triacylglycerol (TAG) which is used as a fatty acid source (135, 
141, 142). TAG accumulation decreases metabolic activity which affects 
antibiotic activity. M. tuberculosis mutants in this pathway are more sensitive to 
multiple antibiotics, and the enzymes involved can be targeted with small 
molecules, resulting in killing (143, 144). Targeting the carbon flux of M. 
tuberculosis could reduce antibiotic tolerance, providing a new avenue for drug 
development. 
Genetic tolerance. Genetic tolerance in M. tuberculosis has recently been 
investigated using strains with mutations associated with clinical resistance 
(145). Transcription factor prpR mutants are significantly associated with clinical 
INH-resistance. Under antibiotic treatment these mutations result in an increase 
in the minimum duration of killing (MDK) compared to wild-type strains, indicating 
these strains are antibiotic tolerant (145). Genetic tolerance mediated by phase 
variation has been observed in certain mycobacterial species (146, 147). 
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However, phase variation has not been observed in M. tuberculosis, and its 
potential role in antibiotic tolerance is currently unknown. Whole-genome 
sequencing (WGS) studies of M. tuberculosis clinical isolates to identify single 
nucleotide polymorphisms (SNPs) associated with resistance phenotypes (145, 
148-150) could aid in the identification of genetic mutations that prolong survival 
under treatment.  
 
Thesis objectives 
 The aim of this work is to better understand how M. tuberculosis survives 
the long and complex treatment regimen. Although antibiotic treatment for TB 
infections has been used since the 1940s, we still do not fully understand the 
physiology of the bacteria during treatment, thus limiting the development of new 
antibiotics and treatment regimens. Significant progress has been made, as 
discussed above; however, much of this work has been performed under defined 
conditions. M. tuberculosis, an obligate intracellular pathogen, encounters many 
different environments and stresses throughout infection which are impossible to 
replicate in vitro. To probe mechanisms of survival in complex host 
environments, I utilized an unbiased, comprehensive genetic approach and the 
mouse model of TB to identify M. tuberculosis mutants with altered susceptibility 
to antibiotic treatment during infection. Specifically, I aim to:  
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1. Identify mutants with altered susceptibility to DS-TB combination 
therapy to gain insight into prolonged survival under complex treatment 
regimens. 
2. Assess mutant fitness under treatment with individual antibiotics to 
identify both drug-specific and broad mechanisms of antibiotic 
tolerance in M. tuberculosis. 
 
Together these data and analyses will provide insights into M. tuberculosis 
physiological state under antibiotic pressure, contributing to the understanding of 
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The currently used multidrug chemotherapy regimen for tuberculosis (TB) 
was developed in a series of clinical trials in the 1980s (14) and remains the 
standard of care for this disease (15). Infections with drug-sensitive strains of 
Mycobacterium tuberculosis are treated with a 6-month regimen that includes 
four drugs, isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol 
(EMB). While this regimen cures 90% of drug-sensitive cases, the long period 
over which antibiotics must be administered represents a major limitation. Not 
only is a complete regimen difficult to deliver, but even in clinical trial settings, 
incomplete sterilization leads to relapse in a significant fraction of patients (49). 
The emergence of drug-resistant strains of M. tuberculosis further confounds 
therapy and necessitates even longer regimens with less effective drugs. 
The factors that necessitate this extended drug regimen for TB remain 
difficult to dissect because the in vitro efficacy of individual drugs does not predict 
their effect during infection. For example, PZA is critical for sterilizing an infected 
host, but it has very modest activity in vitro, where it may act via different 
mechanisms (151). Conversely, both INH and RIF cause relatively rapid cell 
death in vitro but kill bacteria much more slowly during infection. As a result, 
virtually all TB drug regimens kill bacteria at a lower rate during infection than 
they do in axenic culture. Two general mechanisms have been proposed to 
explain the generally drug-tolerant phenotype that is observed during infection. 
Growth in mammalian tissue triggers changes in mycobacterial gene expression 
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and metabolism that can reduce drug efficacy (61, 143, 152). In addition, a 
number of distinct stochastically generated subpopulations have been observed, 
which arise either via asymmetric cell division (118) or nonheritable regulatory 
events (119). Some of these subpopulations are relatively insensitive to 
antibiotics in vitro and could prolong the treatment period necessary for 
sterilization. While none of these mechanisms involve heritable genetic changes, 
many other bacteria rely on high-frequency reversible genetic variation to 
produce subpopulations that are tolerant to environmental insults (112). This 
process of phase variation generally relies on specific DNA sequences, such as 
homopolymeric regions, that are subject to frequent mutation. While phase 
variation has been observed in several mycobacterial species (146, 147), it has 
not been specifically characterized in M. tuberculosis, and its potential role in 
determining drug efficacy is unknown. 
To understand the processes that determine drug efficacy during infection, 
we employed two complementary approaches. A forward genetic study identified 
bacterial functions that alter drug efficacy in mice. In parallel, whole-genome 
sequence analysis of M. tuberculosis clinical isolates identified genetic variants in 
candidate genes that are associated with resistance. Together, these 
approaches defined a variable homopolymeric region in the glpK gene that 
controls glycerol metabolism and drug efficacy. Heritable genetic variation at this 
site produces a drug-tolerant phenotype that reduces treatment efficacy and is 




Genetic determinants of drug efficacy in the mouse model  
To specifically define bacterial functions that limit efficacy during infection, 
we used transposon sequencing (TNseq) to identify mutations that alter bacterial 
killing. Groups of mice were infected with a nearly saturated library of M. 
tuberculosis transposon mutants via the intravenous route. After allowing 2 
weeks for bacterial growth and the establishment of adaptive immunity, animals 
were treated with a regimen based on first-line TB chemotherapy, a mixture of 
INH, RIF, PZA, and EMB (HRZE) (Figure 2.1A). Each drug in this regimen was 
shown to be effective individually at the dose given, and the four-drug mixture 
reduced organ burden by more than 100-fold after 14 days of treatment (Figure 
2.1B). To identify mutations with relatively rapid effects on bacterial killing by 
antibiotics, mutant pools were recovered from the spleen after 1 week of therapy 
by plating organ homogenates. This analysis was performed in the spleen 
because this organ contained an adequate bacterial population size to ensure 
that complexity of the library was maintained throughout the infection. In vivo-
selected libraries were compared to each other using TNseq, which quantifies 
the relative abundance of each mutant in a given pool by sequencing all the 




Figure 2.1 | Antibiotic treatment of M. tuberculosis infected mice. 
 A, Spleen CFU from BALB/c mice infected with transposon mutant library both 
untreated (circles) and after HRZE treatment (squares). Antibiotic treatment was started 
at 14 dpi (indicated by gray arrow). Plotted means from 3 biological replicates with 
standard deviations are shown. B, Change in CFU after treatment with the indicated 
antibiotic for 5 weeks. The change in CFU between pretreatment and posttreatment 
samples is presented. Significance was calculated using unpaired t test: *, P = 0.03; **, 
P = 0.002; ***, P = 0.0002; ****, P < 0.0001. 
 
 
Mutant pools were collected from three groups of animals. A pretreatment 
pool was collected immediately before drug administration. One week later, pools 
from antibiotic-treated or untreated groups were collected. This study design 
allowed the relative fitness of each bacterial mutant to be assessed in the 
presence and absence of drug therapy. Pairwise analyses of the treated and 
untreated pools with the pretreatment library identified distinct sets of genes that 
altered bacterial representation under each condition (Appendix Tables A2.1 – 
A2.3). As many antibiotics act in a growth rate-dependent manner, we 







Figure 2.2 | Genetic strategy to define bacterial functions that limit drug efficacy. 
A, Relative abundance of individual mutants, measured by log2 fold change, in untreated 
mice (x axis) and HRZE-treated mice (y axis). Significantly altered mutants after 
treatment are indicated in black. B, Functional classes of mutants with altered 
susceptibility in vivo. Classification from Mycobrowser. C-F, Normalized abundance of 
mutations in pretreatment (black) and after HRZE treatment (red) at individual TA 
dinucleotide insertion sites in pncA (C) ppe50-ppe51 (D) glgA-glgC (E) and glpK (F). 
Shown are the average numbers of unique sequence reads (y axis) plotted versus TA 
sites (x axis). 
 
When the relative abundance of each mutant in untreated animals was 
compared with their abundance in time-matched drug-treated mice, we found no 
global correlation between bacterial fitness in the presence and absence of 
antibiotic (Figure 2.2A). However, several individual mutations were observed 
that reduced fitness under both conditions. Thus, to more formally focus our 
study on drug-related phenotypes, we performed a three-way analysis to identify 
those mutations that alter fitness preferentially in antibiotic-treated animals. This 
analysis defined 61 mutants that increased, and 8 that reduced, the effect of 
therapy (Appendix Tables A2.4 and A2.5). These mutants corresponded to a 
variety of functional pathways (Figure 2.2B). In several cases mutation resulted 
in dramatic alterations in fitness after drug exposure, as the relative 
representation of these mutants under the pre- and posttreatment conditions 
varied by more than 100-fold. 
A number of functions found to alter bacterial fitness in drug-treated mice 
were already known to impact drug efficacy. For example, mutants lacking PncA, 
which converts PZA into its active pyrazinoic acid form (31), were highly 
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overrepresented in the treated mice, highlighting the singular importance of PZA 
in the activity of this regimen (Figure 2.2C). In addition, we found that mutations 
in mmaA1, mmaA2, and cmaA2 sensitized the bacterium to drug treatment. All of 
these genes encode functions necessary for mycolate modification, and chemical 
inhibition of these partially redundant activities has been shown to increase 
cellular permeability to antibiotics (154). Additional protein families associated 
with cell wall structure altered drug efficacy. PE/PPE family members have been 
implicated in cell envelope integrity (155), and we found that mutations in the 
ppe50-ppe51 pair increased killing (Figure 2.2D). Conversely, the loss of 
enzymes (ppsA, ppsC, and drrA) necessary for the synthesis of the major cell 
envelope lipid, phthiocerol dimycocerosate, decreased clearance. Drug access 
appeared to be similarly limited by multiple classes of efflux pumps, as mutations 
in members of the ATP-binding cassette (rv1747), major facilitator superfamily 
(rv3728), and MmpL (mmpL8 and mmpL10) families were found to increase 
bacterial clearance (Appendix Table A2.4). 
In addition to these known mechanisms, we identified a number of novel 
functions that altered bacterial killing. Prominent among these were pathways 
involved in carbon metabolism. For example, mutation of both assayable steps of 
the glycogen synthetic pathway (glgA and glgC) increased antibiotic activity 
(Figure 2.2E). This pathway promotes carbon storage through carbohydrate 
anabolism, a general process that has been previously implicated in drug 
tolerance (143). In addition, we identified the glpK gene, which encodes the sn-
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glycerol-3 kinase of M. tuberculosis. Twenty-six of the 29 insertional mutants in 
this gene showed a similar decrease in clearance rate upon drug treatment 
(Figure 2.2F). When pools isolated before and after treatment were directly 
compared, only pncA mutations produced a statistically significant reduction that 
was greater than those in glpK (Figure 2.3). This relatively dramatic phenotype 
was explored in more detail. 
  
  
Figure 2.3 | Genes with altered susceptibility to HRZE treatment in vivo. 
Log2 fold change of individual mutants (gray dots) 1 week posttreatment compared to 
pretreatment. Significantly altered mutants are indicated by black circles. 
 
 
Glycerol metabolism increases drug efficacy in vitro and during murine 
infection 
GlpK is responsible for phosphorylating the 3-position of glycerol, which is 
necessary for its catabolism via the lower glycolytic pathway. To determine if 
glycerol catabolism per se was capable of enhancing the activity of TB drugs, the 
effects of INH, RIF, and moxifloxacin (MOX) were compared in media containing 
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glycerol or other carbon sources known to be used during infection, fatty acid and 
cholesterol (132, 156). These carbon sources supported different growth rates, 
which can confound endpoint- based determinations of antibiotic activity, such as 
standard MIC measurements. As a result, we quantified the growth rate (GR) of 
bacteria over a time course and determined the concentration of each drug that 
was necessary to decrease this rate by 50%, which is expressed as GR50 (157). 
Using this approach, we found that glycerol catabolism produced a modest but 
reproducible decrease in the GR50 for several drugs. Growth in glycerol 
significantly increased the efficacy of RIF and MOX compared to growth in 
valerate and enhanced the efficacy of INH and MOX compared to growth in 
cholesterol (Figure 2.4). 
  
  
Figure 2.4 | Glycerol metabolism broadly increases drug efficacy in vitro. 
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Top left, Growth of H37Rv on cholesterol and treated with moxifloxacin at the indicated 
concentrations. Growth was measured by yellow fluorescent protein (YFP) fluorescence. 
Top right, GR50 for moxifloxacin (MOX) in medium containing either glycerol, valerate, 
or cholesterol. Bottom, GR50 ratios for INH (circles), RIF (squares), and MOX (triangles) 
grown on different carbon sources. Shown are valerate/glycerol (left) and 
cholesterol/glycerol (right). Significance was calculated using one-sample t test with a 
theoretical mean value of 0: *, P = 0.05; **, P = 0.01. 
  
To further investigate the role of glycerol metabolism in drug efficacy, a 
glpK deletion mutant of M. tuberculosis was constructed. The ΔglpK mutant was 
unable to grow in media containing glycerol as the sole carbon source (Figure 
2.5A), indicating that the deleted gene encodes the sole glycerol-3 kinase 
activity. The effect of antibiotics on the growth rates of glpK-sufficient and glpK-
deficient strains was then compared in media containing different carbon 
sources. When glycerol was present in the medium, the ΔglpK mutant was 
significantly less sensitive to INH and RIF than the wild-type or the 
complemented mutant (Figure 2.5B). This difference largely disappeared when 
glycerol was replaced with either the nonglycolytic substrate, butyrate, or a 
glycolytic product that bypasses the triose phosphate pool, pyruvate. The 
differential effects of these carbon sources indicated that the assimilation of 
exogenous glycerol was primarily responsible for glpK’s influence on drug 
sensitivity. PZA sensitivity was assessed at pH 5.8 to maximize the in vitro 
efficacy of the drug. However, under these conditions, glpK deletion did not alter 
PZA sensitivity. As INH, RIF, and MOX have distinct mechanisms of action, the 
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effect of glycerol catabolism on antibiotic activity in vitro did not appear to be 
specific to a particular drug or target pathway. 
 
  
Figure 2.5 | ∆glpK antibiotic susceptibility in vitro. 
A, Growth kinetics of H37Rv (circles), ∆glpK (triangles), and complement (squares) 
strains on glucose (left) and glycerol (right). Plotted means from 3 biological replicates 
with standard deviations are shown. B, Growth of H37Rv (black bars), ΔglpK (gray bars), 
and complement glpK (striped bars) strains after treatment with INH or RIF in media 
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containing glycerol, butyrate, or pyruvate and PZA in media containing glycerol or 
dextrose at pH 5.8. Growth was assessed by the growth constant, k, normalized to no-
antibiotic controls and plotted as ratios (treated/untreated), where 1 is the growth 
constant without antibiotic (indicated by a dotted line). Antibiotic concentrations started 
at 2 g/ml, 1 g/ml, and 400 g/ml for INH, RIF, and PZA, respectively, and were serially 
diluted 2-fold for 6 dilutions. Significance was calculated using an unpaired t test with 
Benjamini-Hochberg multiple-testing correction. *, P = 0.03; **, P = 0.002; ***, P = 
0.0002; ****, P < 0.0001. 
 
The mouse model was then used to explore the role of glpK during 
infection. Consistent with both our TNseq data and previous work (158), deletion 
of the glpK gene did not affect the growth or persistence of M. tuberculosis in the 
lungs of mice after aerosol infection (Figure 2.6A). To quantify the effect of glpK 
deletion on the efficacy of individual drugs, mice were inoculated via the 
intravenous route with a mixture of wild-type and ΔglpK bacteria and treated with 
antibiotics, as was done for the initial TNseq screen. Another mutant lacking the 
ppe51 gene, which TNseq predicted to be hypersensitive to multidrug treatment 
(Figure 2.2D), was included as an additional control. Since this study did not 
require maintaining the complex mutant mixture needed in the TNseq study, 
more prolonged treatment regimens could be used. As we observed previously, 
all drug regimens reduced the bacterial burden, and PZA or combination therapy 
had the greatest effect (Figure 2.6B). Surviving bacteria were recovered by 
plating at the indicated time points, and the relative abundance of the three M. 
tuberculosis strains was determined by quantitative PCR. Both mutants 
demonstrated the predicted phenotypes in animals treated with the four-drug 
combination therapy for 2 weeks, as the ΔglpK mutant was cleared significantly 
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more slowly and the Δppe51 mutant significantly more rapidly than the wild-type 
(Figure 2.6C). These phenotypes were even more pronounced in animals treated 
with PZA alone. In contrast to the broadly sensitizing effect of glycerol catabolism 
in vitro, the ΔglpK mutant behaved similarly to the wild type in mice treated with 
RIF, INH, or EMB. 
 
   




A, Lung CFU of H37Rv (circles) and ∆glpK (triangles) strains from BALB/c mice after 
aerosol infection with a dose of 500 to 700 CFU/mouse. Shown are plotted means from 
4 biological replicates with standard deviations. B, Spleen CFU from BALB/c mice after 
intravenous infection with pooled mutant strains both untreated (black circles) and 
treated with the indicated antibiotic. Plotted means from 4 biological replicates with 
standard deviations are shown. C, Relative abundance of ΔglpK (top) and Δppe51 
(bottom) strains compared to that of the wild-type in vivo after antibiotic treatment. 
Treatment times were 14 days for PZA and MIX, 28 days for RIF, and 35 days for INH 
and EMB. Individual points are biological replicates normalized to day 0 ratios. 
Significance was calculated using unpaired t test with Benjamini-Hochberg multiple 
testing correction: *, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001. D, Lung 
CFU of H37Rv, ΔglpK, and complement strains from BALB/c mice after aerosol infection 
and treatment with PZA. Data represent two competition infections: 1:1 H37Rv and 
ΔglpK (black and blue circles, respectively) strains, dose of 700 to 1,000 CFU/mouse, 
and 1:1 H37Rv and complement (black and gray squares, respectively) strains, dose of 
300 to 500 CFU/mouse. Treatment with PZA was started at 21 dpi and continued to 35 
dpi. Shown are plotted means and standard deviations, and individual points are 
biological replicates. Limits of quantification are indicated by dotted red lines. 
Significance was calculated using unpaired t test with Benjamini-Hochberg multiple 
testing correction: *, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001; ns, not 
significant. 
 
The decreased efficacy of PZA against the ΔglpK mutant was also found 
in the lungs of mice infected via aerosol. In this model, treatment with PZA 
between 21 and 35 days post infection reduced the bacterial burden of wild-type 
and ΔglpK complemented strains by at least 1,000-fold but had a significantly 
reduced effect on the glpK-deficient mutant (Figure 2.6D). Thus, while glycerol 
catabolism can nonspecifically alter antibiotic susceptibility in vitro, glpK deletion 
preferentially reduced the effect of PZA and a PZA-containing multidrug regimen 





Glycerol catabolic defects are associated with extensive drug resistance in 
Korea  
As the glpK deletion did not alter bacterial fitness during infection and 
conferred a benefit upon drug treatment, we hypothesized that mutations altering 
glycerol catabolism are positively selected during the evolution of drug resistance 
in natural populations. As a first test of this hypothesis, we characterized a panel 
of Korean M. tuberculosis isolates that varied in drug sensitivity profiles, from 
fully sensitive strains to extensively evolved clones that were phenotypically 
resistant to more than ten different antibiotics (Appendix Tables A2.6 and A2.7). 
To investigate whether glycerol catabolic defects were selected during the 
evolution of resistance in these strains, we subcultured a random subset of drug-
sensitive or extensively resistant isolates in media containing glycerol as the sole 
carbon source. Drug-sensitive strains grew at a rate similar to that of a standard 
laboratory strain (H37Rv). However, while the extensively drug-resistant isolates 
could grow in butyrate, none of the tested isolates could grow in the glycerol-
















Figure 2.7 | Growth of extensively 
drug-resistant strains on individual 
carbon sources. 
 
Growth kinetics of drug-susceptible (DS) 
and drug-resistant (DR) clinical isolates 
on glycerol- or butyrate-containing media. 
Shown are plotted means from 3 











The whole-genome sequences (WGS) of these isolates were determined. 
Based on WGS, this collection was predominantly comprised of a Korean 
sublineage of East Asian strains (159), and the multidrug-resistant (MDR) 
phenotypes could generally be attributed to known high-level resistance-
conferring mutations. Inspection of the WGS data revealed that the glycerol 
catabolic defect in 9 of the 11 tested strains could be attributed to loss-of-function 
mutations in the glpK gene (Appendix Table A2.8). These strains all harbored a 
one-base expansion of the same homopolymeric sequence (GGGGGGG) in the 
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5 half of the glpK open reading frame. The sequence of the glpK homopolymer 
was verified in the entire panel by targeted Sanger sequencing (Figure 2.8A). 
This mutation is predicted to eliminate GlpK enzymatic activity, as it introduces a 
premature termination codon that eliminates the majority of the open reading 
frame, and the same homopolymer expansion has been previously observed in 
M. bovis strains lacking glycerol kinase activity (160). An additional missense 
mutation altering amino acid 169 was identified in an otherwise glpK wild-type 
allele, but the functional significance of this mutation is unclear. Two of the 
phenotypically glycerol-deficient strains carried no obvious mutations in glpK or 
other glycerol catabolic genes. Thus, while glpK frameshifts appear to be the 
most common lesion associated with glycerol catabolic defects in this collection, 
other mechanisms contribute in a fraction of isolates. 
All ten of the glpK frameshifts identified in this panel were found in 
multidrug- resistant strains, particularly the highly evolved strains that were 
resistant to more than eight different drugs (Figure 2.8B). Based on the 
phylogenetic relationship between these strains, the identified glpK frameshifts 
represent at least three independent mutational events. Alternative tree 
topologies necessary to accommodate fewer mutational events were significantly 
less likely (P < 10 −4 ). Thus, in this relatively small collection of strains, 
inactivating mutations in glpK were frequent and associated with defective 






Figure 2.8 | Glycerol catabolic mutations associated with XDR strains. 
A, Sanger sequencing of glpK from H37Rv and clinical isolate KT0149-1. The 
homopolymer region is in the first domain of the protein. One-bp insertion changes 
downstream amino acid sequence and introduces a premature stop codon at amino acid 
252. B, Phylogenetic tree of M. tuberculosis isolates from Korea with various drug 
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susceptibility profiles: DS (orange); DR, 1 to 4 antibiotics (blue); DR, 5 to 7 antibiotics 
(green); and DR >7 antibiotics (red). Mutations in glpK gene are indicated: frameshift 
mutations, purple stars; missense mutations, purple circles. 
 
GlpK frameshift mutations are common in M. tuberculosis isolates and 
associated with drug resistance in Peru 
Frameshift mutations in homopolymeric DNA sequences can represent 
high-frequency and reversible events (112). To assess the frequency of this 
mutation in a larger population and to further explore its association with drug 
resistance, we analyzed the whole-genome sequences of a larger collection of 
isolates from Peru. Of 1,031 sequenced strains, 68 isolates harbored 
nonsynonymous variants in the glpK gene. Of these, 45 contained a single-base 
expansion of the glpK homopolymer and 2 contained a two-base expansion. 
These frameshifts were found in all phylogenetic clades of M. tuberculosis, 
indicating that this mutation has arisen through multiple distinct mutational events 
in different lineages of the pathogen (Figure 2.9A and B). In total, homopolymer 
expansion accounted for 66% of the nonsynonymous glpK variants, and 4.6% of 
all isolates harbored frameshift mutations disrupting the glpK open reading 
frame. 
As we found in the smaller set of Korean strains, glpK frameshifts were 
significantly associated with drug resistance. No instances of glpK frameshifts 
were found in the 90 phenotypically drug-sensitive strains. In contrast, 44 of the 
739 isolates that met the WHO criteria for MDR carried these mutations (P = 3 x 
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10−5 ). In this large collection, we were also able to test the association between 
glpK genotype and resistance to individual drugs and found significant 
associations with RIF, INH, and ethionamide (ETH) (Figure 2.9C). The lack of 
observed association with PZA resistance could have been due to the 
unreliability of this phenotypic assay. Indeed, using a genotypic assay we found a 
significant association between glpK frameshifts and nonsynonymous pncA 
variants (P = 0.001). Thus, the glpK homopolymer is the site of the majority of 
variation in this gene, and expansion of this hypervariable region is associated 
with the evolution of drug resistance. 
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Figure 2.9 | GlpK mutations associated with drug resistance in clinical isolates 
from Peru. 
A, Phylogenetic tree of M. tuberculosis isolates from Peru. GlpK mutations are indicated 
(red circles). B, Representation of GlpK mutations in different lineages: lineage 
distribution of 1,031 GWAS samples (outer); distribution of 68 glpK mutations (middle); 
distribution of 45 single-base expansions, T57GT, of the glpK homopolymer (inner). C, 
Association between glpK mutations and drug resistance. Statistical significance (*) 
based on Bonferroni correction with a type 1 error rate of 0.01. INH, isoniazid; RIF, 
rifampin; RBU, rifabutin; EMB, ethambutol; PZA, pyrazinamide; STR, streptomycin; LIN, 





Drug tolerance has been proposed to contribute to both relapsing TB 
disease and the emergence of drug-resistant clones (161). Most current models 
to explain tolerance in mycobacteria are largely restricted either to nonheritable 
processes, such as changes in gene expression or functionally asymmetric cell 
division, or stably heritable mutations (145). Our data provide a new mechanism 
by which alterations in a hypervariable region in the glpK gene produces bacteria 
that persist during antibiotic treatment and could contribute to the emergence of 
drug-resistant clones. 
Insertions and deletions in a homopolymeric region of an open reading 
frame is a common mechanism to produce high-frequency reversible phenotypic 
variation in bacteria. These mutations are generally thought to result from 
slipped-strand mispairing during DNA replication. However, additional DNA repair 
mechanisms, such as mismatch repair (162) or base excision repair (163), can 
alter the frequency and directional bias of the process. The exclusive bias for +1 
and +2 frameshifts in the glpK gene of clinical isolates argues for a more complex 
process than simple replicative error, and the ultimate frequency of mutants may 
also be influenced by the specific fitness effect of each frameshift. As a result, it 
is difficult to anticipate the rate of variation that occurs during infection. 
Regardless, we identified +1 and +2 frameshifts in 6% of the Peruvian MDR 
isolates. Since clinical samples are routinely cultured in glycerol-containing 
media, which would be expected to select for reversion to the wild-type glpK 
 
 40 
coding sequence, it is likely our data underestimate the frequency of glpK 
mutants. The observed prevalence of this mutation is clearly high enough to 
produce a significant population of glpK-deficient clones that alter drug efficacy. 
Our studies in the mouse model demonstrate that glpK-deficient bacteria 
are drug tolerant during infection. The mechanism(s) that underlies the drug 
tolerance of glpK-deficient bacteria is likely to be complex. Common fates for 
glycerol-3-phosphate are catabolism via the lower glycolytic pathway, 
incorporation into anabolic pathways, and spontaneous degradation to 
methylglyoxal. As a result, glycerol assimilation can alter growth rate, 
metabolism, and cellular structure. While not yet conclusive, our in vitro studies 
argue against some of these mechanisms. Both the in vitro effects of glycerol 
supplementation and the in vivo effects of glpK expression were independent of 
growth rate (Figures 2.2 and 2.5), and the differential effect of glpK in glycerol 
versus pyruvate growth media indicates that glycolytic flux per se is not the major 
determinant of drug efficacy. Thus, we speculate that the abundance of the triose 
phosphate pool or some derivative of this pool is primarily responsible for the 
general enhancement of antibiotic efficacy that we observed upon glycerol 
assimilation in vitro. 
The nonspecific effect of glpK on multiple drugs that we observed in vitro 
is consistent with previous studies that identified frameshifts in the glpK 
homopolymer in mutants selected for spontaneous resistance to investigational 
anti-mycobacterial compounds in vitro (158). Similarly, glpK mutations have also 
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been found in conjunction with additional mutations in strains selected to be drug 
tolerant (164) or PZA resistant (41) in vitro. Despite these relatively general 
effects on drug activity in vitro, glpK deletion preferentially reduced the efficacy of 
PZA-containing regimens in the mouse model used in this study. This apparent 
discrepancy could reflect differences in drug exposure, bacterial physiology, or 
GlpK functions in these two settings. The poor activity of PZA in vitro, where we 
observed no effect of glpK on PZA activity, makes it difficult to dissect these 
mechanisms in a more controlled system. Regardless, the identification of 
mutations that affect PZA efficacy only during infection highlights the importance 
of performing the original TNseq screen in an animal model. 
The prevalence of glpK-deficient strains in natural populations and the 
preferential survival of these bacteria in drug-treated animals suggested that 
glpK-deficient clones contribute to the persistence of M. tuberculosis during 
therapy and provide precursors for the emergence of clones with high-level 
resistance-conferring mutations. It is unlikely that the effects of glpK variation 
would be noted in standard phenotypic drug susceptibility testing (DST). This 
situation is similar to common variation in the prpR gene, which specifically 
influences drug tolerance but not DST results (145). These observations raise 
the possibility that genotypic tests for common drug tolerance-inducing variants 
could predict treatment failure and eventually be used to tailor therapy. We note 
that our TNseq study identified a number of additional loss-of-function mutations 
that alter drug efficacy, and the genome contains more than 100 genes with 
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homopolymeric regions that are at least as long as the one found in glpK (165). 
Together, these observations suggest that many phenotypically distinct 
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The current regimen for tuberculosis (TB) chemotherapy was developed 
through a series of large clinical trials in the early 1970s (166). The resulting 
“short-course regimen” consists of four drugs, isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA), and ethambutol (EMB) (15). Combining these agents 
reduced the duration of treatment from 12-18 months to as little as 6 months 
(14). The wide-scale application of this regimen is generally considered a public 
health success and is estimated to have cured 58 million patients in the last two 
decades (5). Despite this success, delivering the extended therapy necessary to 
prevent recurrent disease is difficult in many settings and TB remains a leading 
cause of infectious death worldwide (5). The rational design of more rapid and 
effective therapies would be facilitated by understanding the mechanisms that 
limit the efficacy of our current drugs. 
It has been clear since the first animal treatment studies, that the 
requirement for prolonged therapy correlates with the relatively slow killing of 
Mycobacterium tuberculosis in tissue (32, 167). Both INH and RIF are rapidly 
bactericidal in laboratory culture, but these agents clear bacteria much more 
slowly from the lungs of infected animals (161). While drug penetration into TB 
lesions can be limiting (74), sub-optimal drug exposure alone is unlikely to fully 
account for persistence of viable bacteria. In addition, bacterial adaptations to the 
host environment have been proposed to limit drug efficacy via a number of 
mechanisms. For example, the rate at which most antibiotics kill is related to 
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growth rate and metabolic activity of bacteria (111, 128, 143), and the relatively 
slow replication of M. tuberculosis during infection correlates with reduced drug 
efficacy (168). More specific adaptations to this environment, such as the 
induction of stress responses (169), changes in cell wall permeability (170), and 
expression of efflux pumps (61), have also been proposed to play an important 
role. 
In addition to these inducible adaptations to the host environment, the 
wide-spread application of TB chemotherapy has also selected for stable genetic 
variants that promote bacterial survival. Most obviously, strains harboring high-
level resistance conferring mutations in drug targets or prodrug activators have 
become common (171). The resulting “resistance” increases the minimal 
inhibitory concentration (MIC) of the corresponding antibiotic in vitro. Recent 
studies have also shown that even small changes in MIC can negatively affect 
treatment outcome (172). In addition, recent bacterial genome-wide associations 
studies (GWAS) have identified genetic variants that are associated with drug-
resistant phenotypes but do not directly affect MIC. Some of these mutations 
compensate for the fitness cost imposed by primary resistance conferring 
variants (96). In other cases, they may promote bacterial survival in the presence 
of antibiotic (145), a phenotype termed drug “tolerance”. While hundreds of drug 
resistance-associated variants have been described (145, 148-150), the vast 
majority have not been functionally characterized. 
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In order to more globally define bacterial pathways that alter drug efficacy 
during infection, we designed a study to identify efficacy-altering mutations 
directly during infection using transposon sequencing (TNseq) in an animal 
model of TB. TNseq provides an unbiased approach to study conditional gene 
essentiality by comprehensively comparing the effect of loss-of-function 
mutations in different environments. Unlike previous studies that focused on 
individual mechanisms that broadly alter drug efficacy in vitro (173-175), our 
unbiased study found that most drug tolerance altering mutations are antibiotic 
specific, unrelated to growth rate, and alter drug efficacy only in the in vivo 
environment. A number of these efficacy-altering genes harbor mutations that are 
associated with drug resistance in clinical M. tuberculosis isolates, indicating that 
similar mechanisms may influence treatment outcome. 
 
Results 
Selection of transposon mutant libraries in antibiotic treated mice 
A differential selection strategy was designed to identify bacterial mutants 
that alter the efficacy of each of the first-line TB therapeutics, INH, EMB, RIF, 
and PZA. Mice were infected with a complex transposon mutant library 
representing >50,000 independent insertion events via the intravenous route. 
The infection was allowed to progress for two weeks to establish the adaptive 
immune responses that accentuate drug tolerance (152). We initially assessed 
bacterial survival in the spleen, since the representation of the entire library could 
 
 47 
be maintained in each individual mouse at this site. Spleen infection is a model of 
intracellular growth in the presence of adaptive immunity, a combination of 
conditions that resembles the primary pulmonary site of infection (176-179). At 
the initiation of drug treatment, the bacterial population had expanded to an 
average of 2x107 CFU/spleen. As expected, different antibiotics cleared the 
bacteria at distinct rates (Figure 3.1A). However, each drug, even the 
bacteriostatic agent, EMB, significantly reduced bacterial burden over 5 weeks of 
therapy. At this time point all drugs had reduced the bacterial burden by >100 
fold, but relatively complex libraries could still be recovered. Similar rates of 
clearance were observed in the lung (Figure 3.1B). Only in PZA-treated mice did 
we observe a decreased rate of killing between 2.5 and 5 weeks, suggesting the 









Figure 3.1| Antibiotic treatment of transposon mutant libraries in vivo. 
CFU from spleens (A) and lungs (B) of BALB/c mice infected with transposon mutant 
library either untreated (black circles) or treated with indicated antibiotic. Treatment was 
started at 14 days post infection. Mean and standard deviation of biological replicates is 
plotted (n = 2-7 per time point). 
 
To identify genes that alter bacterial fitness in this environment, we used 
TNseq to quantify the relative abundance of each transposon mutant in libraries 
recovered before infection, immediately before the initiation of therapy, from mice 
treated for 1, 2.5 or 5 weeks, or from untreated mice at the same time points 
(Figure 3.2). Surviving bacteria were recovered from the spleen of each mouse 
by plating and extracting genomic DNA. Transposon-chromosome junctions were 
ligated to unique molecular identifiers (UMI), amplified and sequenced (153). The 
relative abundance of each mutant in a pool is estimated based on the number of 
corresponding UMI sequences. This design allowed the independent 
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quantification of mutant fitness under the pressures imposed by the host and by 
the combined pressure of host immunity and antibiotic therapy. 
 
 
Figure 3.2 | Genetic strategy to identify mutations that alter susceptibility to 
antibiotic treatment in mice. 
Diagram of TNseq screen design. BALB/c mice were infected via intravenous route with 
2x106 bacteria/mouse. At 14 days post infection pretreatment libraries were collected, 
via plating, and treatment regimens were initiated. Time points were collected, via 
plating, from untreated and treated mice at 21, 32, and 49 days post infection. 
Comparison of transposon insertion abundance pre- and posttreatment identifies 




Identification of genes necessary for bacterial fitness in untreated animals  
Initially, TNseq libraries recovered from the untreated mice were analyzed 
to determine the relative fitness of each mutant over the time course of our 
infection. Libraries recovered at each time point were compared to the input 
libraries used for the infection. In total, 562 genes were found to be required for 
optimal fitness in vivo by 49 days post infection (Figure 3.3A and Appendix Table 
A3.1). We observe up to 77% overlap with genes previously reported to be 
required for replication in the mouse model using similar approaches (176, 178, 
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180). These genes encode a wide variety of functions previously verified to be 
necessary for replication in mice, including type VII protein secretion (ESX1), 
cholesterol (Mce4) and fatty acid (Mce1) catabolism, and siderophore transport 
(IrtAB, MmpL4/S4). The 231 novel genes identified in our study likely reflects the 
longer period of infection, and more accurate quantification that resulted from 
greater number of animals used. 
The availability of time-course data allowed the assessment of mutant 
fitness at different stages of infection. The two week time point captures the early 
expansion of the bacteria, before the onset of the adaptive response. The later 
time points reflect additional pressures imposed by T cells that control bacterial 
replication. As expected, we observed a progressive depletion of mutants over 
this time course (Figure 3.3B), and distinct sets of genes were found to be 
important in establishing infection or persisting at later time points. For example, 
biotin biosynthetic mutants were dramatically under-represented at the earliest 
time points, reflecting their known inability to replicate in vivo (181) (Figure 3.3C). 
In contrast, Mce4 mutants were well-represented at the early time point, but 
became progressively depleted from the pool, reflecting their specific deficit in 
fitness upon exposure to adaptive immunity (156) (Figure 3.3D). These data 
validated our methodology, and provide insight into the stresses M. tuberculosis 
may encounter during different times of infection independent of drug treatment. 
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Figure 3.3 | Genes required for 
optimal fitness in vivo. 
 
A, Volcano plot of in vivo libraries 
compared to in vitro input library at 
indicated time points. Q-value <0.05 is 
indicated by dashed line. Genes 
meeting significance (Q-value <0.05) 
are indicated by filled circles. B, 
Heatmap of the relative abundance of 
293 genes significantly 
underrepresented in vivo at each time 
point over the untreated time course. 
Genes are hierarchical clustered 
based on log2 fold change at individual 
time points. Time points are in order of 
infection length from shortest (left) to 
longest (right). C and D, TNseq 
phenotype of genes/operons 
significantly underrepresented in vivo 
at each time points: biotin biosynthesis 
genes, (C); mce4 operon, (D). 
Significance (Q-value <0.05) is 











Identification of mutants with altered susceptibility to antibiotics 
A critical requirement for TNseq-based comparisons is maintaining the 
complexity of each library to reduce stochastic effects. Treatment decreases the 
number of viable bacteria, which could result in decreased representation of 
mutants across the genome. As a result, we first assessed the complexity of the 
libraries recovered from drug treated mice. Initial analyses, calculating the 
average reads derived from transposon insertions in each gene, indicated that 
libraries exposed to extended RIF or PZA treatments were less complex than the 
rest (Figure 3.4). This effect was particularly clear for PZA, where the library 
became dominated by mutants with a disrupted pncA gene, which encodes the 
activator for the prodrug. A similar, but less pronounced, effect was found upon 
RIF treatment, where mutations in the cmaA2 gene became the most abundant 
strains in each sample from extended RIF treatments. The cmaA2 gene encodes 
a cyclopropane synthase which modifies the mycolate layer of the cell wall and 
alters cellular permeability (154). In both cases, transposon insertions throughout 
these genes were enriched, indicating that the loss of gene function was directly 
related to decreased drug efficacy. While a small number of other mutants 
appeared to be enriched upon extended therapy, these were not consistent 
between samples and represented single insertion events, likely reflecting the 
presence of spontaneous resistance conferring mutations that are unlinked to the 
insertion. Thus, the lack of complexity in these libraries led to the exclusion of 




Figure 3.4 | Complexity of antibiotic treated libraries. 
A, Average reads of transposon insertions for each open reading frame (ORF) in the 
H37Rv genome. Top: PZA treated libraries, pncA is indicated by the green line, and 
average reads for each TA site in pncA at 5 weeks posttreatment. Bottom: RIF treated 
libraries, cmaA2 is indicated by the orange line, and average reads for each TA site in 
cmaA2 at 5 weeks posttreatment. B, Average reads of transposon insertions for each 
ORF in the H37Rv genome in INH treated libraries (top) and EMB treated libraries 
(bottom). 
 
We next compared mutant abundance between pre- and post-treatment 
samples to quantify mutant survival during therapy (Figure 3.5A and Appendix 
Tables A3.2 – A3.9). We first compared mutant fitness in treated versus 
untreated animals, by comparing each time point to the pretreatment control 
 
 54 
sample, to estimate the relationship between replication rate and drug efficacy 
(Figure 3.5B). We observed the most overlap in the context of INH, a drug with 
clear growth rate dependent effects in vitro (182). However, this effect was not 
apparent for other drugs, indicating that distinct bacterial functions influence 
survival in the presence and absence of drugs. 
We next assessed the number of mutants with altered susceptibility to 
treatment. For each antibiotic regimen we observed mutants that were both 
under- or over-represented in the posttreatment samples (Figure 3.5C). The 
genes identified are involved in a range of distinct functions and include genes in 
pathways known to alter antibiotic efficacy. For example, pncA, the 
pyrazinamidase that activates PZA, and glpK mutants were found to be less 
sensitive to PZA treatment, consistent with previous studies in Chapter II (183). 
Conversely, mutants increasing efficacy included ppe50/51, previously shown to 
increase efficacy of combination treatment (183). We also identified multiple 
transporter mutants which are putative antibiotic efflux pumps, including ABC-
transporters Rv1747 and Rv1273 which were more susceptible to INH and RIF, 
respectively. Overall, we found 160 mutants that altered efficacy of antibiotic 





Figure 3.5 | Mutants with altered susceptibility to antibiotics. 
A, Volcano plots of treated libraries at individual time points compared to pretreatment 
libraries. Treatment lengths indicated by symbol: triangles 1 week; squares, 2.5 weeks; 
circles, 5 weeks. Negative log2 fold change = underrepresented posttreatment. Positive 
log2 fold change = overrepresented posttreatment. Q-value <0.05 is indicated by dashed 
line. Genes meeting significance (Q-value <0.05) are indicated by filled symbols. B, 
Scatterplot plotting the relative abundance, log2 fold change, for each gene in untreated 
libraries (x axis) or treated libraries (y axis). Genes significantly altered posttreatment are 
in black. The red dotted line indicates the threshold for genes that are attenuated in vivo 
and less susceptible to antibiotic treatment. C, Number of genes with a significant 
decrease in transposon insertions (left) and a significant increase in transposon 






Validation of mutant phenotypes in an aerosol infection model 
To determine how well the TNseq study predicted the phenotype of loss-
of-function mutations, a series of deletion mutants were generated: rv3822 
(chp1); rv1184 (chp2); rv1174c (TB8.4); rv1901 (cinA); rv1747; rv1273c; rv3136 
(ppe51); rv0248c; rv0503c (cmaA2). These genes were selected based on 
statistical criteria that consider each distinct transposon insertion in a gene to be 
an independent assessment of the loss-of-function phenotype. As a result, genes 
that are predicted to alter drug efficacy, contain a number of independent 
insertions that all produce a similar effect (Figure 3.6A-I). 
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Figure 3.6 | Transposon insertions pre- and post-treatment in genes with altered 
susceptibility. 
Average number of unique sequencing reads (y axis) plotted versus the TA sites in the 
genome (x axis) for pretreatment (black) and posttreatment (INH, blue; EMB, purple; 
RIF, orange; PZA, green). Mean and standard deviation of biological replicates are 
plotted. A, chp1 (rv3822) B, chp2 (rv1184c) C, TB8.4 (rv1174c) D, cinA (rv1901) E, 
rv1747 F, rv1273c G, ppe51 H, rv0248c I, cmaA2 (rv0503c) 
 
 
We also included mutants that disrupt different cellular functions and produce 
both qualitatively and quantitatively distinct phenotypes. For this analysis we 
included data from Chapter II, TNseq from mice treated with the combination 
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regimen HRZE (consisting of INH, RIF, EMB, and PZA) using a parallel treatment 
regimen (183). 
Individual deletion strains were constructed to contain a barcode at the 
site of deletion which served as an identifier for downstream quantification via 
sequencing. To measure susceptibility of the knockout strains, mutant and wild-
type strains were mixed into a pool of nine strains for infection via either 
intravenous (i.v.) or aerosol routes. Treatment was initiated at two weeks post 
infection, and the duration was adjusted to produce a similar decrease in CFU for 
each of the bactericidal regimens and maintain library complexity (Figure 3.7). At 
indicated time points, bacteria were isolated via plating the spleen or lung for i.v. 
and aerosol infections, respectively. The relative abundance of each mutant to 
wild-type was calculated for each strain and normalized to their pretreatment 
abundance, allowing a direct comparison to the TNseq data (Figure 3.8A-I). 
 
 
Figure 3.7 | Antibiotic treatment of mutant and wild-type pooled infections. 
A, Spleen CFU from BALB/c mice post intravenous infection. Treatment was started at 
14 days post infection. The data represents two infections, indicated by closed and open 
triangles. Mean and standard deviation are plotted, individual points are biological 
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replicates. Treatment conditions are indicated by color: untreated (black), INH (blue), 
EMB (purple), RIF (orange), PZA (green), HRZE(red). B, Lung CFU from BALB/c mice 
post aerosol infection. Treatment was started at 21 days post infection. The data 
represents two infections, indicated by closed and open squares. Mean and standard 
deviation are plotted, individual points are biological replicates. Treatment conditions are 
indicated by color: untreated (black), INH (blue), EMB (purple), RIF (orange), PZA 
(green), HRZE(red). 
 
In almost every case, the altered susceptibility phenotypes predicted by 
TNseq were validated using deletion mutants upon i.v. and/or aerosol infection. 
Many mutants were predicted to enhance the efficacy of individual antibiotics. 
These included genes that were among the ten strongest hypersusceptible 
phenotypes for RIF (rv1184c, rv3822, and rv1174c) and INH (cinA) (Figures 
3.8A-D). Additionally, mutations affecting two ABC transporters, Rv1747 and 
Rv1273c, indicated that these proteins could function as efflux pumps for INH 
and RIF, respectively (Figures 3.8E and 3.8F). PZA specific effects were 
observed as well. We confirmed ppe51 mutant strains have increased 
susceptibility to PZA containing regimens (Figure 3.8G), consistent with previous 
work in Chapter II (183). Other mutations were predicted to decrease efficacy. 
For example, mutants lacking the succinate dehydrogenase component, 
Rv0248c, were consistently cleared less rapidly than wild-type bacteria. This 
phenotype was observed upon treatment with different regimens (INH, RIF, and 
HRZE), suggesting that this mutation produces tolerance to many unrelated 
antibiotics (Figure 3.8H). CmaA2 mutants were predicted to have a complex 
phenotype, with opposing susceptibilities to EMB and RIF (Figure 3.8I). We 
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validated CmaA2 mutants as more susceptible to EMB treatment, consistent with 
previous studies (154), and less susceptible to RIF, consistent with our initial 
analyses of library complexity (Figure 3.3). These opposing phenotypes may 
compensate for each other during combination therapy, as we observe a neutral 













Figure 3.8 | Validation of mutant phenotypes.  
A-I, The relative abundance, log2 fold change, of mutants post TNseq (circles), i.v. 
(triangles), or aerosol (squares) infections. Mean and standard deviation of biological 
replicates for i.v. and aerosol infections are plotted. Significance is indicated by 
increased symbol size: TNseq, resampling Q-value <0.05; i.v. and aerosol, unpaired t 
test with Benjamini-Hochberg multiple testing correction P <0.05. Conditions are 
indicated by color: untreated (black); INH (blue); EMB (purple); RIF (orange); PZA 
(green); HRZE (red). HRZE data was obtained from Chapter II (183). J, Lung CFU of 
H37Rv (black), ∆Rv1273c (orange), and complement (grey) strains post aerosol 
infection and treatment with RIF. Data represents two aerosol infections of combined 
bacterial strains, 1:1 Rv and ∆ (filled squares) and 1:1 Rv and complement (open 
squares). Treatment was administered starting at 21 days post infection. RIF treatment 
was for 3 weeks. Mean and standard deviation are plotted, individual points are 
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biological replicates. Significance was determined using unpaired t test with Benjamini-
Hochberg multiple testing correction: *(0.03); **(0.002); ***(0.0002).  
 
To assess whether the relative abundance determined by sequencing 
mutant pools reflected genuine differences in viable bacteria, we mixed the 
putative efflux pump mutant strain, ∆rv1273c, and its complemented strain and 
performed additional infections using CFU as a measure of abundance. Using a 
competitive model in which each mutant was mixed at a 1:1 ratio with wild-type 
and inoculated via the aerosol route we observed that the ∆rv1273c mutant was 
cleared more rapidly than wild-type or the complemented strain by RIF treatment, 
as anticipated (Figure 3.8J).  We conclude that the TNseq data provide an 
accurate assessment of relative mutant abundance in this system. 
 
Mutations produce drug-specific effects 
Having validated the accuracy of the TNseq data, we analyzed the 
composite dataset to understand more broadly how bacterial functions alter drug 
efficacy. Again, we included a previously generated HRZE treatment condition 
from Chapter II, that was produced using identical methodology (183). When 
compared to the pretreatment time point, the number of mutants identified with 
altered abundance varied for each antibiotic condition (Figure 3.9A). The majority 
of mutations only had significantly altered susceptibility to a single agent, while a 
smaller subset had effects in multiple conditions (Figure 3.9A). The largest 
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overlap, 13 genes, was observed between INH and EMB, two drugs that inhibit 
cell wall synthesis by interrupting mycolate or arabinogalactan production.  
 
  
Figure 3.9 | Mutants with altered susceptibility to treatment are specific to 
individual treatment regimens. 
A, Left: the number of genes with a significant change in transposon insertions under 
each condition. Right: Venn diagram displaying the overlap between treatment 
conditions. B, Dendrogram displaying the relationship between treatment conditions and 
individual time points. Relationship was determined by hierarchical clustering of 
 
 66 
significantly altered genes based on TNseq log2 fold change at each time point. HRZE 
data was obtained from Chapter II (183). 
 
Similarities between conditions was also evident upon hierarchical clustering of 
significantly altered genes (Figure 3.9B). Conditions clustered primarily based on 
regimen. Higher order similarities based on mechanism of action were also seen, 
as the cell wall inhibitors (INH and EMB) were found in a branch distinct from the 
other conditions. In addition, PZA clustered closely with HRZE, suggesting that 
the bactericidal activity of the combination regimen is largely driven by PZA. 
While these simple comparisons indicated that each treatment generally 
selected a distinct set of mutants, this analysis was insufficient to clearly define 
bacterial functions that were selectively affected by each treatment. We therefore 
devised a multidimensional analysis to identify the bacterial genes that are most 
responsible for defining the treatments. Principle component analysis (PCA) was 
applied to transposon insertion counts of genes across conditions to map them 
onto orthogonal axes (linear combinations of conditions). We then performed a 
varimax rotation (184) to maximally re-align the first principle components with 
treatment conditions, resulting in six abstract dimensions that differentiate the 
antibiotics based on their effects on conditional gene essentiality. All treatment 
groups were assigned to a distinct dimension, except for PZA and HRZE which 
were similar enough to share one (Figure 3.10A). This analysis also identified a 
clear inverse correlation between INH treatment and the untreated condition that 
we previously inferred (Figure 3.5B). The bacterial genes most closely aligned 
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with each varimax dimension were identified based on their rotated PCA 
loadings, and the significance of these associations was determined using a 
projection resampling approach (see Appendix A1: Materials and Methods). This 
analysis identified between 1 and 20 genes that are significantly associated with 
individual treatment conditions (Figure 3.10B and Appendix Tables A3.10 – 
A3.14). For example, mutations in an operon consisting of  ppe1, rv0097, and 
nrp, were found to increase survival in the presence of INH, an effect that is 
consistent with previous work (182). Increased abundance of mycobactin 
mutants distinguishes EMB from the other treatment conditions. Genes 
associated with the RIF dimension include previously validated genes rv1184c, 
rv3822, and cmaA2 (Figure 3.8). Prominent among these 9 genes were 7 that 
are involved in cell wall, lipid, or arabinan metabolism (pks2, phoR, mmaA3, 
mmaA2, cmaA2, ephD, rv1635) (185-189), suggesting that the permeability of 
the mycobacterial envelope is a primary determinant of RIF activity during 
infection. The PZA/HRZE dimension is associated with pncA, the activator of the 
PZA prodrug, as well as mutations in the ppe51 genes that are involved in 
glycerol/glucose uptake (190) and was previously found to enhance the activity of 
HRZE (183). In addition, mutations in several genes dedicated to the synthesis of 
the cell envelope lipid, phthiocerol dimycocerosate (PDIM), decreased HRZE 
efficacy. The untreated dimension is associated with a single gene, rv2563, that 







Figure 3.10 | Multi-dimensional analysis to identify mutations associated with 
individual antibiotic treatments.  
A, Correlation between individual time points and conditions with each varimax loading. 
B, Heatmap of genes significantly associated with a varimax dimension. Signal is based 
on TNseq log2 fold change. Boxes indicate genes significantly associated (Q-value < 
0.05) with dimensions. HRZE data was obtained from Chapter II (183). 
 
Many susceptibility phenotypes are specific to the in vivo environment 
To evaluate the importance of the infection environment in shaping the 
mechanisms of drug susceptibility, we investigated whether mutations found to 
alter efficacy in animals also had an effect in standard culture conditions. We first 
compared the mutants found in our in vivo study with those previously found to 
alter the MICs of INH, EMB, or RIF in vitro using an analogous TNseq approach 
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(175). We observed a small but significant overlap of genes post INH (in vivo = 
68 genes, in vitro = 90 genes, overlap = 8 genes, P = 0.0004), EMB (in vivo = 54 
genes, in vitro = 67 genes, overlap = 4 genes, P = 0.02), and RIF treatment (in 
vivo = 59 genes, in vitro = 75 genes, overlap = 10 genes, P = 4 x 10-7), identifying 
pathways that alter treatment efficacy both in vitro and during infection. The 8 
gene overlap between in vivo and in vitro INH treatments included the validated 
cinA gene (Figure 3.8) that increases susceptibility when mutated. Despite these 
similarities, the majority of mutations found to alter in vivo efficacy do not appear 
to alter in vitro MIC values. 
To more directly quantify in vitro effects, we took advantage of our deletion 
mutant set (Figure 3.8). Each mutant was exposed to the antibiotic that resulted 
in the most differential selection for that strain in vivo (RIF or INH), and both the 
MIC50 and rate of killing was determined in vitro. While MIC differences between 
wild-type and three mutants met statistical significance, none differed by more 
than 2-fold (Table 3.1). When the rate of killing was measured, no differences 
were observed under RIF treatment. In INH treatment only a single mutant, ∆cinA 
displayed increased killing that was consistent with the in vivo phenotype (Figure 
3.11). Thus, consistent with the TNseq comparison, this analysis indicated that 






Figure 3.11 | Rate of killing of mutants in vitro. 
Viable bacteria determined by CFU of H37Rv and deletion mutants post RIF treatment 
(0.5 g/mL) (A) or INH treatment (0.6 g/mL) (B). Mean and standard deviation of 













Table 3.1 | Antibiotic susceptibility of deletion strains in vitro. 
  IC50 (g/mL  SD) 
Strain INH RIF 
 H37Rv  0.03 ± 0.002  0.0033 ± 0.0003 
 ∆rv0248c  0.04 ± 0.005 *  0.0035 ± 0.0002 
 ∆cmaA2  0.03 ± 0.001  0.0025 ± 0.0003 * 
 ∆rv1174c  0.03 ± 0.001  0.0033 ± 0.0004 
 ∆chp2  0.03 ± 0.001  0.0029 ± 0.0007 
 ∆rv1273c  0.03 ± 0.005  0.0032 ± 0.0006 
 ∆rv1747  0.03 ± 0.004  0.0028 ± 0.0009 
 ∆ppe51  0.05 ± 0.005 *  0.0041 ± 0.0001 * 





Natural variants in efficacy-altering genes are associated with drug 
resistance 
In the mouse model, we identified many genes that have the capacity to 
alter antibiotic efficacy (Figure 3.5C and Appendix Tables A3.2 – A3.9). 
Reasoning that naturally-occurring polymorphisms in these genes might be 
selected in the context of antibiotic exposure, we investigated if there was 
overlap between genes identified our mouse studies and those previously found 
to contain resistance-associated single nucleotide polymorphisms (SNPs) in 
clinical isolates. We utilized data from three published GWAS studies (145, 148, 
150) that identified genes that are subject to convergent evolution in drug 
resistant isolates. We compared these genes to the loss-of-function mutations 
that we found to either increase or decrease antibiotic killing in the mouse, since 




naturally occurring polymorphisms could increase, decrease, or alter the 
functions of these genes. Of the 328 genes identified by GWAS, 14 were also 
identified in our TNseq study with a Q-value of < 0.05, and 21 overlapped with a 
Q-value less than 0.1 (Figure 3.12 and Table 3.2). Genes known to alter drug 
sensitivity (pncA) and tolerance (glpK) were identified, along with a number of 
genes that have not been shown to influence drug efficacy. For example, we find 
that disruption of the nonribosomal peptide synthase, nrp, produces tolerance to 
INH in the mouse, which likely explains the association of nrp variants with 
clinical INH resistance (145). Similarly, loss of pks2 function reduced RIF killing 
in mice, and SNPs in the pks2 gene are associated with clinical ofloxacin 
resistance (148). As individual resistance traits in multi-drug resistant isolates are 
linked, these observations are consistent with pks2 mutations contributing to this 
phenotype either by increasing RIF tolerance or influencing the effects of multiple 
drugs, including fluoroquinolones, which were not tested in the mouse. While the 
overlap between these datasets was relatively small, this analysis allowed us to 
functionally implicate variants in at least 14 M. tuberculosis genes in the evolution 
of drug resistance. As many of the efficacy altering mutations found in the mouse 
model have little effect in vitro (Figure 3.11 and Table 3.1), we speculate that the 
effects of these natural variants may not be apparent under similar in vitro 
conditions. If so, these variants could represent cryptic determinants of treatment 





Figure 3.12 | Comparison between in vivo susceptibility and association with 
clinical resistance. 
328 genes associated with clinical resistance are plotted by genomic order, x axis, and 
Q-value from TNseq conditions are indicated, y axis. Dashed lines indicate Q-value < 
0.05 and < 0.01. TNseq hits overlapping with genes associated with clinical resistance 
are indicated by filled circles. 
 
 
Table 3.2 | Genes that alter drug susceptibility in mice and contain resistance-
associated SNPs in clinical isolates 
Gene  Phenotypes GWAS dataset GWAS phenotype 
Rv0101 (nrp) INH; EMB Hicks et al. (145) INH 
Rv0244c (fadE5) EMB Zhang et al. (148) KAN 
Rv0353 (hspR) INH Farhat et al. (150) RIF; INH; EMB; CAP 
Rv0859 (fadA) INH Zhang et al. (148) OFX; KAN 
Rv2043c (pncA) PZA; HRZE Farhat et al. (150) 
AMI; CAP; EMB; ETA; INH; 
KAN; MXF; PZA; RFB; RIF; 
STR; LIN 
Rv2344c (dgt) INH Hicks et al. (145) INH 
Rv2571c HRZE Farhat et al. (150) 




Rv2942 (mmpL7) INH; EMB Farhat et al. (150) RIF 
Rv3211 (rhlE) INH Hicks et al. (145) INH 
Rv3267 INH Hicks et al. (145) INH 
Rv3696c (glpK) 
INH; EMB; RIF; 
PZA; HRZE Farhat et al. (150) 
AMI; INH; KAN; RFB; RIF; 
CAP; LIN; EMB; ETA; PZA 
Rv3825c (pks2) RIF Zhang et al. (148) OFX 
Rv3859c (gltB) EMB Farhat et al. (150) STR 
Rv3877 (eccD1) HRZE Zhang et al. (148) CAP 
Rv0560c * PZA  Hicks et al. (145) INH 
Rv0600c * HRZE Zhang et al. (148) KAN 
Rv1282c (oppC) * HRZE Hicks et al. (145) INH 
Rv1330c (pncB1) * INH Farhat et al. (150) KAN; CAP; ETA; RIF; STR 
Rv1860 (apa) * HRZE Farhat et al. (150) STR,RIF 
Rv2080 (lppJ) * RIF Zhang et al. (148) ETH; KAN 
Rv3919c (gid) * INH Farhat et al. (150) 
EMB; INH; MXF; PZA; RFB; 







Many studies investigating antibiotic efficacy and new drug target 
discovery are performed in vitro. While it is possible to change discrete aspects 
of the culture conditions to mimic individual stresses (123, 144, 175, 191, 192), 
Red = underrepresented in drug treated TNseq samples; Green = overrepresented in drug 
treated TNseq samples; “GWAS phenotype” = the drug resistance pattern associated with 
SNPs. INH (isoniazid); EMB (ethambutol); RIF (rifampicin); PZA (pyrazinamide); KAN 
(kanamycin); CAP (capreomycin); OFX (ofloxacin); MXF (moxifloxacin); AMI (amikacin); ETA 




these models do not fully recapitulate the complex environment encountered by 
the bacterial population during infection. In this study, we identified genes 
important for bacterial survival under antibiotic pressure in the mouse model of 
TB, where the bacteria grow intracellularly (179) in the presence of a fully 
functional adaptive immune response. By collecting data across several time 
points, we were able to discern a number of new insights into the processes 
necessary to sustain an infection and persist through antibiotic treatment. 
This time-resolved study provides the most detailed assessment of M. 
tuberculosis genes necessary to persist in the mouse model to date, identifying 
562 genes (Figure 3.3 and Appendix Table A3.1). Our data are consistent with 
previous studies, and identified a large number of known virulence factors. We 
also identified 231 genes that were not found in previous TNseq studies, 
reflecting the increased accuracy of UMI based quantification of transposon 
insertions and increased number of replicates and time points. These included 
functions already known to be important, such as a number of genes encoded in 
a large genomic region dedicated to cholesterol catabolic functions (kshA, 
rv3538, rv3549c, echA20, rv3557c, rv3562, rv3570c, rv3575c) (136, 193). 
Similarly, several additional genes related to Type VII protein secretion were 
identified, cyp143, ppe27, and esxN are components of the ESX5 system (194), 
esxW is homologous to ESX substrates and has been associated with TB 
transmission (195), and rv3866 (espG) is a component of the ESX1 system 
(196). A number of novel functions were identified as well. For example, we 
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found genes encoding a succinate dehydrogenase complex (sdhA, sdhB, sdhD), 
the proton translocating NADH dehydrogenase (nuoE, nuoK), and the Mce3 
transporter that is homologous to lipid importers (mce3A, mce3B, mce3C, and 
lprM). Overall, this dataset enhances our understanding of the genomic 
requirements for infection. 
When infected animals were treated with antibiotics, we only found a small 
number of genes that broadly alter drug efficacy. These included glpK, which is 
necessary for glycerol metabolism and has been shown to alter the effect of 
HRZE in vivo in Chapter II (183), and several drugs in vitro. Similarly, the 
mutation of the putative glutamine transporter encoded by rv2563 and rv2564 
broadly sensitizes the bacterium to different drugs. These observations highlight 
the importance of primary metabolic functions in general alterations in drug 
sensitivity. A much larger collection of mutations produced relatively drug-specific 
effects (Figure 3.9), and suggested primary mechanisms that determine the 
efficacy of some antibiotics. For example, the majority of genes associated with 
RIF treatment are likely to be involved in cell wall formation, such as 
acyltransferases Rv1184c and Rv3822 and cyclopropane synthase CmaA2. 
While rv1184c and rv3822 mutants are more susceptible to RIF, mutations in 
cmaA2 result in increased survival, indicating that changes in permeability can 
affect RIF efficacy in multiple ways. More generally, the abundance of cell wall 
modifying enzymes indicates that permeability is an important determinant of RIF 
efficacy during infection, which is consistent with previous in vitro observations 
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(197-199). Similarly, mutants in the mycobactin biosynthesis pathway were 
overrepresented specifically post-EMB treatment, indicating a role for iron 
utilization in EMB efficacy. Finally, the specific correlation between in vivo fitness 
and drug efficacy for INH, a drug known to be affected by growth rate in vitro 
(143, 182), suggested that INH is preferentially affected by the decreased 
replication rate of the bacterium during infection. 
Drug efflux may also produce drug-selective effects. For example, 
Rv1273c is predicted to be a multi-drug transporter based on sequence 
homology (200), and we found this mutant was only hypersusceptible to RIF. 
Similarly, loss of the ABC transporter encoded by Rv1747 specifically increased 
INH susceptibility. Despite these in vivo effects we found no evidence that 
mutating these genes altered drug susceptibility in vitro, suggesting that both 
systems are regulated. Indeed, Rv1747 is an unusual ABC transporter that is 
controlled via phosphorylation by PknF (201), indicating a potential mechanism of 
inducing INH tolerance in response to environmental cues. In contrast, Rv1273c 
expression is increased in clinical isolates (63), leading to the hypothesis that this 
may be an inducible efflux pump, similar to a previously identified mycobacterial 
drug efflux system that is expressed during intracellular growth (61). 
While we did not globally assess the effect of transposon mutations on 
antibiotic efficacy in vitro, we compared our in vivo dataset to a previous TNseq 
study (175) and directly measured in vitro effects for a selection of mutants. Both 
efforts indicated that many of the efficacy-altering mutations that we identified in 
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the mouse model have a minimal effect on in vitro MIC or rate of killing (Figure 
3.11 and Table 3.1), suggesting that the observed chemical-genetic synergies 
are specific to the host environment. This observation has important implications, 
as it suggests the possibility that many genetic variants that alter treatment 
outcome do not produce an effect that is measurable in standard drug 
susceptibility testing (DST). 
Genetic variants that are selected by drug exposure, can be identified via 
GWAS approaches, using the thousands of available whole-genome sequences 
from M. tuberculosis clinical isolates (145, 148, 150). While these data are 
immediately useful for genotypic drug susceptibility assessment (202, 203), the 
functional roles played by the majority of these variants remains unknown. In this 
work, we leveraged our TNseq data to identify a number of variants that are likely 
to directly alter drug efficacy, suggesting new mechanisms that are relevant to 
treatment outcome (Figure 3.12 and Table 3.2). As many of the efficacy altering 
mutations found in the mouse model have little effect in vitro, these variants 
could represent cryptic determinants of treatment outcome that only alter drug 
efficacy in the appropriate environments. However, the relatively modest overlap 
between the TNseq and GWAS datasets was also notable. It is possible that this 
observation indicates that only a small fraction of the variants identified by GWAS 
directly alter drug efficacy. However, this conclusion should be approached with 
caution, as there are significant physiological differences between human and 
mouse TB, and the TNseq approach only assesses the effect of loss-of-function 
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mutations. Thus, the ultimate functional assessment of natural genetic 
polymorphisms still requires the individual investigation of each variant. 
Understanding how Mycobacterium tuberculosis survives prolonged 
antibiotic pressure also suggests new strategies to improve treatment. Our data 
indicate that a large number of potential synergies exist that could be exploited to 
accelerate bacterial clearance. While we do not assess sterilization or ultimate 
“cure” in this model, rapidly eliminating viable bacteria remains an important goal. 
While the relatively drug-selective effects of these synergies represents a 
potential challenge, our data indicate that more effective regimens are possible 
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CHAPTER IV: Discussion 
 Mycobacterium tuberculosis is an ancient pathogen, evolving in parallel 
with humans, that remains a modern-day global health problem. As with many 
bacterial infections, the discovery and introduction of antibiotics revolutionized 
the treatment of tuberculosis - leading some scientists to believe that tuberculosis 
(TB) would be eradicated. Famously, Selman Waksman, who was involved in the 
discovery of streptomycin, stated: “the ancient foe of man, known as 
consumption, the great white plague, tuberculosis, or by whatever other name, is 
on the way to being reduced to a minor ailment of man. The future appears bright 
indeed, and the complete eradication of the disease is in sight” (204). However, 
the development of antibiotic resistance, the lack of an effective vaccine, the 
increase in active disease due to co-morbidities such as HIV and diabetes, and 
multiple hurdles with transmission control have all contributed to TB becoming 
the largest global cause of death due to a single infectious agent.  
 Antibiotic treatment of TB remains an effective weapon against disease 
and transmission. Diagnosis and treatment of latent infection helps prevent 
progression to active disease, therefore preventing spread, and treatment of 
active disease has an 85% cure rate (5). However, these treatments require 
months of antibiotics, three to four months for latent infections and six months of 
multiple drugs for drug-susceptible (DS) TB, creating a burden on the patient and 
the healthcare system. Additionally, we have been using the same treatment 
regimen for decades, resulting in bacterial mutations that cause high-level 
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resistance against these antibiotics. Multi-drug resistant (MDR) and extensively-
drug resistant (XDR) infection rates have risen over the past years, each 
requiring longer treatment regimens with more toxic antibiotics and decreased 
cure rates.  
 Improving our current treatment regimens and developing new antibiotics 
effective against M. tuberculosis remain important goals in the fight against TB. 
Drug discovery for effective anti-mycobacterials is difficult and, in the past 
decades, only two antibiotics have been approved for use: bedaquiline and 
pretomanid. A number of factors contribute to the lack of success in drug 
development, starting with the bacteria. M. tuberculosis is effective at preventing 
killing by decreasing antibiotic import, by modifying antibiotics to prevent activity, 
and by exporting antibiotics out of the cell. Additionally, M. tuberculosis is an 
obligate human pathogen and alters its physiology to adapt to multiple 
environments and stresses that are impossible to replicate in vitro, creating an 
obstacle in identifying antibiotics that are as effective in vivo. The use of the 
mouse model in our studies to understand M. tuberculosis mechanisms of 
survival allows us to identify potential targets for new and synergistic treatments 
in a physiologically relevant disease model that mimics the complex disease 
pathology found in humans. 
 Using knowledge about our current antibiotics to discover new treatments 
has had prior success. Notably, derivatives of the rifamycin antibiotic class have 
variable efficacies against susceptible and drug-resistant M. tuberculosis (205-
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207). However, our current regimen for DS-TB treatment was implemented with 
minimal knowledge about the mechanism of action of the antibiotics or resistance 
mechanisms. Improved understanding of the efficacy of the current antibiotic 
regimen and M. tuberculosis survival during prolonged antibiotic exposure in the 
context of an in vivo infection is crucial to improving treatment. In these studies, 
we used unbiased, comprehensive genetic approaches and the mouse model of 
TB to identify bacterial mechanisms which alter treatment efficacy, providing 
insight to M. tuberculosis antibiotic tolerance and the development of resistance 
during infection.  
 Treatment is always administered as combination therapy; therefore, we 
first aimed to identify mutants with altered susceptibility to the standard DS-TB 
combination regimen, commonly referred to as HRZE (Chapter II). We observed 
many mutants with increased susceptibility. These are potential new targets for 
synergistic treatments (Appendix Tables A2.1 and A2.4). We also observed a 
small number of mutants with decreased clearance (Appendix Tables A2.2 and 
A2.5), including glycerol kinase mutants. Mutations in glpK have no observed 
fitness defect in vivo and result in increased survival under pyrazinamide 
containing regimens, including combination therapy (Figure 2.6). Our observation 
of loss of function mutants, with no fitness cost, and prolonged survival led to the 
hypothesis that glpK mutations would be present in clinical isolates. We 
confirmed our hypothesis with the observation that glpK mutations evolve 
independently in multiple strains and lineages of TB in two distinct geographical 
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cohorts (Figure 2.8 and 2.9). These mutations are also significantly associated 
with drug resistance phenotypes. The majority of these mutations were +1bp 
frameshift mutations in a homopolymer region of the open reading frame, 
providing a potential new genetic mechanism of antibiotic tolerance in M. 
tuberculosis. 
 Phase variation, such as frameshifting, has not been previously described 
in M. tuberculosis. Previous work has shown selection against long 
mononucleotide regions (165), indicating that the presence of remaining 
homopolymeric regions in M. tuberculosis may be genetic mechanisms of 
regulation that confer a fitness advantage. Therefore, phase variation in a small 
number of genes may have a greater role in adaptation to environments and 
prolonged survival under antibiotic treatment. Reducing the rate of clearance of 
M. tuberculosis allows for the potential accumulation of mutations, thus 
increasing the risk of high-level resistance-conferring mutations. Loss-of-function 
mutations which prolong survival were previously described in clinical isolates 
(145), and the high prevalence of glpK frameshift mutations in drug-resistant 
strains indicates that this mechanism may be an efficient method for producing 
tolerant populations. Preliminary investigation has identified a number of genes 
with homopolymers that contain SNPs associated with drug-resistant 
phenotypes. Further investigation into the rate of frameshifting within the glpK 
gene and other homopolymeric regions will provide a platform to study the 
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function of phase variation in M. tuberculosis and how it may influence infection 
and treatment outcomes.  
 Discovery of new effective combination therapies for treatment of TB is 
essential for improving therapy. Since the addition of RIF and PZA to the 
standard regimens, the length of treatment has remained at six months. Previous 
clinical trials aiming to shorten DS-TB treatment length have had minimal 
success in reducing relapse rates (49, 208-210). Here, we identified mutations 
with altered susceptibility to individual first-line antibiotics (Chapter III). We 
observed that a majority of mutant phenotypes were specific to an individual 
antibiotic (Figure 3.9). This confirms mechanism-of-action studies showing that 
these antibiotics target different essential pathways (Figure 1.1). However, it also 
indicates that a majority of tolerance mechanisms are distinct for each antibiotic. 
Multidimensional analyses, of these datasets identified bacterial genes/pathways 
responsible for defining the bacterial response to the different treatments (Figure 
3.10). For example, we observed a number of enzymes involved in cell wall 
modification associated with RIF treatment, indicating permeability as a potential 
determinant of RIF efficacy. Insight into M. tuberculosis physiology and survival 
under mono-therapy treatment could improve our knowledge on desired 
characteristics of new drugs for new combinations. 
A potential caveat of high-throughput genetic screening is that observed 
phenotypes are the result of the screen and not the mutations generated. To 
determine how well our TNseq studies predict mutant phenotypes under more 
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defined infection conditions, we generated a series of deletion mutants. Between 
the two studies (Chapter II and III), we have validated the observed phenotypes 
using deletion mutants in multiple infections for several genes of interest using a 
variety of experimental techniques (Figure 2.6 and 3.8). These phenotypes are 
genuine differences in viable bacteria, as we have also validated two genes of 
interest via colony forming unit (CFU) plating as a measure of abundance. 
Additionally, we observed that the majority of phenotypes were specific to the in 
vivo environment, through in vitro minimum inhibitory concentration (MIC) and 
rate of killing assays (Figure 3.11 and Table 3.1) and overlap with previously 
published datasets (175).  
 Comparing bacterial genome-wide association studies (GWAS) with our in 
vivo studies, we identified a number of genes which alter susceptibility to 
antibiotics in vivo that contain mutations in clinical isolates associated with 
resistance phenotypes (Figure 3.12 and Table 3.2). A majority of SNPs 
associated with clinical resistance identified have yet to be functionally 
characterized. Utilizing overlap with genetically tractable in vivo studies, such as 
those performed here, could aid in identification of variants relevant to treatment 
outcome. For example, we identified loss-of-function mutants that are more and 
less susceptible to antibiotic treatment, and this knowledge could provide 
mechanistic insight into observed genetic variation. Additionally, these data 
provide a list of clinically-relevant genes which could be further studied in 
tractable lab models.  
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 Small changes in antibiotic efficacy can have negative impacts on 
treatment outcome (172). In our studies, we identified multiple loss-of-function 
mutations altering drug efficacy which have the potential to produce distinct drug 
tolerant populations (Appendix Tables A2.2; A2.5; A3.3; A3.5; A3.7; A3.9). 
Identification of mutations that result in prolonged survival under antibiotic 
therapy, like those identified in these and other studies (145), have the potential 
to expand genotypic testing for drug tolerant variants that alter treatment 
outcome (202, 203). Through clinical trial studies, it has been observed, that for 
some patients, the six month regimen is longer than necessary (49, 209-211). 
However, it is near impossible to predict which patients can benefit from a shorter 
treatment and which patients require longer regimens. Identifying patients who 
are at risk of relapse through testing for drug tolerant variants could allow for 
more personalized treatment, through alterations of regimens to prevent negative 
outcomes. 
 Here, we describe the identification of M. tuberculosis mechanisms of 
survival during antibiotic treatment which are specific to the infection environment 
and clinically relevant. While decades of research has provided a wealth of 
knowledge on TB infections and M. tuberculosis survival, there are still many 
unknowns inhibiting improvement of treatment and control of TB. Combining 
comprehensive genetic tools previously used to identify conditionally-essential 
genes in M. tuberculosis and the highly developed mouse model of TB to mimic 
the infection environment, we have provided a foundation for the identification of 
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a new genetic mechanism of antibiotic tolerance, many potential targets for new 
synergistic treatments, and the characterization of clinically-relevant mutations 





















APPENDIX A1: Materials and Methods 
 
Transposon sequencing 
BALB/cJ (stock no. 000651) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA). Housing and experimentation were in 
accordance with the guidelines set forth by the Department of Animal Medicine of 
University of Massachusetts Medical School and Institutional Animal Care and 
Use Committee and adhered to the laws of the United States and regulations of 
the Department of Agriculture. Eight- to 12-week-old female animals were 
infected with 106 CFU of a himar1 transposon library (131) via the intravenous 
route. Groups of mice were treated with antibiotics starting at 14 days post 
infection. Antibiotics were administered via drinking water at the following 
concentrations: 0.1 g/liter isoniazid (Sigma), 0.6 g/liter ethambutol (Sigma), 0.1 
g/liter rifampin (Sigma), and 15 g/liter pyrazinamide (Sigma). At the indicated 
time points, mice were sacrificed, spleens and lungs were isolated and 
homogenized, and CFU numbers were determined by plating dilutions on 7H10 
agar with 10 g/ml kanamycin. For library recovery, approximately one million 
CFU per mouse were plated on 7H10 agar with kanamycin (10 g/ml). Genomic 
DNA was extracted (153), and the relative abundance of each mutant was 
estimated as described previously (153). Statistical analysis of log2 fold change 




In Chapter II, a three-way analysis was used. The three-way analysis 
measures the difference in log2FC (Δlog2FC) measured under two selective 
conditions relative to a common starting condition:  
                       Δlog2FC = log2FC(condition 1) – log2FC(condition2) 
In the present case, condition 1 was 14 days post infection plus 7 days of 
antibiotic treatment, condition 2 was 21 days post infection, and the starting 
condition was 14 days post infection (the start of drug treatment). Statistical 
significance was assessed by resampling. For each gene, the sampling 
distribution of Δlog2FC was obtained by resampling with replacement of the 
insertion counts at each TA within the gene (after normalization across all 
libraries). Counts for replicates were pooled prior to resampling. For each of 
10,000 resamples, Δlog2FC was calculated. The P value was taken as the 
fraction of the cumulative frequency distribution of Δlog2FC falling outside 
Δlog2FC = 0, on the negative side for values measured as Δlog2FC > 0, or on the 
positive side for values measured as Δlog2FC < 0 (equivalent to a 1-tailed test). 
The resulting P values were adjusted for multiple testing by Benjamini-Hochberg 
false discovery rate. 
In Chapter III, libraries were analyzed via hierarchical clustering and multi-
dimensional analyses. Hierarchical clustering (using hclust() in R, with average-
linking clustering) was applied to vectors of log2FC for each gene across all 
conditions. PCA and Varimax rotation were performed on log-fold-changes LFCs 
using the procedures prcomp() and varimax() in R, where the LFC for each 
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condition was calculated as the log2 of the ratio of the mean insertion count in 
that condition relative to the grand mean across all conditions. 
 
Projection resampling 
In order to identify genes significantly associated with individual Varimax 
dimensions in Chapter III, we devised a sampling-based version of the 
permutation test. For a given gene G, we collected the normalized insertion 
counts at all TA sites in the gene across all replicates in all conditions (drug 
treatments). Let W[c,v] be the matrix of weights (loadings) of each condition c 
(i.e. drug) projected onto each Varimax dimension v. The normalized insertion 
counts in each condition were randomly re-distributed onto the Varimax 
dimensions with probability proportional to the loadings, where the weights W[.,v] 
were converted to a probability distribution by dividing by i W[.,i]. Let D be the 
Varimax dimension of interest for testing the association of gene G. The re-
distributed observations for g were divided into two groups, A: those counts 
associated with dimension D, and B: those counts not associated with dimension 
D. Finally, the significance of the difference in mean counts in A versus B was 
determined by a permutation test, where a null distribution on the difference in 
means was generated by randomly permuting the counts between groups A and 
B 10,000 times, from which a p-value for the association of gene G with 
dimension D was derived. P values were adjusted post-hoc by the Benjamini-
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Hochberg procedure (213) for multiple tests correction (to limit the false-
discovery rate to 5%). 
 
Mycobacterium tuberculosis strains and culturing 
M. tuberculosis H37Rv was maintained in Middlebrook 7H9 medium 
containing oleic acid-albumin-dextrose-catalase (OADC), 0.2% glycerol, and 
0.05% Tween 80 and grown with shaking (200 rpm) at 37°C. Hygromycin (50 
g/ml) or kanamycin (20 g/ml) was added when necessary. All work with M. 
tuberculosis adhered to the CDC-NIH Guide for Biosafety in Microbiological and 
Biomedical Laboratories (214). Deletion strains were constructed by allelic 
exchange as previously described (215) and this work adhered to NIH Guidelines 
for research involving recombinant DNA molecules. Genes were replaced by the 
vector pKM464 carrying one of seven unique q-Tag sequences to identify each 











Table A1.1 | Deletion strains constructed in this study. 
    Reference Nucleotides     
Strain Organism genome deleted Plasmid1 Barcode2 
∆Rv0248c M.tb H37Rv 298898 - 300763 pKM464 qTag-19 
∆cmaA2 (Rv0503c) M.tb H37Rv 593901 - 594779 pKM464 qTag-19 
∆Rv1174c M.tb H37Rv 1305699 - 1305984 pKM464 qTag-22 
∆chp2 (Rv1184c) M.tb H37Rv 1324562 - 1325588 pKM464 qTag-23 
∆Rv1273c M.tb H37Rv 1422332 - 1424020 pKM464 qTag-24 
∆Rv1747 M.tb H37Rv 1973660 - 1976197 pKM464 qTag-29 
∆ppe51 (Rv3136) M.tb H37Rv 3501829 - 3502901 pKM464 qTag-26 
∆glpK (Rv3696c) M.tb H37Rv 4138237 - 4139720 pKM464 qTag-22 
∆cinA (Rv1901) M.tb H37Rv 2147692 - 2148924 pKM464 qTag-25 




∆glpK mutant characterization 
In Chapter II, the ΔglpK strain in vitro growth and antibiotic susceptibility 
was determined. The ∆glpK strain was cultured in glycerol-free 7H9. Glycerol-
dependent growth was assessed in minimal medium containing asparagine (0.5 
g/liter), KH2PO4 (1 g/liter), Na2HPO4 (2.5 g/liter), ferric ammonium citrate (50 
mg/liter), MgSO4·7 H2O (0.5 g/liter), CaCl2 (0.5mg/liter), ZnSO4 (0.1mg/liter), 
0.1% tyloxapol, and either 0.1% glycerol or 0.1% dextrose. For in vitro antibiotic 
susceptibility testing, isoniazid (INH) and rifampin (RIF) were used at 2 and 
1g/ml, respectively, and serially diluted 2-fold. Bacteria were inoculated to a 
starting optical density at 600nm (OD600) of 0.05 in 96-well plates with 7H9 
medium containing OADC, 0.05% Tween 80, and 0.2% glycerol, butyrate, or 




pyruvate. Pyrazinamide (PZA) was used at 400g/ml and serially diluted 2-fold. 
Bacteria were inoculated to a starting OD600 of 0.01 in inkwells containing 7H9 
medium supplemented with OADC, 0.2% glycerol, and 0.05% tyloxapol at pH 5.8 
and grown with shaking. Growth was monitored by OD600. Conditions were 
assessed in triplicate. Antibiotic efficacy was determined by comparing growth 
rate under increasing drug concentrations. OD600 was plotted and the rate 
constant (k) value was determined for all conditions using an exponential growth 
model. Rate constants posttreatment were normalized to levels for no-antibiotic 
controls. 
In Chapter II, ΔglpK mutant fitness in vivo was determined. Mice were 
inoculated with a 1:1 mixture of ΔglpK (hygromycin resistant) and H37Rv 
(harboring pJEB402 chromosomally integrated plasmid encoding kanamycin 
resistance) strains via the aerosol route. At the indicated time points, mice were 
sacrificed and CFU numbers in spleen and lung homogenate were determined by 
plating on 7H10 agar. Fitness in the presence of antibiotic was assessed by a 
similar competitive assay. Mice were infected with a pool of strains at equal ratios 
via the intravenous route (106 total CFU/mouse). Groups of mice were treated 
with antibiotics starting at 14 days post infection, as described for the TNseq 
study. At the indicated time points, approximately 10,000 CFU from the spleen 
homogenate of each mouse were plated on 7H10 agar. Genomic DNA was 
extracted for quantitative real-time PCR analysis (216). Briefly, the abundance of 
the constant and variable regions of the q-Tag present in each mutant was 
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determined by TaqMan PCR assay, as described previously (216), and used to 
calculate a variable/constant region ratio for each strain. The abundance of each 
mutant strain was then plotted relative to that of wild-type H37Rv (mutant/wild 
type). Values were normalized to initial day 0 ratios. 
 
GR50 determination 
In Chapter II, the GR50 values were determined for H37Rv. Bacteria were 
grown in minimal medium with 0.1% glycerol, 0.1% valeric acid, or 0.1% 
cholesterol on 96-well plates. Isoniazid (INH), rifampin (RIF), and moxifloxacin 
(MOX) were used at 1, 0.062, and 1 g/ml, respectively, and serially diluted 2-
fold. A no-antibiotic control was included in each experiment. Bacteria were 
inoculated to a starting OD600 of 0.05, and growth was monitored by OD600 and 
fluorescence. Conditions were prepared in triplicates. Antibiotic efficacy was 
determined by growth rate inhibition. The exponential growth constant (k) value 
was determined for all conditions. The k value of each antibiotic concentration 
was normalized to the k value of the no-drug control. The GR50 value was 
determined as the concentration of antibiotic that resulted in a 50% decrease in 
growth rate, as previously described (157). 
 
In vitro antibiotic susceptibility 
In Chapter III, MIC testing was performed. Bacteria were inoculated to a 
starting OD600 0.05 in 96-well plates with 7H9 medium containing OADC, 0.2% 
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glycerol and 0.05% Tween 80. Isoniazid (INH) and rifampin (RIF) were used at 
0.4 and 0.05 g/mL, respectively, and serially diluted 2-fold for a total of 6 
dilutions. Growth was monitored by OD600 and conditions were assessed in 
triplicate. IC50 was determined by plotting OD versus concentration of antibiotic 
and plotting a curve using [inhibitor] versus response model. 
For kill curves performed in Chapter III, bacteria were inoculated to a 
starting OD600 0.05 in inkwells containing 7H9 medium containing OADC, 0.2% 
glycerol and 0.05% Tween 80. At OD600 ~0.8-1.0 antibiotics were added to a final 
concentration of 0.6 and 0.5 g/mL for INH and RIF respectively. At indicated 
time points samples from the cultures were taken and CFU/mL was determined 
by plating on 7H10 agar with 50g/mL hygromycin. Conditions were assessed in 
triplicate. 
 
In vivo antibiotic susceptibility 
In Chapter III, mice were infected with pools of strains at equal ratios via 
the intravenous route (106 total CFU/mouse) or aerosol route (500-1000 
CFU/mouse). Groups of mice were treated with antibiotics, as described for the 
TNseq study. Treatment was administered starting at 14 days post infection for 
i.v. infections and 21 days post infection for aerosol infections. At indicated time 
points, approximately 10,000 CFU from the spleen or lung (for i.v. and aerosol 
infections, respectively) homogenate of each mouse were plated on 7H10 agar. 
Genomic DNA was extracted for sequencing  as described previously (153). 
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Sequencing libraries spanning the variable region of each qTag were generated 
using PCR primers binding to regions common among all qTags, similar to 
previously described protocols (217), see Table A1.2 for primer details. During 
this PCR, a unique molecular identifier was incorporated into the sequence to 
allow for the accurate counting of input templates and account for PCR 
jackpotting. The libraries were sequenced to 1000-fold coverage on an Illumina 
NextSeq platform using a 150 cycle Mid-Output kit with single end reads. Total 
abundance of each mutant in the library was determined by counting the number 
of reads for each q-Tag with a unique molecular counter. Relative abundance of 
each mutant in the pool was then calculated by dividing the total abundance of a 
mutant by the total abundance of reads for wild-type H37Rv. This value was then 
normalized to the relative abundance at the pretreatment time point to obtain the 
final relative abundance for each mutant in the pool. Statistical significance was 




Table A1.2 | qTag sequencing primers. 
ID Dir. Round Sequence 
Ftotal1 FW 1 CCCTACACGACGCTCTTCCGATCTGCCNNNCNNNCNNNggagcgtgtccatctggtgt 
Ftotal2 FW 1 CCCTACACGACGCTCTTCCGATCTTCNNNCNNNCNNNggagcgtgtccatctggtgt 
Ftotal3 FW 1 CCCTACACGACGCTCTTCCGATCTCNNNCNNNCNNNggagcgtgtccatctggtgt 
Ftotal4 FW 1 CCCTACACGACGCTCTTCCGATCTAACNNNCNNNCNNNggagcgtgtccatctggtgt 
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Ftotal5 FW 1 CCCTACACGACGCTCTTCCGATCTCTGCNNNCNNNCNNNggagcgtgtccatctggtgt 
Rtotal1 RV 1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAgaccacaacggtttccatatg 
Rtotal2 RV 1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGAgaccacaacggtttccatatg 
Rtotal3 RV 1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCAGAgaccacaacggtttccatatg 
Rtotal4 RV 1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCCGGAgaccacaacggtttccatatg 
Rtotal5 RV 1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCCATGAgaccacaacggtttccatatg 
F501 FW 2 
AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTACACGAC
GCTCTTCC 
F502 FW 2 
AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTACACGAC
GCTCTTCC 
F503 FW 2 
AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTACACGAC
GCTCTTCC 
F504 FW 2 
AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACGAC
GCTCTTCC 
F505 FW 2 
AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTACACGAC
GCTCTTCC 
F506 FW 2 
AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTACACGACG
CTCTTCC 
F507 FW 2 
AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTACACGAC
GCTCTTCC 
F508 FW 2 
AATGATACGGCGACCACCGAGATCTACACGTACTGACACACTCTTTCCCTACACGAC
GCTCTTCC 
R701 RV 2 CAAGCAGAAGACGGCATACGAGATCGAGTAATGTGACTGGAGTTCAGACGTGTGC 
R702 RV 2 CAAGCAGAAGACGGCATACGAGATTCTCCGGAGTGACTGGAGTTCAGACGTGTGC 
R703 RV 2 CAAGCAGAAGACGGCATACGAGATAATGAGCGGTGACTGGAGTTCAGACGTGTGC 
R704 RV 2 CAAGCAGAAGACGGCATACGAGATGGAATCTCGTGACTGGAGTTCAGACGTGTGC 
R705 RV 2 CAAGCAGAAGACGGCATACGAGATTTCTGAATGTGACTGGAGTTCAGACGTGTGC 
R706 RV 2 CAAGCAGAAGACGGCATACGAGATACGAATTCGTGACTGGAGTTCAGACGTGTGC 
R707 RV 2 CAAGCAGAAGACGGCATACGAGATAGCTTCAGGTGACTGGAGTTCAGACGTGTGC 
R708 RV 2 CAAGCAGAAGACGGCATACGAGATGCGCATTAGTGACTGGAGTTCAGACGTGTGC 
R709 RV 2 CAAGCAGAAGACGGCATACGAGATCATAGCCGGTGACTGGAGTTCAGACGTGTGC 
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R710 RV 2 CAAGCAGAAGACGGCATACGAGATTTCGCGGAGTGACTGGAGTTCAGACGTGTGC 
R711 RV 2 CAAGCAGAAGACGGCATACGAGATGCGCGAGAGTGACTGGAGTTCAGACGTGTGC 




In Chapter III, competition infections were performed by infecting mice 
with a 1:1 mixture of ∆Rv1273c and H37Rv (harboring pJEB402 chromosomally 
integrated plasmid encoding kanamycin resistance) or 1:1 mixture of ∆Rv1273c 
complement strain and kanamycin-resistant H37Rv via the aerosol route (500-
1000 CFU/mouse). After 21 days post infection RIF was administered to groups 
of mice. At indicated time points mice were sacrificed and CFU in lung and 
spleen homogenate was determined by plating on 7H10 agar containing either 
hygromycin (50g/ml) or kanamycin (20g/ml). 
 
Phenotypic and genotypic analysis of Korean strains 
Strains were collected from the National Culture Collection for Pathogens, 
which is maintained by the Korea Centers for Disease Control and Prevention. 
Phenotypic DST testing for each strain was conducted by an absolute 
concentration method using Löwenstein-Jensen agar with critical concentrations 
of TB drugs (in g/ml): isoniazid (0.2), rifampin (40), ethambutol (2), streptomycin 
(10), kanamycin (40), prothionamide (40), cycloserine (30), para-aminosalicylic 
“ID” = primer identifier name. “Dir.” = annealing direction of the primer. “Round” = the PCR 
reaction the primer is used (1 or 2). Purple = annealing sequence. Red = unique molecular 




acid (1), ofloxacin (2), pyrazinamide (50; pH 4.65), capreomycin (40), 
moxifloxacin (2), amikacin (40), levofloxacin (2), p-nitrobenzoic acid (500), and 
rifabutin (40). Strains were classified as resistant if drug-containing media 
produced more than 1% of the CFU observed in control cultures. To test growth 
on glycerol, M. tuberculosis was grown in Middlebrook 7H9 broth with 0.5% 
glycerol, 0.05% tyloxapol, catalase, and fatty acid-free bovine serum albumin 
(Sigma). Inocula were cultivated in 7H9-OADC-Tween 80 to an OD of 0.1 to 0.2, 
washed with phosphate-buffered saline plus tyloxapol (0.05%), and diluted to 
~106 CFU/ml. 
Genomic DNA was sequenced either by Ion Torrent (yielding an average 
read length of 170 bases) or Illumina (300-base paired-end reads) platforms. In 
both cases, reads were aligned using bwa mem (version 0.7.12) against 
Mycobacterium tuberculosis H37Rv reference GenBank accession no. 
NC_018143.2. Variants were called using GATK 3.3-0 (218, 219) by following the 
developer’s best practices: (i) picard 1.96 MarkDuplicates, (ii) GATK Realigner 
Target Creator, (iii) GATK IndelRealigner, (iv) GATK BaseRecalibrator, (v) GATK 
UnifiedGenotyper, and (vi) GATK GenotypeGVCFs. Base recalibration was 
performed iteratively using the initial Ion variant calls, obtained without 
recalibration, to obtain a set of polymorphic sites for use in step 4. Final filtering 
was performed separately for single-nucleotide polymorphism (SNP) and 
insertion/deletion (indel) calls: for SNPs, FS of >60.0, MQ of <40.0, MQRankSum 
of < −12.5, and ReadPosRankSum of < −8.0; for indels, FS of >200.0 and 
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ReadPosRankSum of < −20.0. Call-passing filters were combined and a final 
filter QD of <20.0 was applied. Only calls passing all filters were combined into 
the final vcf file (a total of 7,418 variants). For phylogenetic analysis, only variant 
SNPs were used. The final alignment (which included the corresponding 
NC_181843.2 reference bases) consisted of 51 taxa X 7,247 positions. A 
maximum likelihood phylogeny was obtained using PHYML version 20120412 
(220) with the generalized time-reversible model. Trees were visualized with 
iTOL (221). Alternative tree topologies were generated using PHYLIP retree 
(222), and SH tests were performed using PAML baseml, version 4.8 (223). 
 
Phenotypic and genotypic analysis of Peruvian strains 
Drug-resistant phenotypes were determined by measuring MICs to 12 
anti-tuberculosis drugs. For strains found to be sensitive at the critical 
concentration recommended by the WHO for each drug (224), we tested two MIC 
levels below the critical concentration, and for those resistant at the critical 
concentration, we tested six levels above it. The testing concentrations deviated 
from the traditional doubling in order to better detect intermediate-level MICs that 
are theoretically achievable levels in patient sera. 
Strains were sequenced on the Illumina platform to produce 100 to 150 
paired-end reads and coverage of at least 50-fold. The paired-end raw sequence 
data were mapped to the H37Rv reference genome using the BWA mem 
algorithm. We used SAMtools (default settings) (225) and pilon (226) to identify 
 
 101 
single-nucleotide variants and insertions and deletions up to approximately 
100bp using a coverage-based approach. We assigned a variant call as missing 
if the valid depth of coverage at a specific site was less than 10 reads, if the 
mean read-mapping quality at the site did not reach 7, or if none of the 
alternative alleles accounted for at least 90% of the valid coverage. The 
genotype of glpK was determined by a binary burden score that represented the 
presence of any nonsynonymous single-nucleotide variant, insertion, or deletion 
observed in that gene. M. tuberculosis genetic lineages were determined using a 
previously published SNP barcode (227). A neighbor-joining tree was derived 
using https://cran.r-project.org/web/packages/ape/index.html. 
A linear mixed model was used to examine the associations between glpK 
genotype and the rank-transformed MICs phenotypes of 12 drugs and pncA 
genotype. We adjusted for the population structure using a genetic relatedness 
matrix (GRM), calculated from a pairwise distance matrix using synonymous 
single-nucleotide variants of the complete genome using the software GEMMA. 
The type I error rate was set at 0.01 after a Bonferroni correction accounting for 







APPENDIX A2: List of genes with altered susceptibility to HRZE 
treatment in vivo and strain characteristics of Korean Isolates 
 
Table A2.1 | Significantly underrepresented                                                                        
genes post HRZE treatment compared to pretreatment 
    HRZE 1wk 
ID gene LFC Q-value 
Rv0111   -1.5986 0.0016 
Rv0407  fgd1 -1.9510 0.0016 
Rv0757  phoP -2.7132 0.0016 
Rv0989c  grcC2 -4.2399 0.0016 
Rv0998   -2.9370 0.0016 
Rv1006   -1.3537 0.0224 
Rv1099c  glpX -4.0453 0.0016 
Rv1212c  glgA -2.2771 0.0016 
Rv1213  glgC -2.2245 0.0016 
Rv1244  lpqZ -1.9977 0.0121 
Rv2048c  pks12 -1.0648 0.0016 
Rv2605c  tesB2 -5.1316 0.0016 
Rv2936  drrA -1.5669 0.0121 
Rv3135  ppe50 -2.1230 0.0016 
Rv3136  ppe51 -2.6363 0.0016 
Rv3419c  gcp -2.6857 0.0461 
Rv3484  cpsA -4.0845 0.0016 
Rv3494c  mce4F -1.2131 0.0461 
Rv3560c  fadE30 -3.5686 0.0432 
Rv3578  arsB2 -1.0654 0.0461 
Rv3693   -2.5123 0.0121 
Rv3822   -0.9614 0.0461 








LFC = log2 fold change. Q-value = significance 
adjusting for multiple tests. Red = LFC  −1.5. 
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Table A2.2 | Significantly overrepresented                                                                            
genes post HRZE treatment compared to pretreatment 
    HRZE 1wk 
ID gene LFC Q-value 
Rv0465c   1.1459 0.0121 
Rv1538c  ansA 1.2808 0.0224 
Rv2043c  pncA 2.4300 0.0016 
Rv2476c  gdh 1.1678 0.0016 
Rv2571c   1.4486 0.0461 
Rv2931  ppsA 1.0627 0.0016 
Rv2933  ppsC 0.8416 0.0121 
Rv2940c  mas 0.8539 0.0121 








Table A2.3 | Significantly underrepresented                                                                          
genes 21 days post infection compared to pretreatment 
    21 dpi 
ID gene LFC Q-value 
Rv0465c   -1.8249 0.0031 
Rv0485   -1.6265 0.0031 
Rv0806c  cpsY -1.5816 0.0031 
Rv1701   -3.2905 0.0031 
Rv2115c  mpa -1.0712 0.0031 
Rv3193c   -2.1654 0.0031 
Rv3849  espR -3.2237 0.0031 






LFC = log2 fold change. Q-value = significance 
adjusting for multiple tests. Green = LFC  1.5. 
 
LFC = log2 fold change. Q-value = significance 
adjusting for multiple tests. Red = LFC  −1.5. 
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Table A2.4 | Significantly underrepresented                                                                        
genes post HRZE treatment using three-way analysis 
    HRZE 1wk 
ID gene ∆LFC Q-value 
Rv0051   -2.0407 0.0000 
Rv0086  hycQ -2.6265 0.0111 
Rv0111   -1.5684 0.0000 
Rv0125  pepA -1.9922 0.0111 
Rv0158   -1.4512 0.0194 
Rv0190   -4.9787 0.0329 
Rv0205   -1.5591 0.0456 
Rv0271c  fadE6 -0.9635 0.0465 
Rv0399c  lpqK -1.5470 0.0277 
Rv0407  fgd1 -1.9285 0.0194 
Rv0503c  cmaA2 -0.9200 0.0000 
Rv0600c   -4.4031 0.0000 
Rv0644c  mmaA2 -2.2617 0.0000 
Rv0645c  mmaA1 -1.6194 0.0000 
Rv0727c  fucA -1.1885 0.0465 
Rv0757  phoP -2.8317 0.0000 
Rv0758  phoR -1.3104 0.0329 
Rv0908  ctpE -1.3085 0.0329 
Rv0941c   -1.5596 0.0493 
Rv0946Ac  -2.2355 0.0371 
Rv0989c  grcC2 -5.0461 0.0000 
Rv1006   -1.3664 0.0493 
Rv1183 mmpL10 -1.1943 0.0194 
Rv1212c  glgA -2.7661 0.0000 
Rv1213  glgC -2.4998 0.0000 
Rv1244  lpqZ -2.7024 0.0111 
Rv1336  cysM -1.9840 0.0000 
Rv1387  ppe20 -1.4186 0.0000 
Rv1508c   -0.7442 0.0456 
Rv1732c   -1.9263 0.0436 
Rv1745c  idi -3.2513 0.0371 
Rv1747   -0.9466 0.0194 
Rv1905c  aao -0.9624 0.0493 
Rv1924c   -1.9230 0.0456 
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Rv2565   -1.2265 0.0465 
Rv2605c  tesB2 -5.2356 0.0111 
Rv2721c   -1.3514 0.0000 
Rv2745c  clgR -2.2730 0.0465 
Rv2938  drrC -1.3242 0.0194 
Rv2945c  lppX -2.6995 0.0111 
Rv2994   -1.3044 0.0000 
Rv3047c   -2.5337 0.0111 
Rv3135  ppe50 -2.8176 0.0000 
Rv3136  ppe51 -2.7915 0.0000 
Rv3217Ac   -4.7511 0.0371 
Rv3223c  sigH -1.7085 0.0456 
Rv3241c   -1.6016 0.0111 
Rv3339Ac   -3.2444 0.0329 
Rv3419c  gcp -3.8452 0.0371 
Rv3492c   -2.8399 0.0111 
Rv3495c  lprN -1.5819 0.0493 
Rv3509c  ilvX -1.0097 0.0000 
Rv3578  arsB2 -1.4009 0.0371 
Rv3689   -1.4143 0.0111 
Rv3692  moxR2 -2.8581 0.0465 
Rv3693   -3.1830 0.0000 
Rv3728   -0.9618 0.0000 
Rv3821   -1.7274 0.0456 
Rv3822   -1.2510 0.0000 
Rv3823c  mmpL8 -1.9440 0.0465 













∆LFC = difference between log2 fold change in HRZE 
treated and untreated animals compared to 
pretreatment. Q-value = significance adjusting for 
multiple tests. Red = LFC  −1.5. 
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Table A2.5 | Significantly overrepresented                                                                         
genes post HRZE treatment using three-way analysis 
    HRZE 1wk 
ID gene ∆LFC Q-value 
Rv0465c   2.6766 0.0000 
Rv0805   1.7278 0.0456 
Rv2043c  pncA 2.1607 0.0000 
Rv2476c  gdh 1.5181 0.0000 
Rv2571c   1.6985 0.0111 
Rv2931  ppsA 0.9703 0.0329 
Rv2933  ppsC 0.7721 0.0277 





















∆LFC = difference between log2 fold change in 
HRZE treated and untreated animals compared to 
pretreatment. Q-value = significance adjusting for 
multiple tests. Green = LFC  1.5. 
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Table A2.6 | Phenotypic drug sensitivity of Korean M. tuberculosis isolates 
determined by LJ Agar Assay 
    Drug Sensitivity by LJ Agar Assay 
Sample Lineage INH  RIF EMB PZA SM KAN PTH PAS CS OFX MFX CPM LEV RBU AMK 
KT0005 Beijing (others) R R R R R R R S R R S R S R R 
KT0022 Beijing (others) R R R R S S R R R R R S R S S 
KT0026 Beijing (K) R R R R R R S S R R R S R R R 
KT0122-1 Non-Beijing S S S S S S R S S S S S S S S 
KT0124 ND S S S S S S S S S S S S S S S 
KT0129 Beijing S S S S S S R S R S S S S S S 
KT0130 ND R R R R R S R R R R R R R R S 
KT0131 Beijing R R S S S S S S S S S S S R S 
KT0132 Beijing S S S S S S R S S S S S S S S 
KT0133 Beijing S S S S S S S S S S S S S S S 
KT0133 Beijing (K) S S S S S S S S S S S S S S S 
KT0134 Beijing R R R S S R R R R R S S R R S 
KT0135 Beijing R R R S S S S S S S S S S S S 
KT0136 ND R R R R R R R R R R R R R R R 
KT0137 Non-Beijing R R R S S S R S R S S S S R S 
KT0139-1 Beijing R R S R R S S S S S S S S R S 
KT0140 Beijing (M) S S S S S S S S S S S S S S S 
KT0144-1 ND R R S R S R R R R R R R R R R 
KT0149-1 Beijing R R R R R R R R S R R R R R R 
KT0155-1 Beijing R R R R S R R R R R R R R R R 
KT0157-1 Beijing R R R S R R R R R R R R R S R 
KT0158-1 Beijing R R R R R R R R R R R R R R R 
KT0159-1 Beijing R R R R R R R R R R S R S R R 
KT0160-1 Beijing R R R R R R R R R R R R R R R 
KT0161-1 Beijing R R R R R R R R R R R R R R R 
KT0181 Non-Beijing S S S S S S R S S S S S S S S 
KT0182 Beijing R R R R R S S R S S S S S R S 
KT0184 Beijing S S S S S S S S S S S S S S S 
KT0185 Beijing (others) S S S S S S R S S S S S S S S 
KT0186 Beijing (K) S S S S S S R S S S S S S S S 
KT0187 Beijing (others) S S S S S S S S S S S S S S S 
KT0188 Beijing (others) S S S S S S S S S S S S S S S 
KT0189 Beijing (M) R R R S R S S S S S S S S S S 
KT0190 Beijing (others) S S S S S S S S S S S S S S S 
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KT0191 Beijing (others) S S S S S S S S R S S S S S S 
KT0192 Non-Beijing R R R R R S R R R R S S R R S 
KT0193 Beijing (others) S S S S S S S S S S S S S S S 
KT0194 Non-Beijing R S S S S S R S S S S S S S S 
KT0196 Beijing (K) R R R S S S S S S R R S R S S 
KT0197 Beijing (K) S S S S S S S S S S S S S S S 
KT0198 Beijing (K) S S S R S S S S S S S S S S S 
KT0199 Non-Beijing R R R R R S R S R R S S R R S 
KT0200 Beijing (K) R R S S R S S S S S S S S R S 
KT0201 Beijing (M) S S S S S S S R S S S S S S S 
KT0202 Beijing (M) S S S S S S S S S S S S S S S 
KT0203 Beijing (others) R R R R R R R R R R S S R R S 
KT1111  Beijing R R R R R R R R R R ND ND ND ND ND 
KTL008 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
KTL009 ND R R R R S S R S R R R S R R S 




























“ND” = not determined. “R”, red filled = resistant. “S”, green filled = susceptible. INH, 
isoniazid; RIF, rifampin; EMB, ethambutol; PZA, pyrazinamide; SM, streptomycin; KAN, 
kanamycin; PTH, prothionamide; PAS, para-aminosalicylic acid; CS, cycloserine; OFX, 




Table A2.7 | Phenotypic drug sensitivity of Korean M. tuberculosis                               
isolates determined by MGIT assay 
    Drug Sensitivity by LJ Agar Assay 
Sample Lineage INH RIF EMB PZA SM KAN OFX MFX CPM 
KT0005 Beijing (others) R R S R S R R S R 
KT0022 Beijing (others) R R S R S S R R S 
KT0026 Beijing (K) R R R S R R R R R 
KT0122-1 Non-Beijing S S S S S S S S R 
KT0124 ND S S S S S S S S R 
KT0129 Beijing S S S S S S S S S 
KT0130 ND R R R R R R R R R 
KT0131 Beijing R R S S S S S S S 
KT0132 Beijing S S S S S S S S R 
KT0133 Beijing S S S S S S S S S 
KT0133 Beijing (K) S S S S S S S S S 
KT0134 Beijing R R S S S R R R S 
KT0135 Beijing R R S S S S S S S 
KT0136 ND R R S R R R R R R 
KT0137 Non-Beijing R R S S S S S S S 
KT0139-1 Beijing R R S S S S S S S 
KT0140 Beijing (M) S S S S S S S S S 
KT0144-1 ND R R S ND R R R R R 
KT0149-1 Beijing R R R R R R R R R 
KT0155-1 Beijing R R R R S R S R R 
KT0157-1 Beijing R R R R R R R R R 
KT0158-1 Beijing R R R R R R R R R 
KT0159-1 Beijing R R S R R R S R R 
KT0160-1 Beijing R R S R R R R R R 
KT0161-1 Beijing R R S R R R R R R 
KT0181 Non-Beijing S S S S S S S S R 
KT0182 Beijing R R S R R S S S S 
KT0184 Beijing S S S S S S S S S 
KT0185 Beijing (others) S S S S S S S S S 
KT0186 Beijing (K) S S S S S S S S R 
KT0187 Beijing (others) S S S S S S S S S 
KT0188 Beijing (others) S S S S S S S S S 
KT0189 Beijing (M) R R S S R S S S S 
KT0190 Beijing (others) S S S S S S S S R 
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KT0191 Beijing (others) S S S S S S S S S 
KT0192 Non-Beijing R R R R R S R R S 
KT0193 Beijing (others) S S S S S S S S S 
KT0194 Non-Beijing R S S S S S S S S 
KT0196 Beijing (K) R S S S S S R R S 
KT0197 Beijing (K) S S S S S S S S S 
KT0198 Beijing (K) S S S R S S S S S 
KT0199 Non-Beijing R R S R R S R R S 
KT0200 Beijing (K) R R S S S S S S S 
KT0201 Beijing (M) S S S S S S S S S 
KT0202 Beijing (M) R S S S S S S S S 
KT0203 Beijing (others) R R R R R R R R S 
KT1111  Beijing ND ND ND ND ND ND ND ND ND 
KTL008 ND ND ND ND ND ND ND ND ND ND 
KTL009 ND ND ND ND ND ND ND ND ND ND 
KTL018 ND 



























“ND” = not determined. “R”, red filled = resistant. “S”, green filled = 
susceptible. INH, isoniazid; RIF, rifampin; EMB, ethambutol; PZA, 
pyrazinamide; SM, streptomycin; KAN, kanamycin; OFX, ofloxacin; 
MFX, moxifloxacin; CPM, capreomycin. 
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Table A2.8 | Growth on glycerol and glpK genotype of                                                    
Korean M. tuberculosis isolates 
    growth on glpK 
Sample Lineage glycerol genotype 
KT0005 Beijing (others) ND WT 
KT0022 Beijing (others) ND WT 
KT0026 Beijing (K) ND WT 
KT0122-1 Non-Beijing ND WT 
KT0124 ND ND WT 
KT0129 Beijing ND WT 
KT0130 ND ND WT 
KT0131 Beijing ND WT 
KT0132 Beijing ND WT 
KT0133 Beijing ND WT 
KT0133 Beijing (K) ND WT 
KT0134 Beijing ND WT 
KT0135 Beijing ND WT 
KT0136 ND negative frameshift 
KT0137 Non-Beijing ND WT 
KT0139-1 Beijing ND WT 
KT0140 Beijing (M) positive WT 
KT0144-1 ND negative frameshift 
KT0149-1 Beijing negative frameshift 
KT0155-1 Beijing negative frameshift 
KT0157-1 Beijing negative WT 
KT0158-1 Beijing negative frameshift 
KT0159-1 Beijing negative frameshift 
KT0160-1 Beijing negative frameshift 
KT0161-1 Beijing negative frameshift 
KT0181 Non-Beijing ND missense 
KT0182 Beijing ND WT 
KT0184 Beijing positive WT 
KT0185 Beijing (others) ND WT 
KT0186 Beijing (K) ND WT 
KT0187 Beijing (others) positive WT 
KT0188 Beijing (others) ND WT 
KT0189 Beijing (M) ND frameshift 
KT0190 Beijing (others) ND WT 
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KT0191 Beijing (others) positive WT 
KT0192 Non-Beijing ND WT 
KT0193 Beijing (others) positive WT 
KT0194 Non-Beijing ND WT 
KT0196 Beijing (K) ND WT 
KT0197 Beijing (K) positive WT 
KT0198 Beijing (K) ND WT 
KT0199 Non-Beijing ND WT 
KT0200 Beijing (K) ND WT 
KT0201 Beijing (M) positive WT 
KT0202 Beijing (M) ND WT 
KT0203 Beijing (others) negative frameshift 
KT1111  Beijing negative WT 
KTL008 ND ND WT 
KTL009 ND ND WT 




























“ND” = not determined. “positive” = growth on glycerol. 
“negative” = no growth on glycerol. “WT” = wild-type glpK 
genotype. “frameshift” = +1bp indel in glpK homopolymer 
region. “missense” = missense mutation in glpK open 
reading frame.  
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Appendix A3: List of genes with altered susceptibility to antibiotic 
treatment in vivo 
 
Table A3.1 | Genes required for optimal fitness in vivo 
    14 dpi 21 dpi 32 dpi 49 dpi 









 Rv0007   -0.0736 0.5005 -0.8733 0.3390 0.2311 0.4949 -2.3103 0.0094 
 Rv0012   -0.9110 0.0243 -1.0468 0.0185 -0.9631 0.0508 -1.0029 0.0839 
 Rv0013  trpG -1.1802 0.4717 -3.2395 0.0241 -2.8004 0.0248 -2.5896 0.0001 
 Rv0018c  pstP -0.7002 0.5005 -1.7374 0.0742 -1.6992 0.1065 -2.8692 0.0094 
 Rv0019c  fhaB -0.7355 0.4997 -4.0004 0.0002 -0.4306 0.4949 -4.7337 0.0001 
 Rv0040c  mtc28 -1.2886 0.0033 -0.9499 0.1054 -0.9612 0.1595 -2.6279 0.0001 
 Rv0043c   -1.1238 0.0033 -1.4789 0.0002 -1.7750 0.0002 -0.0676 0.4931 
 Rv0047c   -0.7765 0.4760 -0.3889 0.4993 -0.8607 0.3634 -2.8475 0.0024 
 Rv0049   -0.0797 0.5005 -0.0497 0.5189 -0.4726 0.4907 -2.1385 0.0168 
 Rv0050  ponA1 -0.5317 0.2612 -0.9956 0.0317 -0.1378 0.4949 -1.4469 0.0001 
 Rv0056  rplI -1.5100 0.0663 -1.9828 0.0040 -2.4378 0.0002 -2.4448 0.0001 
 Rv0069c  sdaA 0.1169 0.5005 -0.3226 0.4875 -0.3267 0.4907 -2.7088 0.0001 
 Rv0078   -0.2505 0.5005 -2.7601 0.0002 -2.2503 0.0002 -1.1039 0.0834 
 Rv0081   -0.1719 0.5005 0.5280 0.3818 -1.1528 0.0049 -0.6125 0.1416 
 Rv0083   -0.0949 0.5005 -0.2571 0.4709 -0.7781 0.0301 -0.7966 0.0448 
 Rv0086  hycQ -0.5142 0.4498 -0.0880 0.4993 -0.0662 0.4949 -1.2465 0.0141 
 Rv0088   -0.5664 0.4725 -0.8086 0.3048 -0.7737 0.3123 -2.4082 0.0035 
 Rv0092  ctpA -0.8076 0.0002 -0.8346 0.0002 -0.1686 0.4824 -0.4786 0.1313 
 Rv0096  ppe1 -1.6387 0.0002 -2.1597 0.0002 -3.1672 0.0002 -3.8170 0.0001 
 Rv0097   -1.8453 0.0002 -2.9783 0.0002 -2.8133 0.0002 -6.5418 0.0001 
 Rv0098  fcoT -1.9332 0.0017 -1.8107 0.0040 -3.9879 0.0002 -6.3198 0.0001 
 Rv0099  fadD10 -1.8030 0.0002 -1.4446 0.0040 -3.6219 0.0002 -4.2028 0.0001 
 Rv0101  nrp -1.4123 0.0002 -1.6367 0.0002 -2.5136 0.0002 -4.0199 0.0001 
 Rv0111   -0.4950 0.1047 -0.8049 0.0116 -1.3985 0.0002 -1.3072 0.0001 
 Rv0119  fadD7 -4.7277 0.0033 -4.8284 0.0002 -4.3985 0.0026 -2.6434 0.0899 
 Rv0126  treS -1.8426 0.1579 -2.5049 0.0568 -3.2871 0.0026 -4.2863 0.0001 
 Rv0129c  fbpC -0.1546 0.5005 -0.7896 0.0453 -0.2192 0.4907 -1.6284 0.0001 
 Rv0135c   -1.8422 0.0243 -2.2867 0.0116 -2.3565 0.0038 -0.8465 0.3903 
 Rv0147   0.4135 0.1609 0.2498 0.4185 0.7173 0.0182 0.3148 0.2952 
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 Rv0154c  fadE2 -0.5898 0.3111 -0.5163 0.3346 -1.6059 0.0002 -1.6914 0.0001 
 Rv0155  pntAa -1.0288 0.0825 -3.6244 0.0002 -1.5716 0.0417 -0.8017 0.3329 
 Rv0157  pntB -1.5891 0.0002 -3.5245 0.0002 -2.7045 0.0002 -3.3195 0.0001 
 Rv0158   -0.7556 0.0033 0.1962 0.4928 -0.6826 0.0266 -0.9992 0.0035 
 Rv0161   -0.6008 0.3450 -0.3155 0.4736 -1.2208 0.0238 -2.0137 0.0001 
 Rv0168  yrbE1B -1.0934 0.0002 -0.5484 0.0515 -1.0055 0.0014 -1.1822 0.0001 
 Rv0169  mce1A -1.0300 0.0002 -0.8155 0.0002 -0.6417 0.0124 -0.9750 0.0001 
 Rv0170  mce1B -1.8030 0.0002 -1.0735 0.0015 -0.4776 0.3402 -1.5752 0.0001 
 Rv0171  mce1C -1.4157 0.0002 -1.1665 0.0015 -0.9394 0.0014 -1.9520 0.0001 
 Rv0172  mce1D -1.1196 0.0002 -0.7589 0.0002 -0.9944 0.0002 -1.1064 0.0001 
 Rv0173  lprK -1.7113 0.0002 -0.7826 0.1107 -1.3334 0.0002 -1.3912 0.0001 
 Rv0174  mce1F -1.2829 0.0002 -1.0273 0.0002 -1.0352 0.0002 -1.1897 0.0001 
 Rv0175   -1.8104 0.0002 -2.3451 0.0002 -1.1083 0.0266 -1.5609 0.0012 
 Rv0176   -0.7049 0.0433 -0.6101 0.1305 -0.4647 0.3351 -0.8928 0.0510 
 Rv0177   -1.5123 0.0002 -2.0679 0.0002 -1.7321 0.0014 -2.1518 0.0001 
 Rv0178   -1.4193 0.0033 -1.6473 0.0028 -0.6535 0.3140 -1.0691 0.1329 
 Rv0179c  lprO -0.1851 0.5005 -0.3477 0.3870 0.0078 0.5003 -0.8495 0.0094 
 Rv0180c   -1.9813 0.0155 -2.1673 0.0116 -1.4426 0.1219 -2.1288 0.0345 
 Rv0191   -0.4619 0.2074 -0.4856 0.1781 -0.8268 0.0172 -0.4253 0.3006 
 Rv0199   -2.2204 0.0002 -5.3603 0.0002 -3.7123 0.0002 -2.5105 0.0001 
 Rv0200   -1.6498 0.0538 -3.2438 0.0002 -3.0138 0.0002 -7.7617 0.0001 
 Rv0201c   -1.4510 0.0002 -1.1499 0.0249 0.0724 0.4949 -0.2405 0.4653 
 Rv0202c 
 
mmpL11 -1.4734 0.0002 -1.5023 0.0002 -1.2760 0.0002 -2.5460 0.0001 
 Rv0204c   -2.3014 0.0002 -1.8011 0.0002 -2.5335 0.0002 -5.5986 0.0001 
 Rv0206c  mmpL3 -3.7015 0.0002 -0.7451 0.4952 -2.5821 0.0266 -1.3448 0.2745 
 Rv0211  pckA -2.0515 0.1101 0.8378 0.4862 -2.2603 0.0495 -3.1188 0.0046 
 Rv0216   -0.6889 0.4146 -1.7643 0.0125 -2.2476 0.0014 -2.0911 0.0012 
 Rv0234c  gabD1 -0.4250 0.4340 -0.6830 0.0936 -0.2346 0.4907 -1.0684 0.0159 
 Rv0238   -0.6234 0.5005 -4.3769 0.0002 -4.4319 0.0380 -1.6790 0.2984 
 Rv0242c  fabG4 -1.4669 0.0033 -1.6821 0.0063 -1.1924 0.0874 -0.6272 0.3269 
 Rv0243  fadA2 -0.7754 0.0615 -1.1223 0.0074 -1.1823 0.0038 -0.8184 0.1013 
 Rv0244c  fadE5 -4.0744 0.0002 -4.0101 0.0002 -2.5009 0.0002 -3.9392 0.0001 
 Rv0247c   -3.2252 0.0002 -4.2422 0.0002 -5.1526 0.0002 -3.4015 0.0035 
 Rv0248c   -3.7168 0.0002 -4.9509 0.0002 -4.0333 0.0002 -3.7416 0.0001 
 Rv0249c   -4.0550 0.0002 -3.4412 0.0002 -4.8405 0.0002 -3.8440 0.0001 
 Rv0256c  ppe2 -0.6634 0.0102 -1.0733 0.0002 -1.1288 0.0002 -0.5425 0.1083 
 Rv0259c   -0.6939 0.4250 0.1102 0.4993 -1.3110 0.0457 -0.3278 0.4439 
 Rv0270  fadD2 -1.7117 0.0002 -1.4878 0.0002 -1.7482 0.0002 -0.9139 0.0001 
 Rv0296c   -0.4097 0.2424 -0.8786 0.0028 -0.7690 0.0124 -1.5452 0.0001 
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 Rv0317c  glpQ2 0.0400 0.5005 -0.8607 0.0308 -0.0914 0.4949 -0.2479 0.4283 
 Rv0321 dcd -0.0844 0.5005 -0.9813 0.1516 -1.6966 0.0026 -0.8357 0.2921 
 Rv0323c   -0.4612 0.4986 0.3194 0.4809 0.4215 0.4501 -1.2960 0.0235 
 Rv0348   -2.4752 0.0033 -0.5203 0.4952 -2.1998 0.0192 -1.0728 0.3862 
 Rv0353  hspR -3.3678 0.0002 -3.8145 0.0002 -3.8608 0.0002 -7.1072 0.0001 
 Rv0361   -0.2670 0.5005 -1.3152 0.1516 -2.2727 0.0133 0.7068 0.4726 
 Rv0364   -1.4382 0.2628 -2.5360 0.0084 1.1020 0.4112 0.7844 0.4250 
 Rv0380c   -1.2282 0.2854 -1.3173 0.2893 -2.7131 0.0038 -3.4558 0.0035 
 Rv0381c   -0.8649 0.0017 -1.0813 0.0002 -1.6017 0.0002 -2.6891 0.0001 
 Rv0385   -0.1833 0.5005 -0.1020 0.4993 -0.2506 0.4907 -1.3164 0.0001 
 Rv0390   -1.4056 0.0074 -1.5706 0.0015 -1.9794 0.0014 -3.2481 0.0001 
 Rv0391  metZ -2.1560 0.0002 -2.2789 0.0002 -2.9601 0.0002 -2.8661 0.0001 
 Rv0400c  fadE7 -1.0015 0.2631 -2.3040 0.0040 -1.1457 0.2424 -1.2127 0.1607 
 Rv0409  ackA -0.8016 0.1047 -1.0259 0.0362 -0.5057 0.4112 -0.0018 0.5149 
 Rv0428c   -0.4260 0.4551 -0.0575 0.4993 -1.2051 0.0049 -0.7587 0.1934 
 Rv0437c  psd -0.5941 0.5005 -2.4763 0.0395 -2.0388 0.1075 -2.3372 0.1138 
 Rv0438c  moeA2 -0.4382 0.3761 -0.8712 0.0423 -0.4179 0.3886 -0.3684 0.4052 
 Rv0449c   0.0148 0.5005 -0.1158 0.4911 -0.5963 0.0133 0.2396 0.3334 
 Rv0450c  mmpL4 -1.7418 0.0002 -2.0418 0.0002 -2.5859 0.0002 -1.8402 0.0001 
 Rv0451c  mmpS4 -1.6533 0.0047 -1.1921 0.0736 -2.5835 0.0002 -1.2555 0.0611 
 
Rv0454Ac   -0.8053 0.0443 -0.5652 0.2977 -0.3593 0.4399 0.1978 0.4676 
 Rv0464c   -0.5841 0.1223 -0.8574 0.0256 -0.1294 0.4949 -0.3415 0.4001 
 Rv0465c   -2.7154 0.0002 -4.5124 0.0002 -3.6451 0.0002 -3.4956 0.0001 
 Rv0470c  pcaA -2.2275 0.0002 -2.0277 0.0002 -2.8250 0.0002 -2.7303 0.0012 
 Rv0472c   -3.8007 0.0002 -4.4982 0.0002 -4.9549 0.0002 -5.3569 0.0001 
 Rv0476   -0.3094 0.3934 -0.1831 0.4795 -0.7533 0.0163 -0.0998 0.4725 
 Rv0485   -2.1144 0.0002 -3.7243 0.0002 -4.7219 0.0002 -5.7242 0.0001 
 Rv0487   -1.1078 0.0130 -0.9409 0.0469 -0.6357 0.2344 -0.9565 0.0896 
 Rv0490  senX3 -0.8693 0.0142 -1.3631 0.0002 -1.8172 0.0002 -2.1472 0.0001 
 Rv0491  regX3 -0.8534 0.0760 -1.5485 0.0002 -1.2761 0.0143 -2.4995 0.0001 
 Rv0497   -0.6616 0.4514 -3.9136 0.0002 -1.7419 0.0441 -1.6842 0.0863 
 Rv0503c  cmaA2 0.4162 0.1047 0.5814 0.0395 0.7585 0.0124 0.4449 0.1246 
 Rv0505c  serB1 1.4280 0.3249 0.1280 0.4993 -1.0522 0.4104 -3.0378 0.0235 
 Rv0508   -1.3914 0.0342 -0.4596 0.4758 -0.7326 0.3776 -1.3979 0.0873 
 Rv0513   -1.4371 0.0372 -1.7696 0.0125 -1.2991 0.1090 -2.1406 0.0132 
 Rv0544c   -1.1154 0.1376 -2.1009 0.0052 -0.8144 0.3724 -1.0617 0.1953 
 Rv0545c  pitA -2.6036 0.0002 -3.7489 0.0002 -5.2221 0.0002 -3.1559 0.0001 
 Rv0546c   -0.5827 0.4997 -0.7725 0.3173 -0.8558 0.2813 -1.6434 0.0338 
 Rv0554  bpoC -1.0957 0.0209 -0.7246 0.1753 -1.3907 0.0038 -0.8248 0.1302 
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 Rv0561c   -1.4845 0.0002 -1.3721 0.0028 -0.3608 0.4291 0.4152 0.4052 
 Rv0588  yrbE2B 0.6227 0.3299 0.8609 0.4314 -0.2214 0.4941 1.1050 0.0461 
 Rv0590A   -0.1980 0.5005 -0.4374 0.4521 -0.5491 0.4236 -1.9469 0.0202 
 Rv0619  galTb -0.4342 0.5005 -2.5255 0.0040 -0.2216 0.4949 -0.1524 0.4916 
 Rv0634A   -1.2557 0.0327 -0.2797 0.4952 -1.1304 0.1080 -0.4271 0.4268 
 Rv0642c  mmaA4 -3.9825 0.0002 -4.8938 0.0002 -1.6500 0.1341 -2.8390 0.0035 
 Rv0645c  mmaA3 0.1032 0.5005 0.6881 0.0166 0.5801 0.0853 -0.0980 0.4721 
 Rv0655  mkl -2.3229 0.0002 -2.9360 0.0002 -2.2613 0.0002 -1.7829 0.0066 
 Rv0692   -0.5551 0.4717 -0.5122 0.4186 -1.8675 0.0002 -2.7774 0.0024 
 Rv0712   -0.5745 0.3386 -0.6192 0.3390 -1.3122 0.0274 -0.8848 0.1548 
 Rv0744c   -0.1713 0.5005 1.0152 0.4768 -0.0338 0.5097 -1.8333 0.0374 
 Rv0747   -0.2825 0.5005 0.4108 0.4149 -0.7615 0.0464 -0.3976 0.3067 
 Rv0750   -0.3144 0.4986 -1.2777 0.0002 -0.0092 0.5008 -0.5875 0.2986 
 Rv0757  phoP -4.2528 0.0002 -4.3726 0.0002 -5.3214 0.0002 -4.2970 0.0001 
 Rv0758  phoR -3.1384 0.0002 -3.1344 0.0002 -3.3451 0.0002 -2.4968 0.0001 
 Rv0761c  adhB -0.4117 0.3872 -0.5378 0.2750 -0.8691 0.0528 -1.1598 0.0211 
 Rv0767c   -0.1823 0.5005 -0.8776 0.0499 -0.4304 0.4144 0.2052 0.4496 
 Rv0784   -1.8352 0.0342 0.9160 0.4993 0.2422 0.4949 -0.4001 0.4916 
 Rv0805   0.0998 0.5005 -1.1795 0.0175 -0.2546 0.4949 -0.1776 0.4635 
 Rv0806c  cpsY -0.4315 0.1691 -1.9803 0.0002 -0.4310 0.2397 -1.0248 0.0001 
 Rv0808  purF -4.1282 0.0002 -1.4605 0.4560 -0.6995 0.4907 0.4427 0.4694 
 Rv0813c   -0.6439 0.0514 -0.8023 0.0084 -0.2109 0.4907 -0.3063 0.4115 
 Rv0815c  cysA2 -0.7802 0.0002 -0.4696 0.1517 -0.6468 0.0301 -0.5716 0.0720 
 Rv0820  phoT -0.2721 0.5005 0.2993 0.4993 -2.0120 0.2812 -4.3314 0.0001 
 Rv0827c  kmtR -1.8120 0.0017 0.4435 0.4646 -0.1162 0.4949 0.5023 0.4266 
 Rv0847  lpqS -0.0328 0.5005 0.8270 0.3245 0.1294 0.4949 -1.6056 0.0076 
 Rv0859  fadA -1.4199 0.1274 -1.4119 0.1821 -1.4331 0.0835 -1.8575 0.0411 
 Rv0860  fadB -0.9708 0.2616 -2.1523 0.0028 -1.3588 0.0865 -1.1045 0.2071 
 Rv0877   -1.6467 0.0002 -0.9004 0.1220 -1.5046 0.0002 -2.2455 0.0001 
 Rv0889c  citA -0.4612 0.3971 -0.9268 0.0241 -0.4070 0.3953 0.0039 0.5003 
 Rv0910   -0.6091 0.4775 -0.9769 0.0790 -1.3551 0.0115 -0.6467 0.2363 
 Rv0924c  mntH 1.0450 0.0233 1.0457 0.0907 1.2391 0.0792 -0.7165 0.2320 
 Rv0928  pstS3 -0.9505 0.2420 1.2712 0.4803 -0.3009 0.4948 -3.2892 0.0001 
 Rv0929  pstC2 -1.6621 0.1157 1.0701 0.4952 -3.4995 0.0002 -2.9881 0.0001 
 Rv0930  pstA1 0.2449 0.5005 -2.4529 0.0063 -0.4126 0.4948 -5.8258 0.0001 
 Rv0954   -0.6048 0.3111 -0.7956 0.2129 -1.2247 0.0172 -1.0425 0.0504 
 Rv0981  mprA -0.2452 0.5005 -0.8889 0.0146 -0.5913 0.1203 -0.0328 0.4940 
 Rv0983  pepD -1.3342 0.0017 -2.2337 0.0002 -1.9674 0.0002 -0.0456 0.5449 
 Rv0987   0.1073 0.5005 0.1139 0.4993 -0.0184 0.4972 0.8641 0.0448 
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 Rv0989c  grcC2 3.0675 0.0002 3.5393 0.0015 2.6511 0.0796 -0.3428 0.4987 
 Rv0994  moeA1 -3.1923 0.0002 -3.2959 0.0002 -3.4041 0.0002 -6.0973 0.0001 
 Rv0998   -3.0680 0.0002 -4.6591 0.0002 -2.7475 0.0061 -3.8274 0.0001 
 Rv0999   -1.0595 0.0002 -1.1973 0.0028 0.0540 0.4949 -0.9119 0.0667 
 Rv1003   -0.3442 0.5005 -1.6698 0.0028 -0.4196 0.4907 -3.4073 0.0001 
 Rv1008  tatD -0.2021 0.5005 -1.1033 0.0028 -0.2573 0.4731 0.1507 0.4651 
 Rv1009  rpfB 0.6295 0.4986 0.9673 0.4409 0.7360 0.4648 -1.4358 0.0482 
 Rv1013  pks16 -0.3869 0.4997 -0.6149 0.3413 -2.1369 0.0002 -1.8732 0.0001 
 Rv1019   -0.6382 0.1888 -0.7036 0.1350 -1.3434 0.0002 -0.4241 0.3579 
 Rv1051c   -0.1340 0.5005 -2.3695 0.0232 0.7844 0.4907 0.2503 0.4772 
 Rv1065   -0.5783 0.1197 -0.4595 0.2588 -0.8724 0.0201 -0.8982 0.0202 
 Rv1069c   -0.4354 0.1095 -0.7877 0.0015 -0.6598 0.0133 -0.3675 0.2630 
 Rv1070c  echA8 -1.2398 0.0002 -1.0526 0.0263 -1.4381 0.0002 -1.1065 0.0228 
 Rv1071c  echA9 -0.4149 0.2936 -0.6284 0.0790 -1.3368 0.0002 -1.0363 0.0066 
 Rv1072   -2.7664 0.4623 -2.9777 0.3902 -2.4162 0.4542 -5.4004 0.0001 
 Rv1082  mca -0.3418 0.4775 -0.9048 0.0232 -0.6485 0.1463 -0.5771 0.3728 
 Rv1085c   -0.4304 0.3914 -0.3460 0.4646 -0.7974 0.0702 -1.0885 0.0123 
 Rv1086   -2.8297 0.0047 -6.0054 0.0002 -6.0448 0.0002 -4.3832 0.0001 
 Rv1096   -2.0521 0.0002 -2.0560 0.0002 -1.7529 0.0002 -1.9198 0.0012 
 Rv1099c  glpX -2.4151 0.0017 -5.8436 0.0002 -1.9419 0.0792 -5.6931 0.0001 
 Rv1100   -2.1938 0.0002 -2.0690 0.0002 -1.5281 0.0133 -1.0495 0.1626 
 Rv1111c   -0.5638 0.3110 -0.9418 0.0272 -1.0676 0.0038 -0.6211 0.2446 
 Rv1126c   -3.8591 0.0062 -0.0278 0.5260 0.5360 0.4953 -3.9322 0.0317 
 Rv1127c  ppdK -1.3217 0.0164 -2.6382 0.0002 -0.9280 0.4529 -4.6803 0.0001 
 Rv1128c   0.1880 0.5005 -0.1449 0.4993 0.0933 0.4949 -2.6697 0.0001 
 Rv1130  prpD -0.8155 0.0155 -0.5530 0.2355 -1.3119 0.0002 -0.3381 0.4016 
 Rv1131  prpC -0.6396 0.5005 -2.8861 0.0002 -0.7555 0.4731 0.0466 0.4988 
 Rv1135A   -0.3403 0.5005 0.0262 0.4993 -1.2472 0.0094 0.1207 0.4805 
 Rv1151c   -0.5052 0.1740 -1.0126 0.0015 -0.8604 0.0143 -0.4226 0.2875 
 Rv1157c   -0.3412 0.5005 -3.0815 0.0084 -3.6962 0.0014 -2.3841 0.0749 
 Rv1161  narG -0.1446 0.5005 -0.3172 0.1737 -0.5131 0.0084 -0.3130 0.1930 
 Rv1167c   -0.2430 0.5005 -1.9988 0.0040 -0.6243 0.4731 -0.3774 0.4439 
 Rv1174c   -0.2222 0.5005 -0.6714 0.1305 -0.9250 0.0230 -0.6067 0.2188 
 Rv1178   -1.4552 0.0002 -1.0464 0.0213 -2.5078 0.0002 -1.6736 0.0001 
 Rv1183 
 
mmpL10 -0.2642 0.4340 -0.2110 0.4462 -0.7217 0.0094 -1.4700 0.0001 
 Rv1193  fadD36 -5.0810 0.0002 -6.4199 0.0002 -5.9588 0.0002 -6.3590 0.0001 
 Rv1194c   0.8474 0.0334 0.3227 0.4460 0.7060 0.1676 0.9905 0.1087 
 Rv1196  ppe18 0.8270 0.0185 0.5589 0.3318 0.4620 0.3308 0.5305 0.3243 
 Rv1205   -1.9818 0.0002 -0.9615 0.2983 -1.8831 0.0115 -2.9220 0.0001 
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 Rv1206  fadD6 -1.6018 0.0002 -1.6631 0.0002 -1.5042 0.0002 -0.9362 0.0001 
 Rv1219c   -0.1138 0.5005 -1.1301 0.0837 -0.4565 0.4499 -2.5241 0.0001 
 Rv1220c   -0.4685 0.4986 -0.6522 0.2977 -1.3264 0.0115 -1.3315 0.0405 
 Rv1234   -0.6742 0.4601 -0.5462 0.4505 -0.9484 0.3223 -2.6089 0.0159 
 Rv1235  lpqY -1.1869 0.0002 -2.2816 0.0002 -2.5994 0.0002 -2.7015 0.0001 
 Rv1236  sugA -1.3505 0.0047 -2.4421 0.0002 -1.6417 0.0026 -3.5776 0.0001 
 Rv1237  sugB -1.7169 0.0047 -5.1169 0.0002 -7.2495 0.0002 -1.1531 0.1162 
 Rv1238  sugC -1.2542 0.0002 -1.4993 0.0002 -2.3173 0.0002 -2.9359 0.0001 
 Rv1244  lpqZ -0.9246 0.1047 -0.5213 0.4114 -1.0115 0.1591 -1.8263 0.0086 
 Rv1272c   -1.6153 0.0002 -1.6974 0.0002 -2.7416 0.0002 -0.4829 0.4718 
 Rv1273c   -1.3745 0.0017 -1.8273 0.0002 -2.8706 0.0002 -2.2600 0.0001 
 Rv1277   -0.1798 0.5005 -0.2732 0.4617 -0.8654 0.0417 -0.2956 0.4328 
 Rv1280c  oppA -0.5114 0.1166 -0.4413 0.3092 -0.6829 0.0404 -0.5155 0.1209 
 Rv1287   -1.8235 0.0002 -0.8510 0.1483 -0.8477 0.1850 -1.7169 0.0001 
 Rv1290A   0.0041 0.5008 -0.5336 0.4646 -1.3211 0.1455 -2.0256 0.0401 
 Rv1314c   -0.9099 0.0185 -1.4189 0.0015 -1.1449 0.0115 -0.9169 0.1098 
 Rv1323  fadA4 -0.5406 0.0453 -1.3166 0.0002 -0.7729 0.0115 -0.5126 0.1610 
 Rv1331   -0.2227 0.5005 -1.0415 0.0185 -0.4864 0.3993 -0.9523 0.0393 
 Rv1332   -0.4383 0.5005 -2.1758 0.0002 -0.7876 0.4158 -3.4950 0.0001 
 Rv1333   0.1211 0.5005 0.5860 0.3869 -0.3260 0.4907 -1.0848 0.0177 
 Rv1336  cysM -0.7195 0.1095 -0.3609 0.4535 -0.5281 0.3206 -1.3541 0.0035 
 Rv1337   -0.7075 0.1012 -0.8522 0.2641 -1.5412 0.0002 -2.1683 0.0001 
 Rv1339   -4.4603 0.0002 -4.1147 0.0052 -2.0582 0.1214 -3.4687 0.0252 
 Rv1345  mbtM -2.6609 0.0002 -2.9079 0.0002 -3.6583 0.0002 -2.4051 0.0001 
 Rv1347c  mbtK -4.9791 0.0017 -5.0452 0.0028 -5.1065 0.0002 -4.4110 0.0001 
 Rv1348  irtA -1.7241 0.0033 -3.6347 0.0002 -4.5783 0.0002 -5.1430 0.0001 
 Rv1349  irtB -3.5275 0.0002 -4.5665 0.0002 -4.8295 0.0002 -5.0782 0.0001 
 Rv1364c   -0.2798 0.4997 -0.8829 0.0249 0.2530 0.4949 -0.4781 0.3862 
 Rv1388  mihF -1.8056 0.1247 -4.2857 0.0040 -4.3189 0.0002 -0.7815 0.4283 
 Rv1401   0.6786 0.5005 0.9544 0.4993 -3.5235 0.0133 -1.5118 0.2306 
 Rv1404   0.3574 0.5032 -2.6024 0.0116 -3.2822 0.0002 -5.5823 0.0001 
 Rv1405c   -2.0594 0.0002 -2.0629 0.0002 -2.7816 0.0002 -3.4065 0.0001 
 Rv1411c  lprG -4.9395 0.0002 -4.5809 0.0002 -4.6283 0.0002 -3.9316 0.0001 
 Rv1421   0.4939 0.5005 -1.5222 0.2806 -1.6199 0.1795 -3.7062 0.0001 
 Rv1422   -0.3872 0.5005 -1.4107 0.1552 -2.0524 0.0319 -4.7647 0.0001 
 Rv1432   -4.0208 0.0074 -3.7968 0.0040 -2.6972 0.0397 -2.2619 0.1138 
 Rv1433   0.0953 0.5005 -0.0581 0.4993 -0.1240 0.4949 -0.9840 0.0035 
 Rv1473   -0.5872 0.1579 -1.4569 0.0015 -1.7160 0.0002 -1.4757 0.0001 
 Rv1475c  can -1.7991 0.3110 -2.7360 0.0521 -3.8725 0.0002 -3.1881 0.1289 
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 Rv1493  mutB -0.7266 0.0251 -0.5944 0.1989 -1.1171 0.0014 -0.9419 0.0168 
 Rv1513   0.3623 0.5005 -1.6694 0.0063 -0.3450 0.4907 -0.4940 0.4336 
 Rv1538c  ansA -1.9600 0.0002 -2.2412 0.0002 -2.7089 0.0002 -1.9346 0.0001 
 Rv1565c   -2.4668 0.0033 -2.8108 0.0015 -3.4036 0.0002 -0.5299 0.4461 
 Rv1566c   -0.4613 0.5005 -0.6088 0.4280 -1.6194 0.0084 -0.4565 0.4336 
 Rv1568  bioA -5.9978 0.0002 -6.3505 0.0002 -8.0330 0.0002 -9.5664 0.0001 
 Rv1569  bioF1 -5.3565 0.0002 -5.9184 0.0002 -7.7267 0.0002 -8.1090 0.0001 
 Rv1589  bioB -6.6021 0.0002 -8.0065 0.0002 -8.7320 0.0002 -9.3914 0.0001 
 Rv1591   -0.0991 0.5005 -0.6771 0.0833 -0.5122 0.2721 -1.5161 0.0001 
 Rv1592c   -2.2688 0.0002 -2.7983 0.0002 -2.8665 0.0002 -1.8388 0.0001 
 Rv1598c   -0.2566 0.5005 -1.6662 0.0002 0.1058 0.4949 0.2644 0.4527 
 Rv1626   -2.9885 0.0002 -3.3412 0.0002 -4.3105 0.0002 -4.0000 0.0001 
 Rv1627c   -0.4578 0.4717 -0.4799 0.4149 -0.7230 0.3068 -1.3604 0.0482 
 Rv1633  uvrB -0.5892 0.3795 -1.5284 0.0002 -1.3802 0.0038 -1.8125 0.0001 
 Rv1638  uvrA -0.5005 0.4585 -1.2534 0.0015 -1.7732 0.0002 -2.1475 0.0001 
 Rv1640c  lysX -1.3278 0.0017 -1.0570 0.0205 -1.1123 0.0094 -2.1173 0.0001 
 Rv1679  fadE16 -1.2336 0.2999 -0.0861 0.4993 -4.9007 0.0002 -0.2996 0.4765 
 Rv1683   -0.0543 0.5005 0.4413 0.4837 0.4932 0.4670 -1.5305 0.0300 
 Rv1692   -0.0180 0.5005 -1.4037 0.0040 -1.5562 0.0038 0.2714 0.4428 
 Rv1698  mctB -1.2093 0.1166 -2.3811 0.0002 -0.7850 0.3068 1.9804 0.4709 
 Rv1700   0.8988 0.5032 0.3842 0.4993 -1.1493 0.3644 -4.4684 0.0012 
 Rv1701   -1.8649 0.1223 -4.7386 0.0002 -3.7203 0.0014 -4.0898 0.0001 
 Rv1740  vapB34 0.3454 0.5005 -1.9117 0.0256 0.6941 0.4858 -0.2798 0.4698 
 Rv1747   -0.1214 0.5005 -0.1465 0.4928 -0.3337 0.3724 -0.8929 0.0094 
 Rv1759c  wag22 -0.9080 0.0273 -0.3862 0.4342 -0.4077 0.4158 0.1014 0.4772 
 Rv1769   -0.7891 0.0262 -0.7459 0.0499 -0.0870 0.4949 -0.4622 0.3097 
 Rv1771   -0.2453 0.4717 -0.5895 0.0389 0.2411 0.4650 -0.0946 0.4699 
 Rv1780   -0.5075 0.1557 -1.2518 0.0002 -0.4645 0.2897 -0.1215 0.4784 
 Rv1785c  cyp143 -0.2140 0.5005 -0.9520 0.0538 -0.2871 0.4907 -2.8602 0.0001 
 Rv1790  ppe27 -0.8564 0.0283 -1.0821 0.0074 -0.9470 0.0154 -1.0583 0.0352 
 Rv1791  pe19 -6.1418 0.0002 -6.9401 0.0002 -5.9168 0.0002 -6.2831 0.0001 
 Rv1793  esxN -2.4577 0.0002 -3.1710 0.0002 -6.5435 0.0002 -5.0796 0.0001 
 Rv1798  eccA5 -5.4898 0.0002 -5.4462 0.0002 -6.1998 0.0002 -7.0075 0.0001 
 Rv1805c   -0.8684 0.4601 -2.8996 0.0002 0.1484 0.4949 3.6503 0.4255 
 Rv1810   -0.1640 0.5005 -0.8009 0.0445 -1.1392 0.0061 -0.5730 0.2799 
 Rv1819c  bacA -0.3191 0.2418 -0.4964 0.0263 -0.7210 0.0014 -0.3692 0.2022 
 Rv1820  ilvG -0.8527 0.0062 -0.5724 0.0947 -0.9062 0.0061 -1.1244 0.0001 
 Rv1821  secA2 -0.4400 0.5005 -1.4174 0.0175 -0.3729 0.4907 -1.5055 0.0324 
 Rv1823   -0.6323 0.2713 -0.7779 0.1818 -1.0536 0.0433 -1.3087 0.0202 
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 Rv1825   -0.4521 0.4304 -0.9147 0.0729 -1.3793 0.0026 -0.6887 0.2134 
 Rv1829   -1.6691 0.0062 -2.5701 0.0002 -3.3129 0.0002 -7.0382 0.0001 
 Rv1831   -0.2324 0.5005 0.1386 0.4993 -0.0440 0.5003 -2.1965 0.0276 
 Rv1836c   -1.0682 0.5005 -1.0208 0.4162 -1.6825 0.1455 -4.4000 0.0001 
 Rv1853  ureD -0.4057 0.5005 -0.6867 0.3902 -1.6975 0.0201 -1.8939 0.0123 
 Rv1860  apa 0.1275 0.5005 -1.3046 0.0074 -0.7730 0.0671 -1.5924 0.0001 
 Rv1906c   -0.7430 0.2355 -1.5282 0.0084 -1.0922 0.0523 -1.1874 0.0899 
 Rv1925  fadD31 -0.4796 0.3914 -0.4537 0.3870 -1.0150 0.0274 -0.7288 0.2236 
 Rv1932  tpx -1.6554 0.0047 -0.8808 0.2082 -2.0578 0.0014 -1.1605 0.1840 
 Rv1957   -1.7927 0.0471 -1.5471 0.1137 -1.8208 0.0449 -1.5659 0.1442 
 Rv1963c  mce3R -1.6612 0.0002 -1.1686 0.0249 -1.9745 0.0002 -0.8604 0.2380 
 Rv1964  yrbE3A -0.4328 0.3049 -0.8072 0.0125 -0.6489 0.1508 0.0541 0.4825 
 Rv1965  yrbE3B -0.1896 0.5005 -0.0373 0.4993 -1.0480 0.0002 -0.0029 0.5071 
 Rv1968  mce3C 0.0641 0.5005 0.1809 0.4993 0.1784 0.4949 -1.7465 0.0024 
 Rv1970  lprM -0.9878 0.2028 -1.4871 0.0290 -0.8309 0.3359 0.2652 0.4663 
 Rv1975   0.0986 0.5005 -0.1783 0.4914 -0.0368 0.4949 0.7840 0.0405 
 Rv1984c  cfp21 -0.0238 0.5005 -0.4820 0.1800 -0.0880 0.4949 0.7862 0.0368 
 Rv2014   -1.0916 0.0002 -0.0722 0.4993 -0.2145 0.4949 -0.2695 0.4662 
 Rv2018   -0.0932 0.5005 -0.3704 0.4993 -0.9508 0.4140 -2.6583 0.0066 
 Rv2030c   -0.5432 0.0334 -0.3054 0.3640 -0.0594 0.4949 0.2455 0.4124 
 Rv2039c   -0.0986 0.5005 -0.0778 0.4993 -0.7358 0.2602 -1.3898 0.0228 
 Rv2043c  pncA 2.5078 0.0002 2.5088 0.0002 2.3324 0.0002 5.1232 0.0001 
 Rv2044c   -0.0133 0.5005 0.3179 0.4879 0.0544 0.4949 1.5943 0.0228 
 Rv2047c   -1.5905 0.0002 -1.5454 0.0002 -1.7637 0.0002 -2.4084 0.0001 
 Rv2048c  pks12 -1.1017 0.0002 -1.8614 0.0002 -1.7407 0.0002 -1.9336 0.0001 
 Rv2051c  ppm1 -0.8315 0.0731 -0.1337 0.4993 -1.8179 0.0002 0.4356 0.4541 
 Rv2052c   -0.7059 0.0017 -0.5646 0.0232 -0.2494 0.4512 -0.1130 0.4613 
 Rv2069  sigC -1.4401 0.0185 -2.9547 0.0002 -3.0863 0.0002 -5.8746 0.0001 
 Rv2091c   -3.0597 0.0002 -4.2093 0.0002 -2.9999 0.0002 -3.2115 0.0001 
 Rv2097c  pafA -3.3495 0.0002 -3.8744 0.0002 -3.9166 0.0002 -2.5265 0.0292 
 Rv2098c   -1.3813 0.0185 -0.7495 0.2874 -1.1303 0.0888 0.6908 0.3067 
 Rv2106   0.3516 0.1885 0.4729 0.0723 0.4647 0.0639 0.5312 0.0374 
 Rv2115c  mpa -2.5436 0.0283 -3.3039 0.0002 -2.8731 0.0094 -1.2562 0.2305 
 Rv2124c  metH -0.1181 0.5005 -0.2874 0.3902 -0.3471 0.2957 -0.9115 0.0046 
 Rv2127  ansP1 -0.8958 0.0002 -0.7031 0.0290 -0.7309 0.0230 -0.8680 0.0086 
 Rv2140c   -3.6968 0.0002 -5.7156 0.0002 -4.4221 0.0002 -7.6009 0.0001 
 Rv2160A   0.2141 0.5005 0.3236 0.4952 0.6625 0.4824 -2.6829 0.0076 
 Rv2170   -0.5364 0.3707 -0.2164 0.4993 -0.7111 0.2687 -1.2285 0.0393 
 Rv2184c   0.0042 0.5005 -0.2406 0.4696 0.2730 0.4650 1.1339 0.0177 
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 Rv2206   -0.9579 0.4601 -0.2924 0.4993 -2.2203 0.0345 -2.1854 0.0872 
 Rv2214c  ephD -0.2371 0.4725 -0.6200 0.0371 -0.2902 0.3886 0.5498 0.1146 
 Rv2221c  glnE -3.9545 0.0316 -2.2701 0.1681 -4.0668 0.0410 -3.3851 0.0001 
 Rv2222c  glnA2 -2.2724 0.0002 -1.6994 0.0002 -2.4081 0.0002 -3.1445 0.0001 
 Rv2224c  caeA -1.4818 0.0002 -1.4234 0.0015 -2.7183 0.0002 -3.2993 0.0001 
 Rv2230c   -0.6245 0.5005 -1.9739 0.0074 -3.7613 0.0002 0.2525 0.4801 
 Rv2239c   -2.1958 0.0047 -2.6590 0.0015 -3.3379 0.0014 -4.2274 0.0001 
 Rv2241  aceE -2.5235 0.0002 -2.1964 0.0002 -4.1822 0.0002 -4.1288 0.0001 
 Rv2249c  glpD1 -1.7600 0.0002 -2.2122 0.0002 -2.0672 0.0002 -1.8022 0.0001 
 Rv2253   -0.0997 0.5005 -0.2883 0.4993 -1.6186 0.0238 -0.1022 0.4846 
 Rv2258c   -0.2977 0.4725 -0.4506 0.3542 -0.1931 0.4907 -0.9981 0.0345 
 Rv2272   -1.2928 0.1579 -0.4950 0.4952 -2.9723 0.0002 -4.9530 0.0001 
 Rv2289  cdh -0.0174 0.5005 0.2570 0.4185 1.0952 0.0328 0.2093 0.4283 
 Rv2344c  dgt -0.6606 0.0233 -1.3957 0.0002 -1.9149 0.0002 -0.3517 0.4772 
 Rv2345   -0.0210 0.5005 -0.2707 0.3077 -0.1720 0.4629 -0.4961 0.0389 
 Rv2358  smtB -1.2393 0.3562 -1.9747 0.1354 -3.0983 0.0410 -2.4995 0.1103 
 Rv2374c  hrcA -3.3674 0.0002 -2.8593 0.0063 -2.3523 0.1288 -5.0488 0.0001 
 Rv2378c  mbtG -4.1813 0.0002 -4.4552 0.0002 -5.5566 0.0002 -5.5278 0.0001 
 Rv2379c  mbtF -4.2011 0.0002 -5.1290 0.0002 -4.8274 0.0002 -6.1962 0.0001 
 Rv2380c  mbtE -6.4114 0.0002 -6.3445 0.0002 -6.8061 0.0002 -7.8800 0.0001 
 Rv2381c  mbtD -4.7324 0.0002 -4.9188 0.0002 -3.7941 0.0002 -4.8801 0.0001 
 Rv2382c  mbtC -4.9356 0.0002 -5.4328 0.0002 -4.5045 0.0014 -4.7969 0.0001 
 Rv2383c  mbtB -5.1678 0.0002 -5.5583 0.0002 -6.4761 0.0002 -5.9313 0.0001 
 Rv2384  mbtA -3.7888 0.0002 -5.1644 0.0002 -4.3154 0.0002 -5.7823 0.0001 
 Rv2386c  mbtI -4.3602 0.0002 -5.8438 0.0002 -4.7597 0.0002 -4.1321 0.0001 
 Rv2387   -0.4085 0.1047 -0.7462 0.0015 -0.3363 0.3679 -1.2261 0.0001 
 Rv2404c  lepA -0.8862 0.0089 -0.9363 0.0095 -1.3114 0.0002 -0.2387 0.4439 
 Rv2427c  proA -1.3652 0.0185 -1.6040 0.0040 -1.0019 0.2496 -2.3308 0.0001 
 Rv2428  ahpC 0.3116 0.5005 0.7889 0.4803 -1.8074 0.0293 -0.3684 0.4669 
 Rv2437   -1.3442 0.0351 -0.3439 0.4940 -0.7391 0.3308 -1.7712 0.0159 
 Rv2451   -1.9585 0.0164 -2.2010 0.0445 -0.2305 0.4949 -1.2088 0.3551 
 Rv2462c  tig -0.3445 0.4997 -0.2149 0.4993 -0.2042 0.4949 -1.8537 0.0001 
 Rv2467  pepN -0.6282 0.0565 -1.1517 0.0002 -0.5202 0.1565 -0.3777 0.3190 
 Rv2474c   -1.8784 0.0164 -2.0530 0.0063 -2.5070 0.0002 -1.6017 0.0504 
 Rv2475c   -1.5857 0.0142 -2.2953 0.0002 -1.9505 0.0014 -1.1701 0.1214 
 Rv2476c  gdh -0.5436 0.0402 -1.1509 0.0002 -1.3255 0.0002 -1.0761 0.0001 
 Rv2481c   0.1363 0.5005 -0.0447 0.4993 -1.4642 0.0049 -0.3755 0.4433 
 Rv2498c  citE -2.6051 0.0002 -2.1374 0.0166 -3.5149 0.0002 -3.3569 0.0001 
 Rv2506   -2.3496 0.0002 -2.8141 0.0002 -3.2859 0.0002 -2.0806 0.0001 
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 Rv2525c   -0.3323 0.3678 -0.5816 0.1237 -0.9436 0.0038 -0.5155 0.1588 
 Rv2535c  pepQ -3.3605 0.0351 -1.2575 0.3902 0.1706 0.4949 -2.8090 0.1228 
 Rv2549c  vapC20 -0.3616 0.4320 -0.5566 0.2983 -0.1523 0.4939 -0.7024 0.0381 
 Rv2563   -1.0743 0.1104 -1.8205 0.0095 -1.6739 0.0221 -0.5595 0.3862 
 Rv2564  glnQ -1.6602 0.0002 -1.2228 0.0074 -1.2882 0.0014 -1.0038 0.0405 
 Rv2566   -0.0276 0.5005 -0.5421 0.0439 -0.2751 0.3534 0.3464 0.2660 
 Rv2567   -0.9809 0.0461 -0.6854 0.2038 -1.2622 0.0143 -2.0588 0.0001 
 Rv2569c   -0.8627 0.2108 -2.7267 0.0002 -1.4189 0.0038 -2.7118 0.0001 
 Rv2583c  relA -2.3969 0.0002 -3.3728 0.0002 -3.4822 0.0002 -3.1439 0.0001 
 Rv2584c  apt 0.2479 0.5005 0.6563 0.2377 -0.1603 0.4907 -0.8348 0.0442 
 Rv2589  gabT -0.3505 0.3594 -0.4975 0.1717 -0.5573 0.0809 -0.9290 0.0012 
 Rv2604c  snoP -2.6342 0.0074 -6.3528 0.0002 -7.3879 0.0002 -6.6923 0.0001 
 Rv2605c  tesB2 -1.7948 0.0074 -1.9553 0.0040 -2.4865 0.0014 -2.2041 0.0123 
 Rv2606c  snzP -6.6609 0.0002 -7.7229 0.0002 -7.5974 0.0002 -8.1542 0.0001 
 Rv2609c   -1.2302 0.0142 -1.2379 0.0116 -1.5104 0.0002 -3.2920 0.0001 
 Rv2633c   -0.8116 0.0412 -0.5524 0.2408 -0.8170 0.0625 -0.4037 0.3715 
 Rv2635   -0.3067 0.5005 0.1287 0.4993 -1.7020 0.0172 -2.1537 0.0001 
 Rv2640c   -3.2954 0.0002 -0.9460 0.2641 -3.3312 0.0002 -4.2575 0.0001 
 Rv2642   -0.0896 0.5005 -1.0661 0.0263 -0.7851 0.2084 0.1257 0.4743 
 Rv2657c   0.2994 0.5005 0.5604 0.4326 0.2177 0.4949 -1.3967 0.0202 
 Rv2672   -0.4688 0.2728 -0.7090 0.1107 -0.5151 0.2606 -1.2450 0.0094 
 Rv2680   -2.4419 0.0002 -0.7338 0.3902 -0.5670 0.4907 -0.9514 0.2189 
 Rv2681   -0.8187 0.0185 -1.0675 0.0028 -0.9364 0.0026 0.4077 0.2822 
 Rv2683   -1.3413 0.0017 -2.5066 0.0002 -1.1819 0.0528 -1.4292 0.0103 
 Rv2684  arsA -2.1937 0.0002 -1.8258 0.0002 -2.2065 0.0002 -2.3585 0.0001 
 Rv2685  arsB1 -0.4488 0.4986 -1.4698 0.0028 -0.9212 0.1423 -1.2233 0.0569 
 Rv2689c   -0.8247 0.0074 0.2178 0.4916 -0.3126 0.3930 -0.1127 0.4698 
 Rv2700   -1.5770 0.2328 -3.1901 0.0136 -4.3041 0.0002 -4.2187 0.0001 
 Rv2702  ppgK -0.3214 0.5005 0.5532 0.4505 -0.6604 0.4212 -1.4846 0.0360 
 Rv2707   -1.7442 0.0002 -1.5500 0.0002 -1.8598 0.0002 -1.9711 0.0001 
 Rv2714   -1.0628 0.0017 -1.2195 0.0028 -0.3496 0.4609 -1.5993 0.0001 
 Rv2716   -0.5274 0.4320 -0.7720 0.1950 -1.4298 0.0073 0.3350 0.4699 
 Rv2733c   -1.3610 0.0002 -1.3606 0.0002 -0.1984 0.4939 -1.4442 0.0001 
 Rv2736c  recX 0.6071 0.5005 1.5914 0.4185 -2.9943 0.0002 1.9529 0.3745 
 Rv2772c   -1.2197 0.0334 -0.8763 0.1800 -1.8002 0.0014 -1.4172 0.0338 
 Rv2778c   -0.3004 0.5005 0.6698 0.3926 0.2532 0.4949 -1.9377 0.0276 
 Rv2788  sirR -1.0232 0.0696 -1.8448 0.0002 -1.4072 0.0115 -0.9996 0.1416 
 Rv2793c  truB -1.5344 0.3249 -4.2019 0.0015 -1.0705 0.4664 -3.1829 0.0159 
 Rv2799   -0.6399 0.0155 -0.4424 0.4326 -1.0853 0.0002 -1.2584 0.0001 
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 Rv2826c   0.3922 0.4601 -0.0697 0.5014 0.5433 0.3724 1.2457 0.0427 
 Rv2829c  vapC22 -0.3249 0.5005 -0.6033 0.4085 0.2442 0.4907 -2.4670 0.0001 
 Rv2861c  mapB -2.1400 0.3756 -2.8632 0.0002 -1.9227 0.3499 -2.2243 0.3083 
 Rv2864c   -0.1587 0.5005 -1.0249 0.0175 -1.0885 0.0094 -1.1890 0.0103 
 Rv2869c  rip -2.2093 0.2206 -3.5198 0.0002 -3.5710 0.0002 -2.8839 0.2436 
 Rv2887   -1.0007 0.3579 -3.8151 0.0002 -0.7289 0.4907 -2.3255 0.0202 
 Rv2896c   -0.0608 0.5005 -0.9457 0.0195 0.0594 0.4949 0.2797 0.4188 
 Rv2901c   -0.7111 0.1104 -0.5561 0.3125 -1.4973 0.0014 -1.3355 0.0046 
 Rv2912c   -0.7049 0.4130 -1.0765 0.0195 -0.2659 0.4949 -2.1282 0.0001 
 Rv2914c  pknI 0.2152 0.4978 0.1178 0.4952 0.3354 0.3953 0.6161 0.0332 
 Rv2923c   -0.3229 0.5005 -0.9100 0.2887 -0.6023 0.4542 -1.8807 0.0252 
 Rv2933  ppsC 0.1550 0.5005 -0.0266 0.4993 -0.1885 0.4629 0.6571 0.0024 
 Rv2936  drrA -0.6553 0.1274 -1.2734 0.0002 -1.2011 0.0014 -1.1105 0.0103 
 Rv2937  drrB -0.7754 0.0704 -0.8947 0.0326 -0.7611 0.1522 -1.6545 0.0001 
 Rv2938  drrC -1.0227 0.0002 -0.5008 0.2078 -1.3520 0.0002 -1.3238 0.0001 
 Rv2940c  mas 0.1600 0.5005 0.1041 0.4968 -0.0801 0.4949 0.6069 0.0066 
 Rv2942  mmpL7 -0.7150 0.0017 -0.6819 0.0166 -1.5984 0.0002 -1.2363 0.0001 
 Rv2945c  lppX -1.2565 0.0033 -0.2470 0.4993 -1.2952 0.0124 -1.2965 0.0066 
 Rv2950c  fadD29 -0.5107 0.0342 -0.5531 0.0249 -0.5244 0.0572 -0.1202 0.4612 
 Rv2966c   -0.7322 0.4764 -1.6591 0.0760 -1.1488 0.3061 -3.1409 0.0046 
 Rv2967c  pca -4.1993 0.0002 -4.5153 0.0002 -4.4449 0.0002 -2.2048 0.0001 
 Rv2985  mutT1 0.1186 0.5005 -1.6208 0.0052 -0.5827 0.3351 -2.9503 0.0001 
 Rv2989   -2.8539 0.0002 -3.4568 0.0002 -3.9179 0.0002 -2.7412 0.0001 
 Rv2997   0.1016 0.5005 -0.0479 0.4993 -0.8228 0.0336 -0.3617 0.3540 
 Rv3005c   -1.5994 0.0002 -1.9212 0.0002 -2.0395 0.0002 -0.8704 0.0300 
 Rv3010c  pfkA -1.2631 0.0062 -0.4941 0.4272 -1.4617 0.0014 -0.4020 0.4237 
 Rv3016  lpqA 0.1701 0.5005 0.3000 0.4728 -1.0009 0.0026 0.0820 0.4794 
 Rv3036c   -0.1670 0.5005 -0.2831 0.4875 0.1138 0.4949 -1.8300 0.0001 
 Rv3041c   0.1733 0.5005 -0.3832 0.4755 -0.7212 0.2084 -1.1112 0.0482 
 Rv3050c   -0.3020 0.5005 -3.4190 0.0002 -0.8129 0.4549 0.9134 0.4552 
 Rv3057c   -1.3053 0.0002 -1.3973 0.0002 -1.2240 0.0002 -1.3634 0.0001 
 Rv3058c   -0.9069 0.0185 -1.9430 0.0002 -1.8481 0.0002 -1.8391 0.0001 
 Rv3077   -0.2830 0.3403 -0.6148 0.0157 -0.2807 0.3688 -0.5133 0.0814 
 Rv3106  fprA -0.2059 0.5005 -0.2696 0.4621 -0.1115 0.4949 -1.1088 0.0086 
 Rv3117  cysA3 -0.7535 0.0002 -0.4809 0.1107 -0.5415 0.0829 -0.4485 0.1568 
 Rv3120   -0.2890 0.4986 -0.4634 0.3765 -0.3686 0.4212 -0.8789 0.0285 
 Rv3131   -0.5631 0.3006 -1.6888 0.0002 -0.9074 0.0859 -1.0175 0.0252 
 Rv3132c  devS -1.2175 0.0002 -1.3782 0.0002 -0.4580 0.4209 -0.5743 0.3083 
 Rv3135  ppe50 -1.1921 0.0002 -0.7732 0.0116 -0.6647 0.0397 -0.9227 0.0057 
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 Rv3136  ppe51 -0.9306 0.0002 -1.0512 0.0002 -1.7017 0.0002 -1.8782 0.0001 
 
Rv3136Ac   -1.0155 0.0047 -0.9865 0.0040 -0.7827 0.0371 -0.2014 0.4461 
 Rv3139  fadE24 -0.7348 0.0893 -1.0480 0.0074 -1.7019 0.0002 0.3578 0.4115 
 Rv3140  fadE23 -0.8647 0.0461 -1.1633 0.0063 -1.5248 0.0014 -0.0731 0.4951 
 Rv3147  nuoC -0.5837 0.3779 -0.3611 0.4862 -0.6805 0.3517 -1.3815 0.0235 
 Rv3149  nuoE -1.2559 0.0164 -0.0638 0.4993 -0.8817 0.3060 -0.6186 0.3596 
 Rv3155  nuoK 0.4925 0.5005 -1.3306 0.1787 0.7707 0.4748 -3.2183 0.0001 
 Rv3160c   -5.1069 0.0002 -5.6280 0.0002 -5.8176 0.0002 -5.9697 0.0001 
 Rv3178A   0.0601 0.5005 0.4148 0.4774 -1.5172 0.0014 -0.5866 0.3272 
 Rv3193c   -3.0544 0.0002 -4.8477 0.0002 -4.8918 0.0002 -2.9883 0.0001 
 Rv3194c   -0.3057 0.4994 -0.2390 0.4952 -1.6649 0.0002 -1.4455 0.0001 
 Rv3195   -0.1717 0.5005 -0.7682 0.0272 -0.4501 0.2602 -0.4965 0.2240 
 Rv3197   -0.9908 0.0033 -1.6737 0.0002 -1.1572 0.0014 -0.9595 0.0338 
 Rv3199c  nudC 0.0953 0.5005 -1.1566 0.0256 -0.0492 0.4949 -0.5580 0.3529 
 Rv3207c   0.2366 0.5005 -0.5667 0.3774 -0.5224 0.4864 -1.5532 0.0094 
 Rv3208A   -0.3020 0.5005 -1.3316 0.0136 -1.7654 0.0002 -2.4655 0.0001 
 Rv3210c   -5.1573 0.0002 -3.4386 0.0002 0.8382 0.4824 -4.1441 0.0012 
 Rv3220c   -3.4496 0.0002 -3.7027 0.0002 -4.2283 0.0002 -4.2332 0.0001 
 Rv3226c   -0.0278 0.5005 -0.9705 0.0084 -0.0840 0.4949 -0.2255 0.4435 
 Rv3228   -1.3594 0.3796 -0.3187 0.4993 -2.3451 0.0002 -1.6586 0.0001 
 Rv3229c  desA3 -0.5304 0.0900 -0.6248 0.0904 -0.6322 0.1011 -1.6643 0.0001 
 Rv3230c   -0.0028 0.5020 -0.3507 0.4079 -1.1924 0.0014 -1.1239 0.0035 
 Rv3249c   -0.6956 0.3468 -0.2732 0.4952 0.3977 0.4805 -2.1354 0.0076 
 Rv3253c   -0.4985 0.1274 -0.2822 0.4185 -0.6345 0.0516 -0.8783 0.0066 
 Rv3261  fbiA 2.3681 0.0731 0.8829 0.4709 1.7016 0.4644 2.7687 0.0292 
 Rv3262  fbiB 3.3359 0.0002 2.3555 0.0002 2.1227 0.3430 4.1120 0.0001 
 Rv3263   -0.3433 0.3779 0.1848 0.4928 -0.1998 0.4824 -0.9410 0.0086 
 Rv3267   -2.0368 0.0295 -1.3232 0.3640 0.5358 0.4954 -3.7031 0.0001 
 Rv3270  ctpC 1.6242 0.4588 0.7511 0.4928 -1.1755 0.4349 -1.7791 0.0001 
 Rv3283  sseA -0.6116 0.2208 -1.4188 0.0002 -0.5156 0.2397 0.5892 0.1349 
 Rv3291c  lrpA -0.9984 0.3090 -2.2062 0.0028 -0.8828 0.3877 0.2244 0.4726 
 Rv3311   -2.5497 0.0002 -2.8067 0.0002 -2.3129 0.0002 -4.5124 0.0001 
 Rv3316  sdhC -2.1135 0.0033 -3.1682 0.0002 -3.5877 0.0002 -3.2114 0.0001 
 Rv3317  sdhD -2.5036 0.0002 -1.3953 0.0084 -3.0063 0.0002 -2.9301 0.0001 
 Rv3318  sdhA -0.1626 0.5005 -1.0684 0.0116 -0.6211 0.2603 -0.7666 0.1083 
 Rv3319  sdhB -1.3605 0.0262 -1.3801 0.0263 -1.8047 0.0049 -1.1682 0.1442 
 Rv3335c   -0.2944 0.5005 -1.3951 0.0063 -0.3056 0.4907 -0.3873 0.4283 
 Rv3340  metC -0.7093 0.5005 -2.4759 0.0116 -1.4002 0.2344 -0.9858 0.3492 
 Rv3342   -0.8511 0.2083 -0.7834 0.3236 -1.5229 0.0336 -2.1733 0.0012 
 
 125 
 Rv3343c  ppe54 0.1682 0.4521 0.2086 0.3343 0.1075 0.4832 0.4420 0.0324 
 Rv3377c   0.2514 0.5005 0.4105 0.3240 0.3823 0.3824 0.8437 0.0159 
 Rv3400   -2.8866 0.0002 -5.2777 0.0002 -4.3978 0.0002 -3.3621 0.0001 
 Rv3412   -1.3717 0.0033 -1.2782 0.0125 -1.0563 0.0404 -1.7182 0.0001 
 Rv3413c   -0.7273 0.0985 -1.6072 0.0002 -1.1513 0.0084 -0.7558 0.1487 
 Rv3416  whiB3 -0.2642 0.5005 -1.4883 0.0445 -1.7428 0.0433 -1.5261 0.1386 
 Rv3420c  rimI -0.8489 0.3111 -1.1874 0.1776 -3.1701 0.0002 -1.8987 0.0259 
 Rv3433c   -1.1853 0.1975 -0.9374 0.2733 -2.2856 0.0002 -3.0852 0.0012 
 Rv3434c   -0.1307 0.5005 -0.8802 0.0213 -0.1409 0.4949 -0.0066 0.5013 
 Rv3449  mycP4 0.0716 0.5005 -0.8132 0.0308 -0.2015 0.4907 -0.0375 0.4959 
 Rv3483c   0.2214 0.5005 -0.3193 0.4436 0.2018 0.4907 -0.8111 0.0381 
 Rv3484  cpsA -5.0188 0.0002 -6.2611 0.0002 -8.9658 0.0002 
-
10.9337 0.0001 
 Rv3492c   -1.7958 0.0002 -1.5401 0.0002 -0.8182 0.3060 -2.6582 0.0001 
 Rv3493c   -1.0918 0.0316 -1.2338 0.0499 -1.9270 0.0002 -4.2693 0.0001 
 Rv3494c  mce4F -1.3386 0.0002 -1.5603 0.0002 -1.8568 0.0002 -2.6439 0.0001 
 Rv3495c  lprN -0.9653 0.0176 -0.9687 0.0345 -1.6443 0.0002 -1.6533 0.0001 
 Rv3496c  mce4D -1.3805 0.0002 -1.2580 0.0002 -2.1654 0.0002 -1.8397 0.0001 
 Rv3497c  mce4C -1.2493 0.0002 -1.0926 0.0002 -1.5014 0.0002 -1.7012 0.0001 
 Rv3498c  mce4B -0.7119 0.1975 -1.3182 0.0084 -1.4692 0.0002 -1.8245 0.0012 
 Rv3499c  mce4A -0.8640 0.0002 -0.7010 0.0980 -1.2866 0.0002 -2.4138 0.0001 
 Rv3500c  yrbE4B -1.3221 0.0002 -1.4297 0.0002 -1.6668 0.0002 -1.7209 0.0001 
 Rv3501c  yrbE4A -1.1581 0.0176 -2.0780 0.0002 -1.1698 0.0362 -1.7263 0.0057 
 Rv3502c   -3.7660 0.0002 -3.4590 0.0002 -5.5212 0.0002 -4.5282 0.0001 
 Rv3526  kshA -0.3081 0.5005 -0.3862 0.4202 -0.3979 0.4516 -1.0156 0.0455 
 Rv3534c  hsaF -0.6865 0.1604 -1.4211 0.0015 -1.6224 0.0014 -1.6862 0.0012 
 Rv3535c  hsaG -1.2357 0.0002 -1.1847 0.0002 -1.9180 0.0002 -2.2344 0.0001 
 Rv3536c  hsaE -0.8593 0.2083 -0.3182 0.4952 -1.1819 0.0651 -2.0939 0.0057 
 Rv3537  kstD -0.8078 0.1345 -0.9540 0.1120 -1.5334 0.0094 -0.5461 0.3932 
 Rv3538   -1.5887 0.0392 -0.8561 0.2977 -0.4345 0.4907 -1.4677 0.1709 
 Rv3540c  ltp2 -3.9207 0.0002 -7.6074 0.0002 -7.8171 0.0002 -7.5925 0.0001 
 Rv3542c   -3.9008 0.0002 -5.1856 0.0002 -4.7792 0.0002 -8.2790 0.0001 
 Rv3543c  fadE29 -2.3784 0.0116 -6.1170 0.0002 -2.9340 0.0002 -5.4349 0.0001 
 Rv3544c  fadE28 -4.3733 0.0002 -6.3029 0.0002 -8.5038 0.0002 -5.0990 0.0001 
 Rv3545c  cyp125 -1.3414 0.0002 -1.7315 0.0002 -1.0047 0.0038 -1.8834 0.0001 
 Rv3546  fadA5 -1.6871 0.0074 -1.5652 0.0619 -2.7189 0.0026 -3.9688 0.0001 
 Rv3548c   -0.8036 0.0855 -0.5766 0.2563 -0.6250 0.2196 -1.2270 0.0259 
 Rv3549c   -1.2528 0.0251 -2.1004 0.0015 -1.8365 0.0038 -2.9842 0.0001 
 Rv3550  echA20 -5.5091 0.0002 -5.9283 0.0002 -6.4657 0.0002 -5.7729 0.0001 
 Rv3551   -5.2372 0.0002 -8.1869 0.0002 -9.2955 0.0002 -9.2714 0.0001 
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 Rv3552   -7.6192 0.0002 -5.5501 0.0002 -6.7970 0.0002 -6.5918 0.0001 
 Rv3553   -3.9610 0.0002 -2.5190 0.0002 -5.1074 0.0002 -3.1633 0.0001 
 Rv3556c  fadA6 -3.5007 0.0002 -2.7480 0.0002 -3.5618 0.0002 -7.6579 0.0001 
 Rv3557c   -0.8088 0.0663 -1.4723 0.0002 -1.2923 0.0026 -0.6799 0.2375 
 Rv3559c   -4.6268 0.0002 -1.6855 0.0676 -7.0904 0.0002 -6.8750 0.0001 
 Rv3560c  fadE30 -1.4048 0.0102 -2.5529 0.0002 -4.0735 0.0002 -3.9364 0.0001 
 Rv3562  fadE31 -1.8481 0.0164 -0.6205 0.4641 -1.3005 0.2084 -3.8749 0.0001 
 Rv3563  fadE32 -2.1000 0.0002 -1.8327 0.0002 -2.3748 0.0002 -2.7289 0.0001 
 Rv3564  fadE33 -3.3294 0.0002 -1.8784 0.0362 -7.8339 0.0002 -5.6001 0.0001 
 Rv3568c  hsaC -1.4442 0.0074 -1.1350 0.0461 -0.3117 0.4949 -2.2780 0.0012 
 Rv3569c  hsaD -3.4797 0.0002 -6.1882 0.0002 -3.7490 0.0002 -2.5706 0.0001 
 Rv3570c  hsaA -0.8546 0.2168 -1.7264 0.0002 -1.2860 0.0500 -0.7644 0.3048 
 Rv3574  kstR -2.7274 0.0002 -2.9688 0.0002 -2.4126 0.0014 0.1045 0.4916 
 Rv3575c   -0.5405 0.1197 -0.6045 0.1027 -0.4782 0.3206 -1.0194 0.0141 
 Rv3614c  espD -4.4361 0.0002 -4.5172 0.0002 -4.1978 0.0002 -2.9828 0.0012 
 Rv3615c  espC -4.0009 0.0002 -4.5043 0.0002 -3.6649 0.0002 -4.2500 0.0001 
 Rv3616c  espA -3.5901 0.0002 -3.9552 0.0002 -4.2429 0.0002 -6.3459 0.0001 
 Rv3620c  esxW 0.3215 0.5005 -0.3833 0.4154 -0.8983 0.0274 0.3963 0.4028 
 Rv3631   -1.1252 0.1040 -0.9995 0.1978 -2.2218 0.0002 -4.5187 0.0001 
 Rv3632   -1.1634 0.0221 -0.9739 0.0755 -2.3245 0.0002 -1.8714 0.0001 
 Rv3656c   0.4446 0.5005 -0.2467 0.4993 -0.0239 0.4997 -2.5383 0.0076 
 Rv3679   0.7384 0.5005 2.6604 0.4916 0.2906 0.4949 -4.2101 0.0001 
 Rv3682  ponA2 -1.1003 0.0243 -1.9552 0.0002 -0.8078 0.1676 -1.8438 0.0001 
 Rv3683   -1.2083 0.0565 -1.3998 0.0612 -0.3434 0.4907 -2.8907 0.0001 
 Rv3687c  rsfB 0.1206 0.5005 -1.6175 0.0431 1.6990 0.2528 0.6037 0.4430 
 Rv3689   0.0273 0.5005 0.1437 0.4993 0.2286 0.4664 -0.8121 0.0132 
 Rv3692  moxR2 -0.4339 0.4997 -0.0437 0.4993 -0.0176 0.4997 -1.2202 0.0046 
 Rv3696c  glpK -1.5989 0.0002 -1.0831 0.0002 -2.1531 0.0002 -1.1299 0.0001 
 Rv3704c  gshA -0.0324 0.5005 -0.5017 0.3092 -0.6581 0.1542 -0.9535 0.0393 
 Rv3716c   -1.4847 0.0392 -1.6854 0.0213 -1.1850 0.1160 -1.2735 0.1216 
 Rv3717   -1.6557 0.0002 -4.5008 0.0002 -4.9351 0.0002 -1.9783 0.0001 
 Rv3719   -0.4878 0.1609 -0.6466 0.0723 -0.9693 0.0002 -0.0948 0.4784 
 Rv3720   -1.0608 0.0002 -1.2871 0.0002 -0.3566 0.4612 -1.1890 0.0001 
 Rv3722c   0.5629 0.5005 -0.5410 0.4993 -2.5928 0.0362 -5.2164 0.0012 
 Rv3723   -2.3892 0.0002 -2.4201 0.0002 -3.2366 0.0002 -1.8959 0.0001 
 Rv3746c  pe34 -0.6735 0.3131 -1.4052 0.0612 -1.6935 0.0238 -1.6086 0.0564 
 Rv3749c   -0.0505 0.5005 0.3153 0.4947 -0.0122 0.5039 -1.3738 0.0066 
 Rv3755c   -1.7567 0.0002 -2.0650 0.0002 -1.5452 0.0002 -1.8266 0.0012 
 Rv3763  lpqH -0.0662 0.5005 -0.3486 0.4837 0.1141 0.4953 -1.6345 0.0405 
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 Rv3779   -1.3583 0.0002 -1.3434 0.0002 -2.2002 0.0002 -3.1611 0.0001 
 Rv3788   -0.0199 0.5005 -0.7022 0.0499 -0.1710 0.4907 -0.1241 0.4699 
 Rv3794  embA 0.5797 0.5005 -3.8555 0.0028 -2.6728 0.0472 1.2698 0.4726 
 Rv3811   -0.0168 0.5005 -0.7100 0.0002 -0.2653 0.3971 -0.3328 0.2898 
 Rv3816c   -1.1421 0.0209 -0.4919 0.4768 -1.1351 0.0410 -1.7040 0.0001 
 Rv3818   -0.0724 0.5005 -0.9712 0.1521 -0.6971 0.3706 -3.5417 0.0001 
 Rv3823c  mmpL8 -1.1150 0.0002 -0.5298 0.2481 -1.0544 0.0002 -1.5136 0.0001 
 Rv3825c  pks2 -0.3698 0.0002 -0.1841 0.2377 -0.3205 0.0163 0.0389 0.4721 
 Rv3830c   -1.0891 0.3959 -0.9297 0.4290 -1.5292 0.1491 -1.7837 0.0393 
 Rv3848   -3.9860 0.0002 -5.8509 0.0002 -4.6037 0.0002 -6.3981 0.0001 
 Rv3849  espR -3.3955 0.0002 -6.2137 0.0002 -4.9030 0.0002 -5.5679 0.0001 
 Rv3855  ethR -0.1825 0.5005 -2.4312 0.0002 -1.9426 0.0002 -2.0892 0.0001 
 Rv3866  espG1 -0.8364 0.0102 -0.7911 0.0643 -0.2323 0.4907 -0.7293 0.1138 
 Rv3867  espH -1.0071 0.1023 -0.9482 0.2137 -2.6310 0.0002 -2.6007 0.0001 
 Rv3868  eccA1 -2.4600 0.0002 -2.8111 0.0002 -2.3753 0.0002 -5.3535 0.0001 
 Rv3869  eccB1 -4.6175 0.0002 -4.7485 0.0002 -3.8557 0.0002 -5.9158 0.0001 
 Rv3870  eccCa1 -3.9342 0.0002 -3.8212 0.0002 -4.1914 0.0002 -5.6461 0.0001 
 Rv3871  eccCb1 -4.4373 0.0002 -4.7247 0.0002 -5.1717 0.0002 -6.8352 0.0001 
 Rv3873  ppe68 -2.6932 0.0002 -2.6952 0.0002 -3.6131 0.0002 -3.4535 0.0001 
 Rv3874  esxB -4.7553 0.0002 -6.5924 0.0002 -3.9850 0.0002 -2.9788 0.0046 
 Rv3876  espI -2.1905 0.0002 -2.0876 0.0002 -2.5518 0.0002 -2.3376 0.0001 
 Rv3877  eccD1 -4.0758 0.0002 -3.5948 0.0002 -4.8600 0.0002 -4.1390 0.0001 
 Rv3881c  espB -1.5131 0.0002 -1.0485 0.0002 -1.4068 0.0002 -1.3242 0.0001 
 Rv3882c  eccE1 -4.3062 0.0002 -4.1300 0.0002 -3.9600 0.0002 -4.8039 0.0001 
 Rv3883c  mycP1 -3.9018 0.0002 -4.0789 0.0002 -4.1048 0.0002 -7.2250 0.0001 









LFC = log2 fold change. Q-value = significance adjusting for multiple tests. Red = LFC  
−1.5. Bold = Q-value < 0.05 at indicated time point.  
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Table A3.2 | Significantly underrepresented genes post INH treatment compared  
to pretreatment 
    INH 1wk INH 2.5wks INH 5wks 
ID gene LFC Q-value LFC Q-value LFC Q-value 
Rv0180c   -0.4245 0.5160 -0.4788 0.5108 -0.3517 0.0008 
Rv0353  hspR 0.0363 0.5160 -1.6864 0.5108 -4.9729 0.0008 
Rv0465c   -2.0776 0.0017 -1.9177 0.0016 1.0625 0.2814 
Rv0505c  serB1 -2.7861 0.5160 -1.4604 0.5108 -5.3713 0.0008 
Rv0767c   -3.2152 0.0297 -3.4108 0.0016 -3.7853 0.0008 
Rv0806c  cpsY -0.9997 0.5032 -0.7100 0.5108 -1.9326 0.0069 
Rv0859  fadA -2.0809 0.0017 0.7065 0.5108 -1.9603 0.0008 
Rv1157c   -0.5784 0.5160 -3.3411 0.5108 -3.1888 0.0008 
Rv1183 mmpL10 -1.2585 0.1321 -2.1866 0.0016 -1.6719 0.0069 
Rv1193  fadD36 -2.0882 0.0017 -2.1222 0.5108 2.0427 0.1907 
Rv1235  lpqY -0.7984 0.5160 -0.7006 0.5108 -2.4641 0.0169 
Rv1328  glgP -1.1282 0.5160 -2.2561 0.0016 -2.4369 0.0008 
Rv1349  irtB -1.1596 0.0017 -1.1713 0.5108 1.4939 0.4666 
Rv1356c   0.1122 0.5160 0.4618 0.5108 -2.5156 0.0169 
Rv1445c  devB -1.2658 0.5201 -2.8609 0.5143 -4.0876 0.0008 
Rv1543   -1.9942 0.3837 -3.4910 0.0016 -1.5454 0.2779 
Rv1747   -1.1588 0.2418 -1.4045 0.0390 -1.3753 0.0491 
Rv1823   -1.2228 0.5160 -1.2871 0.5108 -3.8516 0.0119 
Rv1901  cinA -3.8215 0.0017 -4.5596 0.0016 -4.9181 0.0008 
Rv2048c  pks12 -1.7110 0.0017 -1.2722 0.0346 -1.0930 0.0667 
Rv2061c   -0.0619 0.5366 -0.1116 0.5206 -4.2577 0.0361 
Rv2140c   -1.9829 0.5160 -2.4595 0.5108 -3.4176 0.0008 
Rv2183c   0.4148 0.5160 -4.8028 0.0016 -4.6649 0.0008 
Rv2344c  dgt -0.4860 0.5160 -1.4186 0.2908 -2.3388 0.0119 
Rv2378c  mbtG -0.9324 0.5160 -0.9637 0.0016 -0.8251 0.0008 
Rv2381c  mbtD 1.5035 0.5160 0.6038 0.5108 -0.3678 0.0008 
Rv2563   -4.1301 0.0017 -4.3760 0.0016 -1.8044 0.3272 
Rv2564  glnQ -3.8129 0.0164 -3.2652 0.0125 -3.4993 0.0119 
Rv2931  ppsA -0.4164 0.5160 -1.5311 0.0125 1.5334 0.0008 
Rv2932  ppsB -0.4673 0.5160 -1.7432 0.0346 1.2914 0.0119 
Rv2933  ppsC -0.5407 0.5160 -1.6448 0.0016 1.3916 0.0008 
Rv2934  ppsD -0.5570 0.5160 -1.7214 0.0125 1.3795 0.0008 
Rv2935  ppsE -0.9301 0.5160 -1.6253 0.0390 1.2650 0.0169 
Rv2940c  mas -0.4319 0.5160 -1.2111 0.0390 1.1273 0.0008 
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Rv2942  mmpL7 -0.7282 0.5160 -1.4662 0.0125 -1.0005 0.2708 
Rv3036c   -1.3248 0.5160 -1.2481 0.5108 -3.4137 0.0326 
Rv3131   -1.8787 0.5160 -3.8044 0.0125 -2.7985 0.0933 
Rv3211  rhlE -3.9017 0.5160 -2.4049 0.5108 -4.7662 0.0008 
Rv3232c  ppk2 -0.0928 0.5160 -0.3110 0.5108 -1.1719 0.0406 
Rv3262  fbiB -1.9417 0.0017 -1.9815 0.5108 -1.8464 0.4793 
Rv3267   0.5915 0.5160 -1.4269 0.5108 -3.2811 0.0008 
Rv3283  sseA -3.5296 0.0017 -2.5805 0.0125 -0.8332 0.4519 
Rv3539  ppe63 -0.0677 0.5160 -0.3359 0.5108 -1.7706 0.0361 
Rv3586   -1.0116 0.5160 -0.6509 0.5108 -3.2116 0.0008 
Rv3848   -2.7843 0.0017 -0.6724 0.5108 0.7922 0.4809 
Rv3849  espR -1.7815 0.5160 -1.8059 0.0016 -1.6599 0.0008 

































LFC = log2 fold change. Q-value = significance adjusting for multiple tests. Red = LFC  
−1.5. Bold = Q-value < 0.05 at indicated time point.  
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Table A3.3 | Significantly overrepresented genes post INH treatment compared    
to pretreatment 
    INH 1wk INH 2.5wks INH 5wks 
ID gene LFC Q-value LFC Q-value LFC Q-value 
Rv0096  ppe1 0.7757 0.5160 1.7328 0.0016 3.0402 0.0008 
Rv0097   1.5404 0.1562 1.9138 0.0390 2.9111 0.0008 
Rv0098  fcoT 1.6116 0.5032 2.1722 0.1722 3.0989 0.0008 
Rv0099  fadD10 1.4461 0.5160 1.7136 0.3895 2.9776 0.0008 
Rv0101  nrp 0.7704 0.0950 1.5810 0.0016 2.3902 0.0008 
Rv0249c   0.2312 0.5160 0.3342 0.5108 2.4865 0.0119 
Rv0485   -0.0257 0.5185 0.5654 0.5108 2.3416 0.0008 
Rv0554  bpoC 2.1364 0.0017 1.2209 0.3370 2.0217 0.0069 
Rv0877   1.0426 0.0950 1.2351 0.0472 1.7533 0.0008 
Rv1345  mbtM 2.9315 0.0017 1.4722 0.0016 2.7578 0.0008 
Rv1798  eccA5 1.8892 0.1301 2.3901 0.0390 1.5407 0.4155 
Rv2069  sigC 0.4126 0.5160 1.5369 0.5108 3.2615 0.0119 
Rv2210c  ilvE 1.2221 NA 1.2043 NA 3.6786 0.0449 
Rv2380c  mbtE 3.1817 0.0017 0.9327 0.5108 2.1159 0.3095 
Rv2383c  mbtB 2.4169 0.0017 0.8960 0.5108 -0.8922 0.4028 
Rv2930  fadD26 -0.0434 0.5185 -0.8710 0.5108 1.8078 0.0008 
Rv2931  ppsA -0.4164 0.5160 -1.5311 0.0125 1.5334 0.0008 
Rv2932  ppsB -0.4673 0.5160 -1.7432 0.0346 1.2914 0.0119 
Rv2933  ppsC -0.5407 0.5160 -1.6448 0.0016 1.3916 0.0008 
Rv2934  ppsD -0.5570 0.5160 -1.7214 0.0125 1.3795 0.0008 
Rv2935  ppsE -0.9301 0.5160 -1.6253 0.0390 1.2650 0.0169 
Rv2940c  mas -0.4319 0.5160 -1.2111 0.0390 1.1273 0.0008 
Rv3135  ppe50 0.6124 0.5160 0.2440 0.5108 1.2726 0.0361 
Rv3220c   1.5534 0.0297 0.1202 0.5108 1.4038 0.0276 
Rv3331  sugI 0.8609 0.5160 0.4698 0.5108 1.5490 0.0069 
Rv3575c   0.4505 0.5160 1.2116 0.1375 1.7785 0.0119 










LFC = log2 fold change. Q-value = significance adjusting for multiple tests. Green = LFC  




Table A3.4 | Significantly underrepresented genes post EMB treatment compared 
to pretreatment 
    EMB 1wk EMB 2.5wks EMB 5wks 
ID gene LFC Q-value LFC Q-value LFC Q-value 
Rv0101  nrp -0.2629 0.5212 -0.3874 0.5284 -1.1784 0.0078 
Rv0111   -0.7440 0.5212 -0.9993 0.5284 -1.5728 0.0254 
Rv0216   -1.3175 0.5212 -1.3104 0.5284 -6.5361 0.0009 
Rv0296c   -0.7958 0.5212 -0.9035 0.5284 -1.8499 0.0078 
Rv0450c  mmpL4 -0.3227 0.5212 -1.1094 0.1927 -2.2812 0.0009 
Rv0503c  cmaA2 -0.5661 0.5212 -0.8557 0.2497 -1.1361 0.0199 
Rv0757  phoP -0.7731 0.5212 -0.6818 0.5284 -5.4654 0.0009 
Rv0806c  cpsY -0.9239 0.5212 -1.3422 0.1927 -2.3371 0.0009 
Rv0998   -1.8514 0.5212 -1.8759 0.0017 -1.7428 0.5091 
Rv1006   -0.3518 0.5212 -0.5826 0.5284 -2.0760 0.0142 
Rv1183 mmpL10 -0.9184 0.5212 -1.0910 0.2477 -1.5218 0.0009 
Rv1235  lpqY -0.9297 0.5212 -1.3086 0.5284 -2.7902 0.0009 
Rv1364c   -1.0143 0.5212 -0.6277 0.5284 -2.5027 0.0427 
Rv1589  bioB -1.3148 0.5212 -0.8198 0.5284 -2.3669 0.0009 
Rv1635c   -0.4318 0.5212 -0.5041 0.5284 -1.1494 0.0199 
Rv1701   -1.8577 0.5212 0.0882 0.5284 -1.7708 0.0009 
Rv2048c  pks12 -0.4964 0.5212 -0.7838 0.4897 -1.6127 0.0009 
Rv2224c  caeA -1.7459 0.5212 -1.6524 0.5284 -4.1851 0.0254 
Rv2476c  gdh -0.5923 0.5212 -0.8331 0.5284 -2.7278 0.0009 
Rv2894c  xerC -2.6890 0.0016 0.1334 0.5284 -0.7989 0.5629 
Rv2936 drrA -0.9407 0.5212 -0.8495 0.5284 -1.8161 0.0479 
Rv2942  mmpL7 -1.1307 0.2866 -0.8315 0.5284 -1.6590 0.0142 
Rv3283  sseA -1.3593 0.5212 -2.2187 0.0299 -1.8270 0.0655 
Rv3543c  fadE29 -2.6011 0.5212 -3.8238 0.5284 -3.6129 0.0009 
Rv3559c   -1.9140 0.5212 -0.1475 0.5474 -1.7859 0.0009 
Rv3823c  mmpL8 0.0202 0.5212 -0.8865 0.5284 -2.8551 0.0009 










LFC = log2 fold change. Q-value = significance adjusting for multiple tests. Red = LFC  
−1.5. Bold = Q-value < 0.05 at indicated time point.  
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Table A3.5 | Significantly overrepresented genes post EMB treatment compared  
to pretreatment 
    EMB 1wk EMB 2.5wks EMB 5wks 
ID gene LFC Q-value LFC Q-value LFC Q-value 
Rv0177   0.8241 0.5212 0.3103 0.5284 1.4909 0.0078 
Rv0244c  fadE5 2.1189 0.0149 1.2743 0.5284 4.6923 0.0009 
Rv0270  fadD2 0.9060 0.1506 1.2120 0.0017 2.2608 0.0009 
Rv0554  bpoC 2.0021 0.0016 2.0906 0.0017 1.4672 0.0655 
Rv0818   0.1970 0.5212 0.9343 0.5284 3.4258 0.0311 
Rv0877   0.8737 0.4430 1.0406 0.0017 3.5486 0.0009 
Rv1151c   0.8294 0.5212 0.8062 0.5284 1.9677 0.0009 
Rv1205   0.3169 0.5212 0.8461 0.5284 2.9183 0.0078 
Rv1206  fadD6 1.4953 0.0016 1.2569 0.0017 3.4614 0.0009 
Rv1345  mbtM 2.6354 0.0016 2.7976 0.0017 2.3265 0.0009 
Rv1626   2.4395 0.0284 2.5178 0.0017 1.7911 0.2876 
Rv1798  eccA5 2.1337 0.0016 -0.0673 0.5284 1.5386 0.5091 
Rv2378c  mbtG 3.4335 0.0016 3.8489 0.0017 3.2231 0.1791 
Rv2379c  mbtF 3.8625 0.0016 4.6703 0.0017 3.2054 0.0009 
Rv2380c  mbtE 5.6454 0.0016 6.1164 0.0017 5.1205 0.0009 
Rv2381c  mbtD 4.4276 0.0016 4.1867 0.0017 3.7573 0.0009 
Rv2382c  mbtC 3.5541 0.0680 4.3838 0.0017 4.1548 0.0009 
Rv2383c  mbtB 4.1328 0.0016 4.5681 0.0017 4.0021 0.0009 
Rv2384  mbtA 3.4323 0.0016 3.6058 0.0017 2.8827 0.0199 
Rv2386c  mbtI 4.5436 0.0016 4.7244 0.0017 3.8018 0.0142 
Rv2567   1.1455 0.5212 0.7535 0.5284 2.4908 0.0078 
Rv2684  arsA 1.1006 0.2866 1.5348 0.0157 3.0202 0.0009 
Rv2689c   0.4044 0.5212 0.8126 0.5284 1.5196 0.0078 
Rv3135  ppe50 1.2821 0.0149 0.8567 0.2785 0.9944 0.0778 
Rv3220c   2.6952 0.0016 2.7328 0.0017 3.6728 0.0009 
Rv3696c  glpK 2.8640 0.0016 2.8913 0.0017 5.6685 0.0009 










LFC = log2 fold change. Q-value = significance adjusting for multiple tests. Green = LFC  




Table A3.6 | Significantly underrepresented genes post RIF treatment                   
compared to pretreatment 
    RIF 1wk RIF 2.5wks 
ID gene LFC Q-value LFC Q-value 
Rv0436c  pssA -0.5678 0.5022 -5.5344 0.0255 
Rv0450c  mmpL4 -1.7122 0.0014 -0.8414 0.0565 
Rv0805   -1.6027 0.3548 -3.0054 0.0098 
Rv0820  phoT -2.2146 0.3373 -4.1651 0.0322 
Rv0989c  grcC2 -2.7020 0.0665 -2.7571 0.0374 
Rv0998   -3.0483 0.0014 -3.0570 0.2339 
Rv1174c   -2.1951 0.0014 -3.8456 0.0011 
Rv1184c   -3.4355 0.0014 -3.5120 0.0011 
Rv1244  lpqZ -1.9205 0.0122 -2.6759 0.0011 
Rv1272c   -1.4369 0.2360 -1.9917 0.0179 
Rv1273c   -4.4242 0.0014 -4.1301 0.0011 
Rv1328  glgP -0.9490 0.1670 -1.7269 0.0011 
Rv1492  mutA -0.2269 0.5022 -1.4187 0.0428 
Rv1543   -3.1632 0.0014 -3.8412 0.0011 
Rv1592c   -1.7169 0.0014 -0.6144 0.4322 
Rv1925  fadD31 -1.5265 0.0372 -1.3086 0.1615 
Rv2004c   -0.9234 0.5022 -2.4414 0.0098 
Rv2190c   -2.1909 0.4452 -5.0327 0.0098 
Rv2224c  caeA -3.0024 0.0014 -1.6165 0.3205 
Rv2241  aceE -3.3945 0.0372 -2.1791 0.1250 
Rv2462c  tig -1.7061 0.0316 -0.7692 0.4720 
Rv2563   -3.4297 0.0014 -1.5044 0.2505 
Rv2564  glnQ -2.0061 0.0122 -0.6872 0.4689 
Rv2985  mutT1 -0.3361 0.5022 -2.7061 0.0255 
Rv3005c   -2.6197 0.0014 -1.5296 0.1191 
Rv3036c   -1.6094 0.1604 -2.7727 0.0011 
Rv3139  fadE24 -2.4794 0.0014 -0.3523 0.4972 
Rv3194c   -1.3651 0.1074 -1.5973 0.0428 
Rv3229c  desA3 -1.0095 0.0316 -0.4218 0.4768 
Rv3484  cpsA -2.7913 0.1207 -4.2602 0.0011 
Rv3682  ponA2 -1.2339 0.4691 -2.7299 0.0322 
Rv3717   -3.4527 0.0372 -1.0415 0.4972 
Rv3779   -1.1374 0.0234 -0.6217 0.4433 
Rv3822   -4.9282 0.0014 -5.3026 0.0011 
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Rv3867  espH -5.3489 0.0014 -2.6985 0.1250 







Table A3.7 | Significantly overrepresented genes post RIF treatment                      
compared to pretreatment 
    RIF 1wk RIF 2.5wks 
ID gene LFC Q-value LFC Q-value 
Rv0079   0.3208 0.5022 1.8283 0.0179 
Rv0248c   1.6133 0.0372 1.7721 0.0011 
Rv0249c   2.0384 0.0451 1.9250 0.0374 
Rv0270  fadD2 0.8636 0.0122 0.7017 0.1125 
Rv0485   -0.3750 0.5022 1.8146 0.0011 
Rv0503c  cmaA2 1.1372 0.0014 2.2285 0.0011 
Rv0554  bpoC 0.6998 0.4778 1.2884 0.0098 
Rv0643c mmaA3 0.7850 0.0934 1.5440 0.0011 
Rv0758  phoR -0.1768 0.5022 1.9234 0.0011 
Rv1345  mbtM 1.9028 0.0014 1.6531 0.0011 
Rv1538c  ansA 0.5687 0.5022 2.0356 0.0011 
Rv2098c   1.7029 0.0316 0.2357 0.4972 
Rv2214c  ephD 1.2531 0.0014 1.3558 0.0011 
Rv2689c   1.1285 0.0122 0.5123 0.4624 
Rv2930  fadD26 0.3658 0.5022 1.2857 0.0374 
Rv2940c  mas 0.0273 0.5022 0.8555 0.0179 
Rv2967c  pca 1.5891 0.3373 2.5459 0.0011 
Rv3220c   1.8870 0.0014 0.9803 0.1191 
Rv3535c  hsaG 0.3171 0.5022 1.3422 0.0489 
Rv3696c  glpK 1.6695 0.0014 1.9889 0.0011 
Rv3820c  papA2 0.4975 0.4928 1.0818 0.0011 
Rv3824c  papA1 0.6877 0.1207 0.9812 0.0011 




LFC = log2 fold change. Q-value = significance adjusting for multiple tests. 
Red = LFC  −1.5. Bold = Q-value < 0.05 at indicated time point.  
LFC = log2 fold change. Q-value = significance adjusting for multiple tests. 




Table A3.8 | Significantly underrepresented genes                                                                      
post PZA treatment compared to pretreatment 
    PZA 1wk 
ID gene LFC Q-value 
Rv0757  phoP -3.8796 0.0020 
Rv1212c  glgA -3.4518 0.0020 
Rv1770   -1.1589 0.0330 
Rv2614A   -3.4209 0.0174 
Rv3135  ppe50 -1.5908 0.0020 
Rv3136  ppe51 -3.6612 0.0020 
Rv3262  fbiB -2.7801 0.0020 
Rv3277   -3.7506 0.0020 
Rv3855  ethR -2.4174 0.0174 











Table A3.9 | Significantly overrepresented genes                                                                   
post PZA treatment compared to pretreatment 
    PZA 1wk 
ID gene LFC Q-value 
Rv1206  fadD6 1.4982 0.0020 
Rv2043c  pncA 3.2043 0.0020 
Rv2476c  gdh 2.0322 0.0020 
Rv2940c  mas 0.8895 0.0470 









LFC = log2 fold change. Q-value = significance 
adjusting for multiple tests. Red = LFC  −1.5.  
Bold = Q-value < 0.05.  
LFC = log2 fold change. Q-value = significance 
adjusting for multiple tests. Green = LFC  1.5.  
Bold = Q-value < 0.05.  
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Table A3.10 | Genes significantly associated                                                                          
with varimax dimension 1, INH treatment 
    Varimax dimension 1 
   INH (1-, 2.5-, 5-weeks) 
ID gene LFC Q-value 
Rv0096 ppe1 -2.2000 0.0000 
Rv0097  -2.0000 0.0000 











Table A3.11 | Genes significantly associated                                                                        
with varimax dimension 2, untreated 
    Varimax dimension 2 
   Untreated 
ID gene LFC Q-value 
















LFC = log fold change of varimax projection. Q-
value = significance adjusting for multiple tests. 
Red = LFC  −1.5.  Bold = Q-value < 0.025.  
LFC = log fold change of varimax projection. Q-
value = significance adjusting for multiple tests. 
Red = LFC  −1.5.  Green = LFC  1.5. Bold = 
Q-value < 0.025.  
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Table A3.12 | Genes significantly associated                                                                          
with varimax dimension 3, PZA and HRZE treated 
    Varimax dimension 3 
   PZA/HRZE (1-week) 
ID gene LFC Q-value 
Rv0805  -1.7000 0.0132 
Rv1592c  -1.8000 0.0220 
Rv2043c pncA -2.8000 0.0000 
Rv2476c gdh -2.1000 0.0000 
Rv2571c  -2.9000 0.0000 
Rv2931 ppsA -1.2000 0.0000 
Rv2934 ppsD -1.1000 0.0000 
Rv2940c mas -0.8000 0.0062 
Rv3136 PPE51 2.4000 0.0000 
Rv3229c desA3 1.6000 0.0132 

























LFC = log fold change of varimax projection. Q-
value = significance adjusting for multiple tests. 
Red = LFC  −1.5.  Green = LFC  1.5. Bold = 
Q-value < 0.025.  
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Table A3.13 | Genes significantly associated                                                                       
with varimax dimension 4, RIF treatment 
    Varimax dimension 4 
   RIF (1-, 2.5-, 5-weeks) 
ID gene LFC Q-value 
Rv0248c   -2.0000 0.0062 
Rv0485   -2.1000 0.0088 
Rv0503c cmaA2 -1.9000 0.0000 
Rv0643c mmaA3 -1.2000 0.0000 
Rv0758 phoR -1.4000 0.0000 
Rv1184c   2.8000 0.0111 
Rv2214c ephD -1.1000 0.0034 
Rv3822   3.5000 0.0000 



























LFC = log fold change of varimax projection. Q-
value = significance adjusting for multiple tests. 
Red = LFC  −1.5.  Green = LFC  1.5. Bold = 
Q-value < 0.025.  
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Table A3.14 | Genes significantly associated with varimax dimensions                                   
5 and 6, EMB treatment 
    Varimax dimension 5 Varimax dimension 6 
   EMB (1- and 2.5-weeks) EMB (5-weeks) 
ID gene LFC Q-value LFC Q-value 
Rv0244c fadE5 0.9000 0.7175 -3.2000 0.0000 
Rv0554 bpoC -1.1000 0.0111 0.2000 0.8173 
Rv1193 fadD36 -2.5000 0.0000 1.2000 0.6827 
Rv1206 fadD6 -0.2000 0.8550 -1.8000 0.0000 
Rv1345 mbtM -0.9000 0.0385 -0.9000 0.0220 
Rv1626   -2.0000 0.0000 0.2000 0.8895 
Rv2378c mbtG -1.6000 0.2460 -2.6000 0.0154 
Rv2379c mbtF -2.6000 0.0000 -0.8000 0.5546 
Rv2380c mbtE -2.1000 0.0000 -2.0000 0.0000 
Rv2381c mbtD -2.9000 0.0034 -0.6000 0.8288 
Rv2383c mbtB -2.4000 0.0000 -1.5000 0.0000 
Rv2384 mbtA -3.7000 0.0000 0.3000 0.8550 
Rv2684 arsA -0.8000 0.3162 -1.7000 0.0000 
Rv3220c   -0.7000 0.5362 -2.2000 0.0000 
Rv3696c glpK 0.2000 0.8979 -1.6000 0.0088 




















LFC = log fold change of varimax projection. Q-value = significance 
adjusting for multiple tests. Red = LFC  −1.5.  Green = LFC  1.5. Bold = 
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